University of South Florida

Scholar Commons
Graduate Theses and Dissertations

Graduate School

4-11-2008

Isolation and Functional Characterization of a
Dioxin-Inducible CYP1A Regulatory Region From
Zebrafish (Danio rerio)
Gary T. ZeRuth
University of South Florida

Follow this and additional works at: https://scholarcommons.usf.edu/etd
Part of the American Studies Commons
Scholar Commons Citation
ZeRuth, Gary T., "Isolation and Functional Characterization of a Dioxin-Inducible CYP1A Regulatory Region From Zebrafish (Danio
rerio)" (2008). Graduate Theses and Dissertations.
https://scholarcommons.usf.edu/etd/578

This Dissertation is brought to you for free and open access by the Graduate School at Scholar Commons. It has been accepted for inclusion in
Graduate Theses and Dissertations by an authorized administrator of Scholar Commons. For more information, please contact
scholarcommons@usf.edu.

Isolation and Functional Characterization of a Dioxin-Inducible CYP1A
Regulatory Region From Zebrafish (Danio rerio)

by

Gary T. ZeRuth

A dissertation submitted in partial fulfillment
of the requirements for the degree of
Doctor of Philosophy
Department of Biology
College of Arts and Sciences
University of South Florida

Major Professor: Richard S. Pollenz, Ph.D.
Brian T. Livingston, Ph.D.
Jessica L. Moore, Ph.D.
Robert L. Potter, Ph.D.
Date of Approval:
April 11, 2008

Keywords: arylhydrocarbon receptor (AHR), cytochrome p4501A1 (CYP1A1), 2,3,7,8,tetrachlorodibenzo-p-dioxin (TCDD), xenobiotic response element (XRE), gene
regulation

© Copyright 2008, Gary T. ZeRuth

Dedication

Dedicated to Melissa S. ZeRuth, without whom I could never have come so far.

Acknowledgements

Acknowledgements are given to Jeff Yoder for help in the initial screening of the
PAC library and helpful discussion of this work. Thanks are extended to Leonard Zon for
providing the PAC library and arraying the pooled clones. Michael Carvan is recognized
for providing p-1897Om1A3luc reporter vector. Jeannette Wentworth is acknowledged
for technical help on the initial screening of the PAC library and the Southern blotting
experiments. Special thanks to Dr. Richard S. Pollenz for mentoring and support.
Acknowledgments are given to the Pollenz Lab members, Edward J. Dougherty and
Sarah E. Wilson for consultation, assistance and support.

Table of Contents
List of Figures

iii

List of Acronyms

v

Abstract

vi

Chapter One: Introduction
Isolation of AHR and ARNT
bHLH-PAS Proteins
AHR Ligands
AHR-mediated Signaling
CYP1A1 Regulation
AHR Regulated Genes
TCDD-mediated Developmental Toxicity in Zebrafish
AHR and ARNT in Fishes

1
1
3
5
8
13
22
26
28

Chapter Two: Results
Isolation of the zfCYP1A upstream region
Induction of the zfCYP1A gene by TCDD
In vitro analyses of AHR/ARNT association with zfXREs
Functional characterization of individual XREs within the
zfCYP1A regulatory region
The pattern of expression controlled by the zfCYP1A and
mCYP1A1 regulatory regions varies in different cell lines
Analysis of the zebrafish CYP1A proximal promoter
Functional analysis of XRE flanking sequence
Identification of additional cis-regulatory regions which
impact the induction of zfCYP1A

32
32
35
42
47
56
60
62
67

Chapter Three: Discussion of Impact, Relevance, and Future Direction

73

Chapter Four: Materials and Methods

87

References

97

Appendices
Appendix A: PAC 133 Sequencing data
Appendix B: Construct Maps
Appendix C: Additional Studies
i

123
123
131
147

Generation of destabilized EGFP and EYFP constructs
ARNT domain Swapping
About the Author

147
153
End Page

ii

List of Figures
Figure 1.1. Comparison of bHLH-PAS Protein Structures

6

Figure 1.2. Common AHR Ligands

9

Figure 1.3. Schematic Overview of AHR-mediated signaling

14

Figure 1.4. Model of CYP1A1 Regulation by AHR

21

Figure 2.1. Comparison of CYP1A Regulatory Regions from
Different Species

34

Figure 2.2. Induction of the zfCYP1A gene by TCDD

36

Figure 2.3. Analysis of the Effect of Orientation and
Position on TCDD-induced Luciferase Activity

39

Figure 2.4. Luciferase Reporter Analysis of the Ability of the
Region Between -580 and +71 to Function as a Promoter

41

Figure 2.5. Analysis of TCDD-mediated Induction from Reporter
Constructs Containing the zfCYP1A Promoter Region
Between -580 and +71 and CYP1A Enhancer Regions
from Different Species

43

Figure 2.6. In vitro Analysis of the Association of zfAHR2 with XREs

45

Figure 2.7. Association of zfAHR2 and rtARNTb with zfXREs

46

Figure 2.8. Comparison of TCDD-induced Luciferase Activity
Between the p-2699/+71 and p-2608/-2100Ur Constructs

49

Figure 2.9. Functional Analysis of zfXREs 1 and 3

51

Figure 2.10. Functional Analysis of zfXREs

53

Figure 2.11. Functional Analysis of zfXREs in Different Cell Lines

55

Figure 2.12. Comparison of XRE8 Function Between the
p-2608/-2100Ur and p-2727/-2100Ur Constructs

57

Figure 2.13. Characterization of Mouse and Zebrafish CYP1A
Promoter and Enhancer Regions in Various Cell Lines
iii

58

Figure 2.14. Analysis of the Zebrafish CYP1A Proximal Promoter

61

Figure 2.15. Comparison of Mouse and Zebrafish XRE Flanking
Regions

63

Figure 2.16. Effect of Mutating Nucleotides Flanking XREs on
AHR/ARNT Binding In Vitro

65

Figure 2.17. Putative Transcription Factor Binding Sites Within
the zfCYP1A Regulatory Region That Are Common
to Both Mouse and Zebrafish

68

Figure 2.18. Analysis of cis-regulatory Elements Within
the zfCYP1A Enhancer

69

Figure 2.19. Effect of HNF-3 Mutation on the Full-length
p-2699/+71 Construct

71

Figure AA1. Schematic Overview of Sequencing Strategy

124

Figure AC1. Strategy for Generating EYFP Construct

149

Figure AC2. Construct Maps of p-EGFP and p-dEYFP

151

Figure AC3. Schematic of ARNT Domain Swapping

160

Figure AC4. Construct Maps of p-hARNT and p-mARNT2

161

Figure AC5. Restriction Enzyme Digestion of p-mARNT2

162

iv

List of Acronyms
AHR – arylhydrocarbon receptor
ARNT – arylhydrocarbon receptor nuclear translocator
XRE – xenobiotic response element
TCDD – 2, 3, 7, 8 – tetrachlorodibenzo-p-dioxin
3MC – 3-methylcholanthrene
BaP – benzo[a]pyrene
DMSO – dimethyl sulfoxide
PAH – polycyclic aromatic hydrocarbon
HAH – halogenated aromatic hydrocarbon
CYP1A1 – Cytochrome P4501A1
SDS-PAGE – sodium dodecyl sulfate polyacrylamide gel electrophoresis
EMSA – electrophoretic mobility shift assay
siRNA – small interfering RNA
HNF-3α- hepatic nuclear factor 3α
CREB – cAMP response element binding protein
Sp1 – stimulatory protein 1
ROS – reactive oxygen species
XME – xenobiotic metabolizing enzyme
ARE – anti-oxidant response element

v

Isolation and Functional Characterization of a Dioxin-Inducible CYP1A Regulatory
Region From Zebrafish (Danio rerio)
Gary T. ZeRuth
ABSTRACT

Cytochrome P4501A1 (CYP1A1) is a phase I bio-transformation enzyme
involved in the metabolism of xenobiotics via the oxygenation of polycyclic aromatic
hydrocarbons (PAHs) including the carcinogen, benzo(a)pyrene. Induction of the
CYP1A1 gene is regulated at the transcriptional level and is ligand dependent with the
prototypical 2,3,7,8,-tetrachlorodibenzo-p-dioxin (TCDD) being the most potent known
inducer of CYP1A1 transcription. This process is mediated by the AHR/ARNT signaling
pathway whereby ligand binds AHR in the cytoplasm allowing its translocation to the
nucleus where it binds with its hertrodimerization partner, ARNT and subsequently binds
DNA at cognate binding sites termed xenobiotic responsive elements (XREs) located in
the 5’ flanking region of the CYP1A1 and other genes.
The zebrafish (Danio rerio) has recently become an important model system for
the study of TCDD-mediated developmental toxicity due to their relative ease of
maintaining and breeding, external fertilization, abundant transparent embryos, and
sensitivity to TCDD similar to mammalian models. It is therefore essential to

vi

characterize the molecular mechanisms of AHR mediated gene regulation in this
organism.
The upstream flanking region of a putative CYP1A gene from zebrafish was
identified by the screening of a PAC genomic library. Sequencing revealed a region
which contains 8 putative core xenobiotic response elements (XREs) organized in two
distinct clusters. The region between –580 to –187 contains XRE 1-3 while the region
between –2608 to –2100 contains XRE 4-8. Only XRE 1, 3, 4, 7, and 8 exhibited TCDDdependant association of AHR/ARNT complexes when evaluated by gel shift assays.
The use of in vitro mutagenesis and Luciferase reporter assays further showed that only
XRE’s 4, 7, and 8 were capable of conveying TCDD-mediated gene induction. The role
of nucleotides flanking the core XRE was investigated through the use of EMSA and
reporter assays. Similar methods were employed on additional transcription factor
binding sites identified by in silico analyses revealing two sites conforming to an HNF3α and CREB motif, respectively, which demonstrate importance to regulation of the
gene.

vii

Chapter One

Introduction

Isolation of AHR and ARNT
The aryl hydrocarbon hydroxylase, (AHH), was identified as being greatly varied
in inducibility amongst different strains of mice in response to polycyclic aromatic
hydrocarbons, (PAHs), and halogenated aromatic hydrocarbons, (HAHs) (Nebert and
Gelboin, 1969; Poland et al., 1974). Through the use of classical murine genetics, it was
further ascertained that these variations were controlled by a single gene locus termed Ah
(Green, 1973; Schmidt and Bradfield, 1996; Thomas and Hutton, 1973). The Ah locus
was later found to code for a receptor, the aryl hydrocarbon receptor (AHR), which is
capable of binding ligand with high affinity leading to the subsequent induction of AHH
(Poland et al., 1976). Polymorphisms in the Ahr were found to be the cause of the
variable inducibility of AHH between mouse strains and[125I]-photoaffinity labeling led
to the discovery of three alleles encoding for high affinity receptors designated Ahrb-1,
Ahrb-2, and Ahrb-3 and a single allele encoding the low affinity Ahrd allele.(Poland and
Glover, 1990; Poland et al., 1987) Purification of the AHR and the development of
antibodies specific to the receptor revealed that differences existed not only amongst
mouse strains, but the molecular weight varied remarkably between species as well
(Hahn et al., 1994; Poland and Glover, 1987; Poland et al., 1991). These innovations
1

additionally led to the generation of the first AHR cDNA and the revelation that the
receptor was the second member of the basic-helix-loop-helix Per-ARNT-Sim (bHLHPAS) family of proteins identified (Burbach et al., 1992; Ema et al., 1992).
Interestingly, the first member of the bHLH-PAS family isolated was the
heterodimerization partner of the AHR, the aryl hydrocarbon nuclear translocator protein,
ARNT, cloned approximately one year earlier (Hoffman et al., 1991). ARNT was
isolated in an attempt to identify constituents of AHR signaling absent in an induction
defective mouse hepatoma cell line containing normal concentrations of AHR capable of
binding ligand but which failed to subsequently localize to the nucleus. (Hoffman et al.,
1991; Legraverend et al., 1982) Due to the ability of ARNT to restore function to the
loss-of-function mutants, the name aryl hydrocarbon nuclear translocator protein was
actually a misnomer as it was later found that ARNT is not required for the nuclearization
of liganded AHR but instead acts as a dimerization partner required for the binding of
DNA.(Dolwick et al., 1993b; Elferink et al., 1990; Reyes et al., 1992) Indeed, studies by
Pollenz et al. (1994) showed that AHR was capable of translocating to the nucleus
following TCDD treatment in ARNT deficient cells and that ARNT was confined to the
nucleus both prior to and following ligand exposure while unliganded AHR was
primarily cytosolic.(Pollenz et al., 1994) The unveiling of the scheme of
heterodimerization between AHR and ARNT laid the foundation for the identification
and characterization of novel members of the emerging super-family of bHLH-PAS
proteins.

2

bHLH-PAS Proteins
While other proteins had been previously identified which contain bHLH
domains, including the well characterized MyoD, AHR and ARNT possess a domain
adjacent to the bHLH which shows homology to the Drosophila Period (Per) and Single
minded (Sim) genes and is termed Per-ARNT-Sim (PAS) after the identifying members
(Burbach et al., 1992; Ema et al., 1992; Hoffman et al., 1991; Huang et al., 1993). The
PAS region is typically composed of approximately 300 amino acids and is divided into
PAS A and PAS B subdomains each consisting of 50 amino acid degenerate repeats
(Burbach et al., 1992; Gu et al., 2000; Nambu et al., 1991). Having a role in
dimerization, the PAS domain has been implicated in heterodimerization between Per and
Sim and homodimerization of Per (Huang et al., 1993). In the case of AHR, the PAS
domains serve as a binding site for chaperone proteins (Whitelaw et al., 1993) and ligand
(Burbach et al., 1992; Dolwick et al., 1993a; Schmidt and Bradfield, 1996; Whitelaw et
al., 1993) as well as assisting in DNA binding (Dolwick et al., 1993a) while AHR/ARNT
dimerization occurs concertedly within the HLH and PAS domains (Reisz-Porszasz et al.,
1994; Schmidt and Bradfield, 1996). In addition to the basic, DNA binding domain, the
HLH, and the PAS domains, the majority of bHLH-PAS proteins contain a C-terminal
transcriptional activation domain (TAD). Unlike the previous domains, however, which
share sequence homology, the TADs lack conservation amongst members of the superfamily (Gu et al., 2000). A graphical depiction of the domain organization within
selected bHLH-PAS proteins is shown in Figure 1.1.
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The existence of transcriptional activation domains supports the fact that most
bHLH-PAS proteins serve as transcriptional regulators which act upon target genes in
order to elicit an adaptive response to environmental stimuli. (Furness et al., 2007;
Kewley et al., 2004; Massari and Murre, 2000) In order to form active transcription
factors, bHLH-PAS proteins are required to dimerize and are thus divided into two
distinct classes. Class I proteins are capable of detecting environmental stimuli but must
dimerize with a Class II protein in order to adopt an active, DNA binding form. While
Class I proteins are incapable of homodimerization or dimerization with another Class I
member, Class II bHLH-PAS proteins are far more promiscuous and confined to the
nuclear compartment where they serve as master regulators capable of homo or
heterodimerization. Some examples of Class I proteins include HIF1 and HIF2α
(hypoxia inducible factors); regulators of the cellular response to hypoxia, (Tian et al.,
1997; Wang et al., 1995; Wang and Semenza, 1995) SIM 1 and 2 (single minded
proteins); involved in neurogenesis and mid-line development, (Ema et al., 1996; Probst
et al., 1997) the circadian rhythm protein, Clock, (Gekakis et al., 1998; King et al., 1997)
and the AHR (aryl hydrocarbon receptor); involved in xenobiotic metabolism. Class II
receptors include ARNT and ARNT2 (aryl hydrocarbon receptor translocator proteins),
BMAL1 and 2 (brain and muscle ARNT-like proteins), and Per. Figure 1.1 shows the
domain structures of representative bHLH-PAS proteins. Of all the bHLH-PAS proteins,
AHR and ARNT remain the best characterized members.
Unlike the Class I AHR which only binds ARNT, ARNT exhibits promiscuity by
dimerizing with AHR, hypoxia inducible factors HIF1α and HIF2α, and Single mined
4

proteins Sim1 and Sim2 (Furness et al., 2007; Kewley et al., 2004). ARNT -/- mice die
in utero at gestational day (GD) 10.5 due to a failure of the placenta to vascularize. Other
defects observed include forebrain hypoplasia, placental hemorrhaging, visceral arch and
neural tube abnormalities, and delayed rotation of the embryo (Kozak et al., 1997).
Phenotypically similar to HIF1α knockout mice, (Ke and Costa, 2006) these findings
implicate ARNT as a compulsory, HIF associated, developmental transcription factor.
ARNT2 is a close structural homolog of ARNT, bearing 57% sequence similarity
in the mouse with divergence primarily within the COOH-terminus (Hirose et al., 1996).
Furthermore, unlike the ubiquitously expressed ARNT, ARNT2 is expressed primarily in
the CNS and kidneys in mice (Jain et al., 1998). ARNT2 -/- mice perish perinatally
bearing a phenotypic resemblance to SIM-1 knock-out mice suggesting that ARNT2 may
be the heterodimerization partner of SIM-1 required for neurogenesis. Data also supports
the hypothesis that ARNT or ARNT2 may have overlapping function prior to embryonic
day (ED) 8.5. While ARNT2 can form dimers with AHR and HIF1α, its primary
function appears to be as a pairing partner for SIM (Jain et al., 1998).
AHR Ligands
Unlike the Class II ARNTs which primarily serve as dimerization partners for the
Class I bHLH-PAS proteins, the AHR serves as a “sensor” of environmental cues;
therefore ligand activation must ensue to initiate the pathway. Ligand binds the AHR in
the form of a structurally diverse array of chemicals both natural and synthetic in nature
which are capable of activating the receptor subsequently leading to the regulation of a
5

Figure 1.1. Comparison of bHLH-PAS Protein Structures
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Fig. 1.1. Comparison of bHLH-PAS Protein Structures. Schematic overview of the
domain structure of representative bHLH-PAS proteins. The domains are indicated. b:
Basic region, HLH: Helix-loop helix domain, PAS A and PAS B: Per-ARNT-Sim motifs,
TAD: Transactivation domain. The scale at the bottom represents number of amino acids.
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battery of genes. Representative AHR ligands are shown in Figure 1.2. The most well
characterized AHR ligands are the polycyclic aromatic hydrocarbons (PAHs) such as
benzo[a]pyrene and 3-methylcholanthrene and the halogenated aromatic hydrocarbons
(HAHs) represented by dibenzo-p-dioxins, biphenyls, and dibenzofurans. Environmental
pollutants, exposure to these chemicals contributes to a broad spectrum of toxic and
biological effects.
PAHs typically exist as the product of combustion and can lead to cancers due to
the generation of ROS (reactive oxygen species) resulting from the metabolism of the
insulting compound and consequent DNA and protein adduct formation and cellular
damage (Gelboin, 1980). While HAHs also lead to toxicological responses in mice
which include wasting syndrome, thymic involution, tumor promotion, teratogenicity,
immunosuppression, reduced fertility, epidermal hyper and metaplasia, and death,
(Poland and Knutson, 1982; Safe, 1990) unlike PAHs, the molecular mechanism behind
these effects are not understood but most, if not all, of these responses rely on the AHR.
The most potent known agonist of AHR is 2,3,7,8-tetrachlorodibenzo-p-dioxin, (dioxin,
TCDD), which has an affinity for the receptor in the pM range versus PAHs which
exhibit binding affinities in the nM to μM range. The toxic effects of TCDD are thought
to stem from the regulation of genes targeted by the activated AHR as opposed to direct
genotoxicity of the compound or its metabolic by-products. Interestingly, the severity of
the response to TCDD depends on multiple factors including the type of cell, sex, age,
and species exposed supporting a gene regulatory mechanism of toxicity over that of
direct cellular damage.
7

To date, no endogenous AHR ligand has been identified however a number of
naturally occurring, non-anthropogenic chemicals have been shown to bind the AHR and
induce target genes, albeit much more weakly than TCDD. A variety of dietary plant
derivatives consisting largely of flavonoids have been identified as weak AHR
agonists/antagonists and may explain an evolutionary purpose for the AHR as an
activator of xenobiotic metabolism enzymes (Denison and Nagy, 2003). The activation
of AHR in the absence of exogenous ligand as well as numerous developmental defects
in AHR null mice suggest that an endogenous, unidentified AHR ligand likely exists and
may possibly be in the form of an indole, tetrapyrole, or an amino acid metabolite
(Denison and Nagy, 2003). While natural or endogenous AHR ligands have yet to be
confirmed, in regard to the elucidation of the molecular mechanisms behind AHR
signaling and the impact on human health, activation by the classical PAHs and HAHs
are relevant. The precise risk to human health is still unknown but TCDD was upgraded
to a Group 1 “human carcinogen” in 1997 by the International Agency for Research on
Cancer and remains the prototypical AHR ligand.
AHR-mediated Signaling
Ligand binding to the AHR is thought to be supported by the fact that the latent
AHR exists as a complex with several other proteins consisting of the 90kD heat shock
protein, Hsp90, the 23kD p23, and the Hepatitis B virus X-associated protein 2, XAP2
(Carver et al., 1998; Denis et al., 1988; Kazlauskas et al., 1999; Ma and Whitlock, 1997;
Meyer et al., 1998; Perdew, 1988). Immunoprecipitation experiments from two
independent laboratories first identified interactions between AHR and a dimer of the
8

FIGURE 1.2. Common AHR Ligands
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Fig. 1.2. Common AHR ligands. Chemical structures of representative AHR
ligands and inducers. Classical halogenated aromatic hydrocarbons are shown at the
top. Classical polycyclic aromatic hydrocarbons are shown in the middle. Naturally
occurring dietary AHR ligands are shown at the bottom.
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molecular chaperone, Hsp90 (Denis, 1988; Perdew, 1988). The role of Hsp90 is thought
to be one in which it stabilizes the AHR in a conformation susceptible to ligand binding
to the PAS domain of AHR (Antonsson et al., 1995; Carver et al., 1994; Coumailleau et
al., 1995; Denis, 1988; Perdew, 1988; Pongratz et al., 1992) and to repress dimerization
with ARNT and DNA binding in the absence of ligand and an additional unidentified
event (Heid et al., 2000; McGuire et al., 1994; Pongratz et al., 1992). Indeed, it has been
established that liganded AHR enters the nucleus along with Hsp90 but dimerization with
ARNT and DNA binding require dissociation from the heat shock protein (Heid et al.,
2000).
In addition to Hsp90, the latent AHR is also complexed with a molecule of the
FKBP52 immunophilin-like, Hepatitis B virus X-associated protein (XAP2, Ara9, AIP1)
(Carver and Bradfield, 1997; Ma and Whitlock, 1997). Originally it was ascertained that
XAP2 maintained the cytoplasmic localization of AHR, thus enhancing its ability to be
activated by ligand (Bell and Poland, 2000; Berg and Pongratz, 2002; Carver et al., 1998;
Kazlauskas et al., 2000; LaPres et al., 2000; Ma and Whitlock, 1997; Meyer and Perdew,
1999; Meyer et al., 2000; Petrulis et al., 2003) however, recent studies have shown that
these observations may be specific to the Ahb-1 allele and that other species do not exhibit
association with XAP2 to the level observed with the b-1 receptor nor does XAP2
maintain a cytoplasmic localization, but instead merely inhibits nucleocytoplasmic
shuttling by interfering with the association of nuclear import receptors (Pollenz and
Dougherty, 2005; Pollenz et al., 2006). The lack of necessity for XAP2 in AHR
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signaling is supported by the fact that AHR exhibits normal functioning in
Saccharomyces cerevisiae which does not possess a homolog of XAP2 (Gu et al., 2000).
The third protein known to exist in the heterotetrameric latent AHR complex is
p23 which is known to interact with Hsp90 in other systems (Chadli et al., 2000; Grenert
et al., 1997; Sullivan et al., 1997). Studies involving the yeast homologs of Hsp90 and
p23, Hsp82 and Sba1 respectively, suggest that p23 blocks the ATPase activity of Hsp90,
stabilizing the Hsp90-AHR interaction (Cox and Miller, 2004). Earlier studies confirmed
this role for p23 when loss the protein from the AHR-Hsp90 complex resulted in ligandindependent interaction between AHR and ARNT. The addition of molybdate, a
chemical known to stabilize p23-Hsp90 interactions, restored normal function suggesting
that a role of p23 is to stabilize the Hsp90-AHR latent complex (Kazlauskas et al., 1999).
The association of p23 with Hsp90 along with the observation that the AHR may
associate with p60 and Hip indicates that the latent AHR complex may be similar to that
seen in other steroid hormones (Nair et al., 1996).
The proposed model for AHR signaling then follows that a small, hydrophobic
ligand, typified by TCDD, passes through the plasma membrane where it binds to the
latent AHR complex within the PAS domain of AHR between amino acids 232-334
(Burbach et al., 1992). The binding of ligand is supported by the folding of the AHR
PAS domain into a favorable lignd binding conformation due to its association with
Hsp90 (Gu et al., 2000). Binding of ligand presumably causes a conformational change
both displacing p23 and allowing for the nuclear translocation of the complex. Within
the nucleus, it is suspected that AHR, due in part to the displacement of p23 by ligand,
11

can form a dimer with ARNT, possibly after phosphorylation of ARNT (Chen and
Tukey, 1996; Long et al., 1998). AHR-ARNT dimerization leads to the dissociation of
the molecular chaperone proteins and the formation of an active, DNA binding complex.
The activated AHR-ARNT recognizes cognate enhancer sequences termed xenobiotic
response elements (XREs) located within the regulatory region of target genes. The XRE
core consensus sequence is defined as: 5’-(T/G)NGCGTG-3’ whereby the basic region of
ARNT binds to 5’-GTG and the AHR basic region binds the remaining nucleotides
(Bacsi et al., 1995; Denison et al., 1988; Fisher et al., 1990; Hapgood et al., 1989; Lusska
et al., 1993; Swanson et al., 1995) and the specificity of binding may be controlled, in
part, by the PAS domain of AHR (Dolwick et al., 1993b). Binding of AHR-ARNT to the
XREs of target genes results in gene regulatory events which are largely dependent on the
COOH-terminal TAD domains of AHR and ARNT (Jain et al., 1994; Whitelaw et al.,
1994).
The endpoint of ligand-mediated AHR signaling is the degradation of the AHR.
Indeed, studies have shown that AHR is rapidly depleted in both cell culture and animals
following TCDD exposure, (Giannone et al., 1995; Ma et al., 2000; Pollenz, 1996;
Pollenz, 2002; Pollenz et al., 1998; Roman et al., 1998) the degradation event is
connected to the nuclear localization of the AHR, (Song and Pollenz, 2002) and likely
occurs via the 26S proteosome (Davarinos and Pollenz, 1999; Ma and Baldwin, 2000;
Wentworth et al., 2004). The mechanism by which the AHR is degraded is yet unknown
but it is suspected that ubiqitination is involved considering most proteins targeted to the
proteosome are ubiquitinated. To date, no evidence of ubiquitination has been identified.
12

CYP1A1 Regulation
A member of the P450 family of cytochromes, the aryl hydrocarbon hydroxylase or
Cytochrome P1-450 1A1 (CYP1A1) is the most well characterized target of ligandactivated AHR and has become the prototype for the study of AHR-mediated signaling.
The product of the inducible CYP1A1 locus is a heme-thiolate monooxygenase
responsible for the metabolism of lipophilic aromatic hydrocarbons. These xenobiotic
metabolizing enzymes receive electrons from NADPH-P450 reductase which activates an
oxygen capable of being inserted into a specific substrate or group of substrates. In the
case of CYP1A1, these substrates are planar aromatic hydrocarbons and the
monooxygenation event of CYP1A1 opens the benzene rings of the PAH allowing for its
subsequent metabolism. Ligands of the AHR, PAHs then induce their own metabolism.
Due to the toxic 2,3,7,8-chlorination of TCDD and similar HAHs, these persistent
chemicals are poorly metabolized by xenobiotic metabolism enzymes yet induce
transcription of XMEs via the activation of AHR nonetheless.
Early experiments revealed that TCDD-mediated CYP1A1 induction did not
occur in AHR or ARNT deficient cells (Jones et al., 1986) and was a primary response
which occurs in the absence of protein synthesis (Whitlock, 1999). Further investigation
demonstrated that TCDD-mediated induction of the gene was controlled by cis-regulatory
elements contained within ~500bp of the 5’ upstream region of the gene in mice (Jones et
al., 1985) which functioned as an enhancer up or downstream of an MMTV promoter
regardless of orientation (Jones et al., 1986). Several features of the enhancer were
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subsequently characterized. Using various truncations of the rat CYP1A1 enhancer
region upstream of a CAT reporter gene driven by an SV-40 promoter and gel retardation
assays, two regions composed of 15 nucleotides which were required for gene induction
following treatment with 3-MC were isolated. Comparisons of the two regions revealed a
5 bp sequence, GCGTG, common between the two required regions which were
designated “xenobiotic responsive elements” or “XREs” (Fujisawa-Sehara et al., 1987).
Experiments with the murine CYP1A1 enhancer region expanded the protein-DNA
interaction to a core sequence, 5’-T(A/T)GCGTG-3’. This sequence was specifically
recognized by AHR/ARNT heteromers but showed that binding of the 7bp core sequence
alone by the liganded receptor was not sufficient to drive activation of the downstream
gene; indicating that the sequence flanking the XRE core is essential for transactivation
(Denison et al., 1988; Hapgood et al., 1989). Subsequent studies attempting to
characterize the role flanking nucleotides play in binding AHR/ARNT in vitro and in
transactivating a downstream reporter produced a modified consensus: 5’(T/G)1YG2C3G4T5G6(A/C)7(C/G)8(A/T)9 -3’ (Lusska et al., 1993; Shen and Whitlock,
1992; Swanson et al., 1995). Indeed, Shen and Whitlock showed that either a C at
position 1, G at position 7, A at position 8, or G at position 9 abolished XRE function in
CAT reporters (Shen and Whitlock, 1992). These observations are in agreement with
studies done by Swanson et al (Swanson et al., 1995). Significantly, experiments which
placed tandem repeats of an XRE upstream of an SV-40 controlled CAT gene showed a
4-fold increase in both induced and constitutive CAT activity in constructs containing
two XREs versus a single XRE (Fujisawa-Sehara et al., 1987). It is also of importance
that either linker scanning mutants, whereby the core XRE was replaced with unrelated
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DNA of the same length, or truncations of the enhancer revealed that the elimination of
any one of four mouse XREs resulted in a 25% decrease in TCDD induced activity.
Removal of all four XREs eliminated responsiveness to TCDD (Fisher et al., 1990).
Additionally, another important component of the CYP1A1 enhancer, a GC-box was
identified between -952 and -943 upstream of the mouse CYP1A1 transcriptional start
site which was capable of being bound in vitro by Sp1 (or a related factor) and when
removed, produced a 5-fold decrease in reporter activity. Interestingly, this site is
incapable of function in the absence of bound XREs (Fisher et al., 1990).
The enhancer region defined above is non-functional unless linked to a functional
transcriptional promoter (Jones et al., 1986; Neuhold et al., 1989). Likewise, the murine
CYP1A1 promoter contains several regulatory elements which fail to function in the
absence of the enhancer. A TATAAA box is located at position -30 upstream of the
transcriptional start site, a proximal and a distal CTF/NF1 site are located at positions -59
and -136 respectively, and a G-box is located at position -130 (Jones and Whitlock,
1990). The TATAAA box is an essential component of the CYP1A1 promoter as
mutation of this sequence reduces gene activation by >80%. The distal CTF/NF1 site and
the G-box appear to bind a functionally equivalent protein as elimination of either one
has no effect on gene activity; however, when both are eliminated a 50% reduction in
inducible activity is observed. Furthermore, footprinting experiments reveal that
mutation of the G-box shifts protection at that site toward the distal CTF/NF1 site (Jones
and Whitlock, 1990). The proximal CTF/NF1 site (identified by others as a BTE site in
the rat CYP1A1 promoter) also contributes significantly to promoter function (Jones and
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Whitlock, 1990; Yanagida et al., 1990). A number of proteins have been shown capable
of binding this sequence including Sp1, Gut-enriched Kruppel-like factor (GKLF), and
BTEB1, 3, and 4 (Imataka et al. 1992, Sogawa et al. 1993, Zhang et al. 1998, Shields et
al. 1998, Kaczynski et al. 2001, Kaczynski et al. 2002). While Sp1 binding leads to
enhanced activation of the gene, (Yanagida et al. 1990, Kobayashi et al. 1996) GKLF and
BTEB1, 3, and 4 binding leads to transcriptional repression of CYP1A1 (Imataka et al.,
1992; Kaczynski et al., 2002; Sogawa et al., 1993; Zhang et al., 1998b). Kaczynski et al.
have proposed a model whereby the constitutively expressed BTEB proteins repress
CYP1A1 activity by competing with Sp1 at the BTE site but this model has yet to be
confirmed.
In the absence of ligand, the CYP1A1 enhancer/promoter is inactive and assumes
a nucleosomal configuration (Wu and Whitlock, 1992; Wu and Whitlock, 1993). Studies
using DNaseI protection and LMPCR have revealed that binding of AHR/ARNT
heteromers at the XREs within the CYP1A1 enhancer results in a disruption of chromatin
structure localized to approximately 180bp surrounding the XRE, followed by the loss of
the nucleosome at the promoter. The relaxation of the nucleosomal promoter allows the
binding of TBP, NF1, and general transcription factors initiating transcription (Ko et al.,
1997; Morgan and Whitlock, 1992; Okino and Whitlock, 1995). As hundreds of base
pairs remain in a nucleosomal configuration between the XRE containing enhancer and
the promoter, the possibility of direct communication between the two regions is
unlikely. Additional studies determined that the loss of the nucleosome at the promoter
was the result of communication via the TAD of AHR bound at the enhancer (Ko et al.,
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1996; Ko et al., 1997). Interestingly, the TAD containing C-terminus of AHR appears to
have no effect on the nucleosomal re-arrangement of the enhancer implying that its effect
on the promoter involves the recruitment or binding to other factors involved in
stabilizing the promoter chromatin (Ko et al., 1996). A likely model is one in which
AHR/ARNT binds at the enhancer and associates with a complex of other proteins
involved in both chromatin remodeling and stabilization of the general transcription
factors at the promoter.
A number of other proteins have been implicated in the regulation of CYP1A1
which may act to either remodel chromatin or stabilize the transcriptional machinery at
the promoter. It has previously been established that Sp1 interacts in vivo with the HLHPAS domain of AHR/ARNT via its zinc finger domain (Kobayashi et al., 1996).
Interaction between these two proteins lends to a potential model in which a DNA loop is
formed by binding of Sp1 at the promoter to AHR/ARNT heteromer at the enhancer.
Furthermore, AHR or ARNT have been shown to interact in vitro with the general
transcription factors TFIIB, IIF, and TBP (Rowlands et al., 1996; Swanson and Yang,
1998) supporting the role of AHR/ARNT in stabilizing the general transcription complex.
Other observed interactions include the HAT co-activator, CBP, interacting at the
transactivation domain of ARNT (Kobayashi et al., 1997) and RIP-140, retinoblastoma
protein (Rb), Nedd8, and promyelocytic leukemia nuclear bodies (PML) interacting with
AHR (Fujii-Kuriyama and Mimura, 2005; Hankinson, 2005), all of which have been
shown to enhance reporter gene expression. Recent studies have also demonstrated the
involvement of the p-160 HAT coactivators, SRC-1 (NCoA-1), NCoA-2 (GRIP-1, TIF18

2), and p/CIP (AIB, ACTR) in mediating TCDD-dependent CYP1A1 expression. ChIP
assays and real time PCR reveal that all three proteins associate with the CYP1A1
enhancer region in vivo within 15 minutes of TCDD treatment, while antibodies specific
to each reduce XRE-driven expression of reporter genes (Beischlag et al., 2002; FujiiKuriyama and Mimura, 2005; Hankinson, 2005; Hestermann and Brown, 2003; Kumar
and Perdew, 1999). Overexpression of the coactivators enhances reporter gene activity
and shows that all three are capable of interacting with AHR while SRC-1 and NCoA-2
interact with ARNT (Beischlag et al., 2002). Further studies need to be performed to
elucidate the precise roles the p-160 family of receptors play in AHR-dependent
signaling.
Brahma/SW12-related Gene 1 Protein (Brg-1) is the ATPase subunit of certain
ATP-dependent chromatin remodeling complexes and has been shown to associate with
the TAD of AHR (Wang and Hankinson, 2002). Overexpression of exogenous Brg-1
enhanced expression of XRE–driven reporters in Hepa-1 cells and restored endogenous
CYP1A1 activity in Brg-1 deficient cells when co-expressed with SRC-1 while an ATPase deficient Brg-1 mutant failed to do so. Finally, ChIP analysis demonstrated that Brg1 associates with the mouse CYP1A1 enhancer region in a TCDD and ARNT dependent
manner implicating its role in AHR-mediated induction of the gene (Fujii-Kuriyama and
Mimura, 2005; Hankinson, 2005; Wang and Hankinson, 2002).
The TRAP/DRIP/ARC mediator complex has also been shown to be involved in
AHR-mediated regulation of CYP1A1. ChIP analyses show that two sub-units of the
mediator complex, Med220 and CDK8 associate with the murine CYP1A1 enhancer
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shortly after binding of AHR/ARNT and p/CIP (10-30 min). RNAi experiments revealed
that depletion of endogenous Med220 resulted in inhibition of endogenous CYP1A1
induction following treatment with TCDD (Wang et al., 2004). While Med220 and
CDK8 have been shown to associate with the CYP1A1 enhancer in vivo, other subunits
of the mediator complex have previously been shown to bind to the general
transcriptional complex suggesting a role for mediator to bridge the enhancer and
promoter regions of CYP1A1 (Malik and Roeder, 2000).
A hypothetical model for CYP1A1 regulation based on the current literature is
shown in Figure 1.4. Additional interactions are currently being evaluated. Indeed, the
estrogen receptor alpha (ERα) has recently been in the spotlight for its possible role as
yet another cofactor. While an overwhelming battery of coactivators have been
implicated in AHR-mediated signaling, it is important to consider that many have
suggested roles based on over-expression of proteins to levels far exceeding what a cell
would experience in a normal, physiological setting or in vitro interactions of artificially
expressed proteins. Furthermore, even as new resources such as ChIP analyses and
quantitative real-time PCR arise as valuable tools in assessing the proteins involved
within this pathway, these procedures are not flawless and could possibly lead to the false
implication of elements which, in reality, are not involved. Care must be taken in the
analysis of future studies to avoid this. Even as a large number of factors are currently
suggested to regulate TCDD-mediated gene induction, it is probable that more will arise.
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Figure 1. 4. Model of CYP1A1 Regulation by AHR

Fig. 1.4. Model of CYP1A1 Regulation by AHR. Hypothetical schematic overview of
AHR-mediated transcriptional regulation of CYP1A1. Numbers indicate proposed events
chronologically. Transcription factors and co-activators are shown bound to DNA and
proteins respectively. See text and references for additional details.
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AHR Regulated Genes
In addition to CYP1A1, ligand activated AHR leads to the induction of a battery
of other genes such as Glutathione S-transferase Ya (Gst-Ya), Uridine DiphoshateGlucuronosyl transferase (UGT1A1), Aldehyde dehydrogenase (ALDH), Quinone
oxidoreductase (NQO1), and additional members of the P450 family of cytochrome
monooxygenases. CYP1A2 and CYP1B1 are both phase I biotransformation enzymes
known to be regulated by AHR. CYP1B1 is expressed constitutively in extrahepatic
tissues such as the mammary, ovary, and prostate (Shimada et al., 1996; Sutter et al.,
1994) and has been implicated in the bioactivation of benzo[a]pyrene and other
procarcinogens. Importantly, CYP1B1 has been shown to be regulated by the AHR and
contains three XREs within a 190bp span of its promoter region (Tang et al., 1996).
Apart from AHR-mediated inducibility and a role in PAH metabolism, CYP1B1exhibits
more differences than similarities to CYP1A1. CYP1B1 is largely expressed in tissues
originating from the mesenchyme while CYP1A1 is expressed ubiquitously. CYP1B1 is
constitutively expressed while CYP1A1 generally shows little to no basal activity in the
absence of liganded AHR. Differences also exist structurally in that CYP1A1 consists of
seven exons, like most other P450s, while CYP1B1 consists of only three exons. While
the regulation of CYP1B1 is poorly understood, it is known that the mouse and human
CYP1B1 promoters lack a TATA box, CTF/NF1 sites, or BTE sites as are found in the
CYP1A1 regulatory region. Instead, the gene is under the control of a TATA-like
sequence located at position -27 relative to the transcriptional start site and a series of
Sp1 sites located within the proximal promoter (Wo et al., 1997). Intriguingly,
22

AHR/ARNT has been shown to bind at only one of the three CYP1B1 XREs while the
other two are bound by a complex of proteins termed anomalous complex or anC (Eltom
et al., 1999; Zhang et al., 1998a). The anC, which binds specifically due to two
nucleotides flanking the consensus XRE sequence, likely functions to inhibit maximal
CYP1B1 induction in the presence of high levels of activated AHR/ARNT by competing
for binding with AHR/ARNT at the 5’ XRE. On the contrary, anC is also likely
responsible for the constitutive activity of Cyp1b1 by synergistically activating the XRE
bound to AHR/ARNT in the presence of very low levels of activated AHR (Zhang et al.,
2003). The specific proteins which make up the anomalous complex or the exact
molecular mechanisms behind the regulation of CYP1B1 are currently unclear.
CYP1A2 is involved in aromatic amine metabolism and the metabolism of a
number of drugs including caffeine and theophylline. CYP1A2 is inducible by PAHs but
unlike CYP1A1, is expressed constitutively and predominately in the liver. The CYP1A2
gene, in mammals, is on the same chromosome and orientated in a head-to-head fashion
with CYP1A1, separated by approximately 23kb. Two regions were identified within the
~2.5kb upstream region of the CYP1A2 gene which are essential for 3-MC-mediated
transcriptional activation (Quattrochi et al., 1994). One of the identified regions, termed
X1, contains an XRE-like sequence which weakly associates with AHR in the presence
of 3-MC. Elimination of this region resulted in an approximately 50% reduction in
activity. The second identified region, termed X2, did not associate with AHR in vitro
but may play a role in 3-MC-mediated induction due to a putative AP1 site (Quattrochi et
al., 1994). Recent studies using a dual reporter vector under control of the 23kb region
between human CYP1A1 and CYP1A2 shows that an XRE cluster near the CYP1A1
23

transcriptional start site may work bi-directionally to regulate CYP1A2 (Ueda et al.,
2006). Further studies need to be performed to elucidate the mechanisms behind
CYP1A2 regulation.
CYP2S1 was identified in 2001 as the only member of the novel, 2S, family of
cytochrome P450s (Rivera et al., 2002; Rylander et al., 2001). CYP2S is a member of
the CYP2 family which like Cyp2a5 and CYP2A6, from mouse and human respectively,
is inducible by dioxin (Gokhale et al., 1997; Rivera et al., 2002). Expression of CYP2S
is similar to that observed for CYP1B1, being prominent in epithelial tissues including
skin, trachea, lung, and intestine (Rylander et al., 2001; Saarikoski et al., 2005). CYP2S1
also resembles CYP1B1 in that it lacks a TATA box within the promoter (Rivera et al.,
2007). Several XREs were identified within the 5.2kb region upstream of the
translational start codon of the mouse Cyp2s1 gene; however studies using reporter
vectors containing combinations of mutated XREs show that TCDD-mediated induction
is attributed only to a region containing three overlapping XREs between -393 and -408
(Rivera et al., 2007). AHR/ARNT was capable of binding all three of the overlapping
XREs in a ligand dependant manner as shown by EMSA. Each of the three XREs was
also able to induce a reporter gene in cell culture; however simultaneous mutation of any
two of the three trimeric XREs severely reduced TCDD responsiveness to near control
levels as did mutation of all three (Rivera et al., 2007). A regulatory region containing a
series of overlapping XREs such as exhibited in CYP2S1 has not been previously
identified. Interestingly, the mouse region which contains the trimeric XREs also was
found to contain three overlapping HREs of which at least one binds HIF1α/ARNT and
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is responsive to hypoxia. (Rivera et al., 2007) The human Cyp2s1 promoter was also
found to contain two overlapping XREs and two overlapping HREs and is responsive to
both dioxin and hypoxia (Rivera et al., 2002). Elucidation of the molecular mechanisms
of CYP2S1 regulation is not only important because CYP2S1 may be partially important
for the toxic effects of PAHs and dioxin, but additionally may help gain a better
understanding of AHR-mediated signaling.
While AHR additionally regulates a number of phase II xenobiotic metabolizing
enzymes which contain XREs within their regulatory regions, these genes also typically
contain antioxidant response elements (ARE) which are bound by nuclear factor
erythroid 2 p45-related factor (Nrf2), the product of another target gene of AHR (Kohle
and Bock, 2007; Miao et al., 2005). In addition to activation by AHR, Nrf2 can be
activated by reactive oxygen species resulting from phase I XME metabolism of PAHs
(Kohle and Bock, 2007; Marchand et al., 2004). Although functional AREs and XREs
have not been identified in the regulatory regions of all phase II genes known to be
regulated by AHR, analysis of NQO1 in AHR (-/-) and Nrf2 (-/-) null mice showed that
TCDD-inducible expression required both AHR and Nrf2 (Kohle and Bock, 2007; Ma et
al., 2004). These findings led to a model whereby phase II XMEs may be regulated
directly by AHR binding to XREs, by coordinate binding of AHR and Nrf2, or by AREs
being bound by Nrf2 which is itself regulated by AHR and ROS. These mechanisms of
cross-talk have yet to be confirmed but may be important in gaining a better
understanding of the complexities of AHR-mediated signaling.
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Cyp1a1 I (-/-) and cyp1a2 (-/-) null mice have shown relatively little protection
against the toxic effects of TCDD when compared to the extensive protection exhibited
by Ahr (-/-) null mice (Bunger et al., 2003; Gonzalez and Fernandez-Salguero, 1998;
Smith et al., 2001; Uno et al., 2004) suggesting that induction of these genes may play
little role in mediating TCDD toxicity. Microarray studies have identified numerous
genes which are putatively regulated by AHR and have shown that the scope of genes
may be far outside that of xenobiotic metabolizing enzymes including genes involved in
reproduction, growth and development, cell cycle control, and differentiation (Tijet et al.,
2006; Yoon et al., 2006). Recent advances in technology such as microarray analyses
may help identify the genes responsible for the toxic response to dioxin, yet it is
imperative that an understanding of the molecular mechanisms of AHR gene regulation
be gained through the characterization of well-defined AHR targets.
TCDD-mediated Developmental Toxicity in Zebrafish
In zebrafish, embryonic dioxin exposure leads to a series of fairly well
characterized developmental defects which include disruption of erythropoiesis, altered
regional blood flow, craniofacial malformation, impaired lower jaw development,
apoptosis and local circulation failure in the dorsal midbrain, edema, retarded
development, and death (Antkiewicz et al., 2005; Belair et al., 2001; Dong et al., 2002;
Henry et al., 1997; Hill et al., 2003; Teraoka et al., 2002). The defects associated with
TCDD toxicity are exhibited between 48-120 hours postfertilization (hpf) with a
reduction in the number of myocytes, reduced blood flow, and a change in the
morphology of pronephric glomerulus being the earliest observed defects (Carney et al.,
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2006). The reduced peripheral blood flow and reduction in the number of myocytes
which occur at 48 hpf as well as a change in the morphology of the heart are the earliest
onset of cardiovascular dysfunction which ensues throughout the first 120 hpf
(Antkiewicz et al., 2005; Carney et al., 2006; Henry et al., 1997; Teraoka et al., 2002).
The morphological changes in the zebrafish heart following TCDD exposure are
primarily due to the blockage of the common cardinal vein from migrating dorsally
toward the heart between 72 and 96 hpf (Antkiewicz et al., 2005; Bello et al., 2004;
Carney et al., 2006). Heart morphology is further affected by an aberration of the normal
looping of the heart which occurs concurrently to defective remodeling of the common
cardinal vein (Antkiewicz et al., 2005; Carney et al., 2006; Chen et al., 1997). These
events lead to a heart which is mis-positioned and has an elongated atrium and a compact
ventricle, although it is unclear whether these are direct effects of AHR regulation or
secondary to a decrease in cardiac output (Antkiewicz et al., 2005; Carney et al., 2006).
Osmoregulatory defects are also observed in zebrafish embryos exposed to
dioxin. Edema is observed in the pericardium and yolk sac at 72 and 96 hpf respectively
(Belair et al., 2001; Dong et al., 2002; Henry et al., 1997). Given that the gills do not
play a role in osmoregulation until after 96 hpf (Rombough, 2002) and studies have
shown that the pronephric kidney is not affected by TCDD prior to the onset of edema,
(Hill et al., 2004) the likely cause of edema is linked to skin permeability and/or the
circulatory defects defined above.
Additional adverse effects of TCDD on zebrafish development include inhibited
growth of the cartilage which forms the lower jaw, increased apoptosis in the dorsal
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midbrain, a reduced brain volume, and a reduction of definitive erythrocytes (Belair et
al., 2001; Henry et al., 1997; Teraoka et al., 2002). The molecular mechanisms behind
these defects are largely unknown but it is not likely that cranio-facial malformations or a
failure of primitive erythrocytes to switch to definitive erythrocytes is secondary to
cardiac dysfunction. The role AHR plays in mediating these effects will be a significant
focus for studies in years to come.
AHR and ARNT in Fishes
Although polymorphisms are apparent in fish as they are in mammals, most fish
exhibit multiple AHR genes whereas only a single gene is present in mammals. These
multiple products are most likely the result of gene duplication events which occurred
throughout the course of evolutionary history (Hahn, 2002). In zebrafish (Danio rerio)
two known Ah receptors were isolated and designated zfAHR1 and zfAHR2 (Andreasen
et al., 2002; Tanguay et al., 1999). Interestingly, while the zfAHR1 is the ortholog of the
mammalian receptors, it is the zfAHR2 which is responsible for the TCDD-mediated
AHR activity in this species (Andreasen et al., 2002; Prasch et al., 2003). Studies by
Andreason et al. show that zfAHR2 is expressed relatively ubiquitously while zfAHR1 is
limited to expression primarily in the liver (Andreasen et al., 2002). The functional
differences between the two receptors likely lies in the ligand binding domains and
transactivation domains of the proteins as shown by experiments using zfAHR1/zfAHR2
chimeras (Andreasen et al., 2002). Like other piscine AHRs, zfAHR2 exhibits great
similarity to mammalian AHR in the b-HLH-PAS domains but lacks the Q-rich region in
the C-terminus essential for mammalian transactivation (Hahn, 2002; Tanguay et al.,
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1999). Studies by Kumar et al. however, suggest that the requirement of this Glutamine
rich region, in humans at least, may be limited to a single hydrophobic residue (Leu-678)
indicating that abundant glutamines may not be required per se for transactivation and
fish AHRs may possess the necessary hydrophobic residue (Kumar and Perdew, 1999).
Furthermore, while the Q-rich domain was deemed necessary for hAHR transactivation,
in mice the Q-rich region of the AHR enhanced the transactivation ability but was not
required (Jain et al., 1994; Sogawa et al., 1995).
Only a single ARNT has been identified in most teleost fishes. Two splice
variants of an ARNT1 homolog have been isolated in rainbow trout (Onchorhynchus
mykiss) and designated rtARNTa and rtARNTb (Pollenz et al., 1996). These proteins are
identical over the first 533 amino acids which include the b-HLH and PAS domains but
diverge in the carboxyl end due to an additional 373 bp sequence in rtARNTb which
causes a frame shift in the product. While both rtARNTa and rtARNTb are capable of
binding AHR in vitro, only rtARNTb appears able to facilitate transactivation of
CYP1A1, likely due to the inefficiency of rtARNTa to bind DNA. Pollenz et al. also
showed that rtARNTa is capable of behaving as a dominant negative inhibitor of
rtARNTb mediated gene induction; however, while rtARNTb is expressed ubiquitously,
rtARNTa is expressed at much lower levels and restricted in its distribution (Pollenz et
al., 1996). Interestingly, a single ARNT was isolated from the Atlantic killifish
(Fundulus heteroclitus) as well; however, phylogenetic analyses revealed that, unlike
rtARNT, the protein was a homolog of mammalian ARNT2 (Powell et al., 1999). In
zebrafish, the three alternatively spliced ARNTs originally identified by Tanguay et al.
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were also homologous to mammalian ARNT2 and were designated zfARNT2a, b, and c
(Tanguay et al., 2000). zfARNT2b was shown to bind zfAHR2 in vitro and could
moderately induce XRE-driven reporters in COS-7 cells, yet zfARNT2 morphants and
zfARNT2 -/- embryos still exhibited the same endpoints of TCDD toxicity observed in
wild type fish (Prasch et al., 2004) suggesting that zfARNT2 is not the ARNT involved in
mediating TCDD toxicity. Three additional alternatively spliced ARNTs were
subsequently isolated from the zebrafish and found to be homologous to the rtARNTb
and mammalian ARNT1. Designated zfARNT1a, b, and c, these three proteins were
found to be expressed continuously throughout the timecourse critical for TCDDmediated developmental toxicity, albeit at considerably lower levels than zfARNT2.
Furthermore, zfARNT1b and c were capable of forming dimers with zfAHR2, capable of
binding DNA in vitro, and inducing XRE-driven reporter constructs. Most importantly,
zfARNT1 morphants showed protection against three of the endpoints of TCDD toxicity:
pericardial edema, reduced blood flow, and reduced lower jaw growth (Prasch et al.,
2006). It is important to note that there may be a species specific difference in XRE
recognition sequences by AHR and ARNT. Tanguay et al. reported that
zfAHR2/rtARNTb dimers failed to bind the murine XRE containing the core sequence 5’
–TTGCGTG- 3’ but actively bound the rainbow trout XRE containing the sequence 5’ –
TAGCGTG- 3’ (Tanguay et al., 1999). Upon isolation of zfARNT1, Prasch et al. showed
binding of zfAHR2/zfARNT2b and c dimers to the same murine XRE indicated above
(Prasch et al., 2006). Surprisingly, mouse AHR/rtARNTb dimers bound both murine and
rainbow trout XRE containing oligonucleotides (Tanguay et al., 1999). Further research
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will have to be done to elucidate the potential differences in DNA recognition between
species.
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Chapter Two

Isolation of the zfCYP1A upstream region

To obtain the sequence of the zfCYP1A1 promoter/enhancer, zfCYP1A1 cDNA
sequence was used to query the Sanger zebrafish genome database. No sequence could
be recovered that contained significant identity to zfCYP1A1 so a zebrafish genomic
PAC library (Amemiya and Zon, 1999) was screened using primers specific to the 5’untranslated region (5’-UTR) and most 5’-region of the open reading frame (ORF) of the
zfCYP1A1 cDNA. Two PACs, designated #133 and #150, containing putative
zfCYP1A1 genes were identified. Restriction enzyme digestion and Southern analysis of
the two PACs identified identical bands that hybridized to the zfCYP1A1 cDNA probe.
A 0.5 kb and 2.5kb HindIII fragment as well as a 12 kb SpeI fragment were subcloned
from PAC #150 and sequenced. The 2.5 kb HindIII fragment contained the putative ATG
start codon and the first 134 bp of coding sequence that showed 100% identity to the
zfCYP1A1 cDNA in Genbank (accession #BC094977). The fragment also contained 14
bp of the 5’UTR with 100% identity to the zf-CYP1A1 cDNA. After nucleotide 14, the
sequence showed minimal identity to zfCYP1A1 cDNA but contained a putative splice
acceptor site at the region when identity was lost. The remaining sequence within the 2.5
kb HindIII fragment showed no identity to the CYP1A1 cDNA and contained substantial
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regions of repetitive DNA that were 80%–90% AT-rich. These results indicate that the
zfCYP1A1 gene contains an intron within the 5’UTR sequence. This is consistent with
the structure of other CYP1A1 genes (Carvan et al., 1999; Kubota et al., 1991; Powell et
al., 2004; Sogawa et al., 1986). The size of the intron is estimated to be >2500 bp, but
the entire sequence could not be obtained due to the high levels of AT-rich regions,
numerous regions of repetitive DNA, and a lack of unique restriction sites to allow
subcloning of smaller fragments. Thus, to obtain the remaining 5’UTR and its 5’flanking region, the SpeI fragment was sequenced with an oligonucleotide
complementary to the missing portion of the 5’UTR. This approach identified the
remaining 74 bp of the 5’UTR and putative CAAT and TATA boxes. Subsequent
sequence analysis identified the splice donor site for intron 1 and a putative
promoter/enhancer that spanned a region 2629 bp upstream from the transcription start
site. Several elements were identified within the isolated region which are characteristic
of previously characterized CYP1A regulatory regions. A putative TATA box is located
at position -31 relative to the transcriptional start site which has been designated +1.
Additionally, two CTF/NF1 sites were identified at positions -53 and -438 and an Sp1
site at -2474. These sites have all been implicated in the regulation of CYP1A1 in other
organisms (Fisher et al., 1990; Jones and Whitlock, 1990; Yanagida et al., 1990).
Importantly, eight putative XREs were identified which conform to the consensus
sequence: T/GNGCGTG. These XREs were designated 1-8 with XRE1 being nearest the
TATA box. Thus, the results indicate that zfCYP1A promoter/enhancer

33

Figure 2.1. Comparison of CYP1A Regulatory Regions from Different Species
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fh1A1-1625/+75
-1625

+75
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m1A1-1674/+57
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h1A1-2580/+71
+71
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Figure 2.1. Comparison of CYP1A regulatory regions from different species.
The location of XREs, indicated by rectangles, are shown in relation to the putative
transcriptional start site. Functional XREs are shaded. The TATA box is represented
by a shaded circle. CTF/NF1 or BTE sites are indicated by triangles. Shaded
triangles have been previously functionally characterized. Small shaded squares
indicate putative HNF-3 sites. Zf = zebrafish; rt = rainbow trout; fh = Fundulus
heteroclitus; r = rat; m = mouse; h = human.
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contains numerous XREs and other consensus regulatory sequences and bears an overall
structure that is similar to the mouse, rat, and trout. A comparison of the zebrafish region
to other characterized CYP1A regulatory regions is shown in Figure 2.1.
Induction of the zfCYP1A gene by TCDD
Since zebrafish have undergone a gene duplication event, they can contain
multiple copies of genes as well as pseudogenes that are nonfunctional (Postlethwait et
al., 1998; Woods et al., 2000). Therefore it was pertinent to verify that the isolated
zfCYP1A gene could support gene regulation and was inducible by TCDD. To address
this question, total RNA was isolated from ZFL cells that were treated with vehicle or
TCDD for 6 h. RT-PCR was carried out to amplify CYP1A and actin mRNA. To confirm
that expression was from the identified zfCYP1A promoter, the CYP1A primers were
complementary to the 5’UTR and ORF and designed to be on either side of the first
intron. Thus, the expected band from the amplification of CYP1A mRNA was 217 bp
whereas a band that was generated by amplifying genomic DNA would be >3 kb. The
results show that a band of 217 bp was weakly visible in the untreated ZFL but was
dramatically elevated in the presence of TCDD. (Fig. 2.2) Amplification of actin shows
that the changes in the level of CYP1A are not related to differences in the level of RNA
used in the assay. Thus, the data are consistent with previous studies that have identified
TCDD-inducible CYP1A in zebrafish (Henry et al., 2001; Miranda et al., 1993) and
support the hypothesis that the identified zfCYP1A gene is indeed inducible by TCDD.
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Figure 2.2. Induction of the zfCYP1A gene by TCDD

Figure 2.2. Induction of the zfCYP1A gene by TCDD. A. The location of
the forward and reverse primers used for reverse transcriptase PCR are
indicated with arrows and shown in relation to the zfCYP1A gene. B.
Triplicate samples of were exposed to 2nM TCDD (TC-6) or 0.05% DMSO
(0) for 6 hours and total RNA was prepared. mRNA was amplified following
reverse transcription with PCR primers specific to β-Actin (357 bp) or
CYP1A (217 bp). PCR products were visualized in a 2% agarose gel
containing ethidium bromide and exposed to UV light. Specific markers of
357, 323, and 200 bp are indicated.
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While the previous experiments suggest that the identified zfCYP1A gene was
inducible by TCDD, it was still important to show that the 5’flanking region contained
specific regions that conferred TCDD-responsiveness. Unfortunately, due to the extreme
AT-rich content and high level of repetitive DNA that is present between -600 and -2000,
it was not possible to generate a construct containing the full 2600 bp of the
promoter/enhancer. Thus, PCR was utilized to amplify the region between -580 and -187
(containing XREs 1-3) and the region between -2608 and -2100 (containing XREs 4-8).
These fragments were ligated in the forward and reverse orientations both upstream and
downstream of the SV-40 promoter in the pGL3promoter vector. TCDD mediated
induction of luciferase activity was then evaluated in the mouse Hepa-1 cell line. The use
of the mouse Hepa-1 line and not the zebrafish ZFL line for these studies was based on
the ability to grow large numbers of cells and the ability to obtain high levels of
transfection efficiency that facilitated the analysis of the luciferase and β-galactosidase
activities. The results shown in Figure 2.3 reveal that the -2608 to -2100 fragment
confers TCDD responsiveness to the SV40 promoter regardless of its location or
orientation. However, the maximal induction (approximately 40-fold) was observed in
the -2608/-2100Rup construct in which the 506bp zfCYP1A fragment was placed in a
reverse orientation upstream of the SV40 promoter. In this context, the magnitude of the
response and the overall level of induction were approximately five-fold higher than
when the fragment was inserted in the forward orientation (-2608/-2100Fup).
Interestingly, when the -2608 to -2100 fragment was placed downstream of the SV40
promoter in either the forward or reverse orientation (-2608/-2100Fdown and -2608/37

2100Rdown), it was also capable of inducing significant levels of luciferase activity in a
TCDD-dependent manner. However, in this context, the orientation of the zfCYP1A
fragment made no difference in the overall level of the response although the magnitude
of the response was 5-fold less than that observed for the -2608/-2100Rup.
In contrast to the results with the -2608 to-2100 fragment, the constructs
containing the proximal region between -580 to -187 (-580/-187Fup and -580/187Fdown) did not exhibit elevations in luciferase activity in the presence of TCDD.
Even when placed in the reverse orientation, the proximal fragment failed to confer
TCDD-responsiveness to the reporter gene construct (Fig. 2.3). This finding is intriguing
since the region between -580 to -187 contains three putative XREs. It was important
then to assess the function of XREs 1-3 in the context of their native promoter. PCR was
used to amplify the region between -580 and +71 and the resulting fragment was ligated
into pGL3Basic to generate the -580/+71Basic construct. This construct was transfected
into Hepa-1 cells and treated with TCDD. The results in Figure 2.4A show that -580/+71
exhibits high levels of constitutive activity which is approximately 35-fold higher than
naked vector however failed to convey TCDD-mediated induction. These results confirm
the observations made on the -580/+71Fup and -580/+71Fdown constructs and
additionally validates the function of this region as a functional promoter. As a positive
control, Hepa-1 cells were transfected with p-1897Om1A3luc that contains the full length
trout CYP1A3 promoter/enhancer. This construct was induced approximately threefold in
the Hepa-1 line. To determine whether the lack of TCDD-responsiveness by the 580/+71Basic construct was related to the analysis in a murine background, the construct
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Figure 2.3. Analysis of the Effect of Orientation and Position on TCDD-induced
Luciferase Activity

Figure 2.3. Analysis of the effect of orientation and position on TCDD-induced
Luciferase activity. The indicated reporter constructs as well as pSV-β-galactosidase
were transfected into Hepa-1 cells and treated with either 2nM TCDD or 0.05%
DMSO for seven hours. Luciferase activity was measured with a Turner Instruments
luminometer. β-Galactosidase levels were measured by spectrophotometry (OD420).
Normalization was carried out by dividing the relative luciferase levels for each
sample by the corresponding level of β-galactosidase . White bars represent DMSO
treated cells while black bars indicate cells treated with TCDD. Bars represent the
mean ± SE of three independent samples. * indicates statistically significant from
vehicle treated controls. P<0.001
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was transfected into the zebrafish liver cell line, ZFL. This line contains zfAHR2 and is
responsive to AHR ligands (Miranda et al., 1993; Woods et al., 2000). The results show
that that -1897Om1A3luc is responsive to TCDD in the ZFL cells and was induced
approximately threefold (Fig. 2.4B) as was observed in Hepa-1 cells, (Fig. 2.4A) whereas
-580/+71Basic exhibits elevated activity well above the parental vector, but is still not
responsive to TCDD. Thus, these studies show that the region of the zfCYP1A gene
containing defined TATA and CAAT boxes (-580 to +71) can function to promote gene
expression in both mouse and zebrafish backgrounds. The region which confers TCDD
responsiveness, however, appears to be located between -2100 and -2608.
In order to determine whether or not the zebrafish CYP1A enhancer region was
able to convey a similar TCDD-responsiveness to the endogenous zfCYP1A promoter as
was observed with the SV-40 promoter of the pGL3promoter vector, the -2100/-2608
region was ligated in either the forward or reverse orientation upstream of the -580/+71
region and transfected into Hepa-1 cells. These constructs were designated p-2608/2100Uf or p-2608/-2100Ur, respectively. Interestingly, the results show that while the
region driving the SV-40 promoter exhibited an approximately threefold greater
induction in the reverse versus the forward orientation, (Fig. 2.3) in the context of the
native promoter the difference was markedly less yielding approximately 18-fold
induction in the forward orientation and 22-fold induction in the reverse orientation. (Fig.
2.5) Despite this difference, the results show that the -2100/-2608 portion of the
zfCYP1A regulatory region is capable of conveying TCDD-mediated induction to its
endogenous promoter. As positive controls, the mouse CYP1A1 regulatory region
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Figure 2.4. Luciferase Reporter Analysis of the Ability of the region between -580
and +71 to Function as a Promoter

Figure 2.4. Luciferase reporter analysis of the ability of the region between -580
and +71 to function as a promoter. The indicated reporter constructs as well as
pSV-β-galactosidase were transfected into Hepa-1 cells (A) or ZFL cells (B) and
treated with 2nM TCDD or 0.05% DMSO for 7 hours. Luciferase activity was
measured with a Turner Instruments luminometer. β-Galactosidase levels were
measured by spectrophotometry (OD420). Normalization was carried out by
dividing the relative luciferase levels for each sample by the corresponding level of βgalactosidase . White bars represent DMSO treated cells while black bars indicate
cells treated with TCDD. Bars represent the mean ± SE of three independent
samples. * indicates statistically significant from vehicle treated controls. P<0.001
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between -1315 and -819 and the rainbow trout CYP1A3 regulatory region between -1897
and -1392 which have been previously shown to exhibit TCDD-responsiveness,
(Carvan et al., 1999; Jones et al., 1986) were ligated upstream of the zf-580/+71 region
and transfected into Hepa-1 cells. While these constructs respectively yielded
approximately ten and threefold levels of induction, the magnitude of the response by the
zf-2100/-2608 region was far greater indicating that zfCYP1A is highly responsive to
TCDD in Hepa-1 cells.
In vitro analyses of AHR/ARNT association with zfXREs
Since the fragments containing XREs 1-3 did not confer TCDD-responsiveness, it was of
interest to determine whether they represented bona-fide regions that actually bound to
AHR/ARNT complexes. To carry out these studies it was first important to establish the
conditions for the detection of zfAHR2/ARNT complexes in vitro. Previous studies
carried out in COS-1 cells have shown that the zfAHR2 can drive reporter gene
expression in the presence of zfARNT2b. (Abnet et al., 1999; Tanguay et al., 2000)
However, recent studies have challenged these findings by showing that zfARNT2b does
not support TCDD-mediated responses in vivo (Prasch et al., 2004; Prasch et al., 2003).
Thus, studies were carried out using rtARNTb and zfARNT2b since rtARNTb has been
shown to form a functional dimer with mAHR in vitro (Necela and Pollenz, 1999; Necela
and Pollenz, 2001; Pollenz et al., 1996). For these studies, zfAHR2, zfARNT2b, and
rtARNTb were synthesized in reticulocyte lysates, incubated with TCDD, and analyzed
by electrophoretic mobility shift assays (EMSA). The results shown in Figure 2.6 reveal
that complexes containing zfAHR2 and rtARNT2b produce a specific shift that is
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Figure 2.5. Analysis of TCDD-mediated Induction from Reporter Constructs
Containing the zfCYP1A Promoter Region Between -580 and +71 and CYP1A
Enhancer Regions from Different Species
Fig. 2.5. Analysis of TCDDmediated Induction from
Reporter Constructs
Containing the zfCYP1A
Promoter Region Between 580 and +71 and CYP1A
Enhancer Regions from
Different Species. A. The
indicated reporter constructs as
well as pSV-β-galactosidase
were transfected into Hepa-1
cells and treated with 2nM
TCDD or 0.05% DMSO for 7
hours. Luciferase activity was
measured with a Turner
Instruments luminometer. βGalactosidase levels were
measured by
spectrophotometry (OD420).
Normalization was carried out
by dividing the relative
luciferase levels for each
sample by the corresponding
level of β-galactosidase .
White bars represent DMSO
treated cells while black bars
indicate cells treated with
TCDD. B. Fold induction was
determined by dividing nRLU
of vehicle treated cells by
dioxin treated cells. Bars
represent the mean ± SE of
three independent samples.
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TCDD dependent and can be competed with antibodies specific to the zfAHR2 protein.
In contrast, no shift was detected in the samples activated with zfAHR2 and zfARNT2b.
These results are consistent with the hypothesis that TCDD-mediated signaling does not
utilize ARNT2 proteins, but occurs through dimers with AHR and ARNT1 proteins
(Prasch et al., 2004; Prasch et al., 2003).
To assess the functionality of the XREs present in the zfCYP1A promoter, duplex
oligonucleotides were prepared that contained the core XRE as well as 6–7 nucleotides of
flanking sequence. Each XRE was then evaluated for binding to zfAHR2/rtARNTb
complexes by EMSA (Fig. 2.7). The results show that only five of the eight XREs
associate with zfAHR2/rtARNTb dimers in a TCDD-dependent manner. XRE3, XRE7,
and XRE8 showed the most intense shifts, while XRE1 and XRE 4 associated with
AHR/ARNT dimers in a TCDD-dependent manner, but showed slightly less intensity.
Since all XREs were labeled to the same specific activity, the reduced intensity of the
shifted bands likely represents a reduced level of affinity between the AHR/ARNT dimer
and the XRE. XRE2 and XRE6 showed no detectable shifts, while XRE5 showed a very
weak shift after prolonged exposure of the film (data not shown). Identical results were
obtained when the zfXREs were evaluated in the presence of mouse AHR/ARNT
complexes. To verify that the lack of binding by XRE2, XRE5, and XRE6 was not due to
the use of zfAHR2 and rtARNTb, studies were repeated using zfAHR2 and zfARNT2b.
However, the use of zfAHR2/zfARNT2b heterodimers also failed to produce a detectable
shift (data not shown). Thus, these results show that only a subset of the XREs are
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Figure 2.6. In vitro Analysis of the Association of zfAHR2 with XREs

Fig. 2.6. In vitro analysis of the association of zfAHR2 with XREs. A. The indicated
proteins were expressed in vitro, resolved by SDS-PAGE, and blotted to nitrocellulose.
Blots were stained with zf-4 IgG (1.0 μg/mL), rt-84 IgG (1.0 μg/mL), or anti-ARNT2
antibodies (1:250) followed by GAR-HRP or RAG-HRP IgG (1:10,000). Reactivity was
visualized by ECL. B. Equal amounts of zfAHR2 were mixed with equal amounts of
either zfARNT2b or rtARNTb and incubated with TCDD (16 nM) or DMSO (1.0%) for 2
h at 30°C. Samples were mixed with [32]P-labeled mXRE in the presence or absence of the
indicated antibodies and resolved on 5% acrylamide/0.5% TBE gels, dried, and exposed
to film.
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Figure 2.7. Association of zfAHR2 and rtARNTb with zfXREs

Fig. 2.7. Association of zfAHR2 and rtARNTb with zfXRES. Equal amounts of
zfAHR2 were mixed with equal amounts of rtARNTb and incubated with TCDD (16
nM) or DMSO (1.0%) for 2 h at 30°C. Samples were mixed with the indicated [32]Plabeled zfXREs and resolved on 5% acrylamide/0.5% TBE gels, dried, and exposed
to film.
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functional in binding to AHR/ARNT in vitro and that there are slight differences in their
affinities for AHR/ARNT dimers. In addition, the results suggest that the inability for the
-580 to -187 fragment to respond to TCDD in the reporter gene studies is not due to the
inability of the XREs to associate with AHR/ARNT complexes.
Functional characterization of individual XREs within the zfCYP1A regulatory
region
Due to the 1.7kb AT-rich region which separates the proximal (-580 to +71) and
distal (-2100 to -2608) cluster of XREs in the zfCYP1A regulatory region, PCR and
PCR-dependant site directed mutagenesis could not be performed to amplify the
complete 2.7kb fragment. Thus, the previous characterization of the zfCYP1A regulatory
region utilized constructs containing only the regions between -2100 to -2608 and -580 to
+71. Before site directed mutagenesis could be employed on the p-2608/-2100Ur
construct in order to determine the functionality of individual XREs, it was imperative to
determine whether its ability to drive a luciferase reporter was representative of the full
length promoter/enhancer. Thus, a full-length construct was generated by cutting the
zfCYP1A promoter/enhancer region from the original PAC clone and ligating it into
pGL3. The full-length p-2699/+71 and p-2608/−2100Ur constructs were then transfected
into Hepa-1 cells and the level of TCDD-induced luciferase activity quantified. It can be
observed in Figure 2.8 that the full-length p-2699/+71 was highly inducible by TCDD
and averaged approximately 20-fold induction over control treated cells. This is
consistent with the p-2608/−2100r construct that averaged approximately 32-fold
induction. The p-2699/+71 construct did exhibit reduced levels of total RLU in both
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control and TCDD exposed cells by comparison to the p-2608/−2100Ur construct, but the
difference between the two constructs may have been due in part to a significantly higher
level of transfection efficiency for p-2608/−2100Ur than the larger, AT-rich p-2699/+71.
Therefore, these studies indicate that both the p-2608/−2100Ur and the p-2699/+71
construct are highly responsive to TCDD exposure and validate the use of p2608/−2100Ur for the analysis of the regulation of the zfCYP1A gene.
Previous experiments have shown that the region between -580 and +71 which
contains XREs 1-3 is incapable of conveying TCDD-mediated gene induction (Fig. 2.4)
even though XRE1 and XRE3 are able to bind AHR/ARNT in vitro in a TCDDdependant manner (Fig. 2.7). To determine whether XRE1 and XRE3 contribute to
maximal induction by acting in concert with XREs in the distal cluster, in vitro
mutagenesis was employed on p-2608/-2100Ur in order to render XREs 1 and 3 nonfunctional, alone or in combination. The mutants, designated p-2608/-2100Ur(-1), p2608/-2100Ur(-3), or p-2608/-2100Ur(-1-3), or the non-mutated control were transfected
into Hepa-1 cells and assayed for luciferase activity. The results seen in Figure 2.9
indicate that the loss of XRE1 or XRE3 does not significantly affect the overall levels of
maximum gene induction by TCDD. Considering the fact that these XREs are capable of
binding AHR/ARNT in vitro, it is intriguing that XRE1 and 3 do not play an apparent
role in the regulation of the downstream gene. It should be noted that the distance of the
elements from the transcriptional start site is likely not the reason behind the functionality
of these XREs, as they failed to drive an SV-40 promoter when placed within the same
position as the functional, distal region of XREs. While it is possible that activated
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Figure 2.8. Comparison of TCDD-induced Luciferase Activity Between the
p-2699/+71 and p-2608/-2100Ur Constructs

Figure 2.8. Comparison of TCDD-induced Luciferase activity between the
p-2699/+71 and p-2608Ur constructs. Hepa-1 cells were transfected with
either p-2699/+71 or p-2608/−2100Ur and treated with TCDD (2 nM) or
DMSO (0.05%) for 15 h. Luciferase activity was measured using a Turner
Instruments luminometer and β-galactosidase activity was determined by
spectrophotometry (OD 420). (A) The normalized relative luciferase units are
shown for the indicated plasmids. Open bars represent control treated cells
while black bars indicate TCDD treated cells. Each bar = mean ± S.E. from
four independent experiments. (B) The fold induction is shown for the
indicated plasmids. Fold induction was determined by dividing the normalized
RLU of samples treated with TCDD by the normalized RLU of control treated
samples presented in (A).
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AHR/ARNT is capable of binding these elements in vitro but not in vivo, the reason for
this would likely be due to chromatin condensation within the region containing XREs
1 and 3 or the inaccessibility of the elements due to interference by other proteins binding
nearby as.opposed to differences in intracellular binding affinities versus those observed
by EMSA. Further experimentation will be required to elucidate the reasons for the lack
of function of these XREs
Contrary to what was observed for the XREs within the proximal region, the
distal region between -2100 and -2608 containing XREs 4 through 8, is capable of
conveying TCDD-mediated gene induction (Figs. 2.3 and 2.5). Additionally, EMSA has
shown that XREs 4, 7, and 8 are capable of being bound by AHR/ARNT in a TCDD
dependant fashion (Fig. 2.7). Therefore, in vitro mutagenesis was also performed on
these three XREs in order to determine their individual contributions to maximal gene
induction. Transfection into Hepa-1 cells and subsequent luciferase analysis shows that
individual mutation of XRE4, XRE7, or XRE8 resulted in significant reductions in both
raw levels of luciferase activity as well as fold-change of induction (Fig. 2.10). While the
transcriptional activity of each XRE does not appear to be equivalent by assessing the
degree of reduction observed by individual XRE mutations, this inequality is more
apparent when more than one XRE is mutated. Indeed, while elimination of any one of
the active XREs (4, 7, or 8), resulted in a 30–50% decrease in TCDD-mediated luciferase
activity, XRE4 or XRE7 alone supported approximately 25% of the maximal luciferase
induction in the absence of additional functional XREs while XRE8 alone showed
minimal activity above p-2608/−2100Ur(−478) or the p-580/+71Basic control. Therefore,
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Figure 2.9. Functional Analysis of zfXREs 1 and 3

Fig. 2.9. Functional analysis of zfXREs 1 and 3. Hepa-1 cells were
transfected with the indicated plasmids and treated with TCDD (2 nM)
or DMSO (0.05%) for 15 h. Luciferase activity was measured using a
Turner Instruments luminometer and β-galactosidase activity was
determined by spectrophotometry (OD 420). (A) The normalized
relative luciferase units are shown for the indicated plasmids. Open bars
represent control treated cells while black bars indicate TCDD treated
cells. Each bar = mean ± S.E. from three independent experiments. (B)
The fold induction is shown for the indicated plasmids. Fold induction
was determined by dividing the normalized RLU of samples treated with TCDD
by the normalized RLU of control treated samples presented in (A).
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these results suggest that in this model system, each of the regulatory sequences does not
provide the same level of regulation to the CYP1A gene as suggested by Fisher et al.
(Fisher et al., 1990). To verify that the previous results were not due to the analysis of
the zfCYP1A promoter in a mouse cell line, studies were repeated using the zebrafish ZFL
liver cell line. This line contains zfAHR2 as well as zfARNT1 and zfARNT2 and is
capable of supporting TCDD-mediated gene regulation (Carvan et al., 2000; Miranda et
al., 1993; Pollenz and Dougherty, 2005; Wentworth et al., 2004; ZeRuth and Pollenz,
2005). In comparison to the mammalian cell lines, transfection of the ZFL cells was
much less efficient and the cells exhibited a higher level of basal activity that resulted in
lower levels of fold induction in several constructs. Nevertheless, the results in the ZFL
line (Fig. 2.11A) showed several similarities to the results in the Hepa-1 line (Fig. 2.10).
First, single mutations of XRE4 or XRE7 resulted in a significant reduction in TCDDinducible luciferase activity. Second, mutation of XRE8 did not affect the luciferase
induction as significantly as loss of XRE4 or XRE7. Thus, as in the Hepa-1 cells, the
contribution of each XRE4 and XRE7 to the induction of the luciferase reporter was
much more prominent than XRE8. To compare the trend of the results across the
different cell lines used in the studies, the results were scaled with the overall fold
induction of wild type p-2608/−2100Ur construct set at 100%. The fold induction yielded
by constructs harboring XRE mutations was plotted as a percentage of the maximal
induction (Fig. 2.11B). The results show that there is a similar trend of the various
constructs when analyzed in Hepa-1 or zebrafish cells with mutation of XRE4 or XRE7
having a more dramatic impact than mutation of XRE8. The graph also contains results
from studies completed in the HepG2 line that is of human origin. In this cell line, the
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Figure 2.10. Functional Analysis of zfXREs

Fig. 2.10. Functional analysis of zfXREs. The indicated plasmids were transfected into
Hepa-1 cells as described for Fig. 2.9. (A) The normalized relative luciferase units are
shown for the indicated plasmids. Open bars represent control treated cells while black
bars indicate TCDD treated cells. Each bar = mean±S.E. from five independent
experiments. Schematics of the constructs are shown to the left of their respective bars.
Open rectangles indicate XREs. Shaded rectangles indicate mutated XREs. The TATAA
box and luciferase cassette are shown. (B) The fold induction is shown for the results
presented in (A) and was determined by dividing the normalized RLU of samples
treated with TCDD by the normalized RLU of control treated samples. a. Statistically
different from p-2608/−2100Ur (p < .001). b. Statistically different from p2608/−2100Ur(−7) (p < .01). c. Statistically different from all constructs except p2608/−2100Ur(−478) and p-580/+71Basic (p < .001). d. Statistically different from p2608/−2100Ur(−8) (p < .001). e. Statistically different from all constructs except p2608/−2100Ur(−4−7) and p-580/+71Basic (p < .001). f. Statistically different from all
constructs except p-2608/−2100Ur(−4−7) and p-2608/−2100Ur(−478) (p < .001).
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basal level of luciferase activity in controls was low for all the constructs and this
resulted in very high levels of fold-change in the presence of TCDD. It can be observed
that the overall trend obtained with the various constructs in the HepG2 line follows that
observed in the Hepa-1 and ZFL cells despite the fact that that overall fold induction
varies dramatically between the cell lines.
In order to determine whether the inability of XRE8 to function alone was due to
the truncation of the fragment immediately upstream of the core sequence, a new
construct was made extending the 5’ end of the insert up to -2727 and designated p2727/-2100Ur. XREs 4, 7, and 8 were mutated individually or in combination as done
previously with p-2608/-2100Ur and evaluated for luciferase activity in the Hepa-1 cell
line. The results in Figure 2.12 show that p-2727/-2100Ur exhibited approximately 60%
higher levels of basal and induced luciferase activity over p-2608/-2100Ur while the
overall fold-induction increased by approximately 17% between the constructs.
Considering the differences in the level of activity and fold-induction is consistent
between p-2608/-2100Ur and p-2727/-2100Ur equivalent mutants, it can be inferred that
the region between -2727 and -2608 contributes to the overall transcriptional activity of
the construct however does not change the functionality of XRE8 or its ability to regulate
the gene in the absence of additional functional XREs. The molecular mechanism that
underlies the inability of XRE8 to function alone is not presently clear but it is possible
that XRE8 is inaccessible prior to AHR/ARNT binding at XRE 4 and 7 or that
AHR/ARNT binding to XRE8 cannot effectively recruit transcriptional coactivators.
Indeed, chromatin relaxation and/or DNA bending has been shown to occur following
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Figure 2.11. Functional Analysis of zfXREs in Different Cell Lines

Fig. 2.11. Functional analysis of zfXREs in different cell lines. (A) The
indicated plasmids were transfected into ZFL cells and treated with TCDD (2
nM) or DMSO (0.05%) for 15 h. Luciferase activity was measured using a
Turner Instruments luminometer and β-galactosidase activity was determined by
spectrophotometry (OD 420). The normalized relative luciferase units are shown
for the indicated plasmids. Open bars represent control treated cells while black
bars indicate TCDD treated cells. Schematics of the constructs are shown to the
left of their respective bars as described for Fig. 2.10A. Each bar = mean±S.E.
from three independent experiments. The number in parentheses indicates the
fold-change for TCDD samples compared to DMSO treated controls. a.
Statistically different from p-2608/−2100Ur (p < .001). b. Statistically different
from paired control. c. Statistically different from p-2608/−2100Ur(−4) and p2608/−2100Ur(−7) (p < .005). (B) Scaled line graph showing the TCDD-induced
luciferase activity as a percentage of the wild type p-2608/−2100Ur construct.
Data were derived from Hepa-1 cells (circles), ZFL cells (triangles), or HepG2
cells (squares).
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AHR/ARNT binding at an XRE (Elferink and Whitlock, 1990; Okino and Whitlock,
1995) and this may impact protein–protein interactions or may prevent access to XRE8
prior to AHR/ARNT binding at XREs 4 or 7. In addition, a putative XF-1 site overlaps
XRE8 and this could also contribute to its lack of function in the absence of binding at
XRE4 and XRE7 as XF-1 binding has been previously been observed in the mouse
CYP1A1 enhancer (Saatcioglu et al., 1990). Since ChIP assays cannot distinguish
binding to enhancer regions that are on the same fragment of amplified DNA, and the
sequential association of AHR/ARNT with XREs in any gene has not been resolve. The
importance of these findings will require additional analysis.
The pattern of expression controlled by the zfCYP1A and mCYP1A1 regulatory
region varies in different cell lines
During the course of the studies in this report, it was noted that the overall level of
gene induction of different reporter constructs varied dramatically when tested in
different cell lines. To formally investigate this observation, four different reporter
constructs containing regions from the zebrafish of mouse CYP1A1 promoter/enhancer
were evaluated in seven different cell lines. The two constructs derived from zebrafish
were the full-length p-2699/+71 construct (ZFL) and p-2727/−2100Ur (ZFA). The
mouse constructs included one containing the region from −1674/+47 from the mouse
CYP1A1 promoter/enhancer (MFL), or the region spanning −1316/−819 ligated upstream
of the zebrafish CYP1A promoter region, −580/+71 (MMA). The cell lines utilized for
these studies and their tissue of origin are detailed in Fig. 2.13A. Interestingly, two
distinct patterns of induction were observed. The results show that the constructs
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Figure 2.12. Comparison of XRE8 Function Between the p-2608/-2100Ur and p2727/-2100Ur Constructs

Fig. 2.12. Comparison of XRE8 function between the p-2608/-2100Ur and p2727/-2100Ur constructs. The indicated plasmids were transfected into Hepa-1
cells and treated with TCDD (2 nM) or DMSO (0.05%) for 15 h. Luciferase activity
was measured using a Turner Instruments luminometer and β-galactosidase activity
was determined by spectrophotometry (OD 420). The normalized relative luciferase
units are shown for the indicated plasmids. Open bars represent control treated cells
while black bars indicate TCDD treated cells. Each bar = mean±S.E. from three
independent experiments. The number in parentheses indicates the fold-change for
TCDD samples compared to DMSO treated controls. * indicates percent of -2608/2100Ur fold induction. # indicates percent of -2727/-2100Ur fold induction.
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Figure 2.13. Characterization of Mouse and Zebrafish CYP1A Promoter and
Enhancer Regions in Various Cell Lines

Fig. 2.13. Characterization of mouse and zebrafish CYP1A promoter and
enhancer regions in various cell lines. (A) Species and tissue of origin, AHR
allele, and presence or absence of ARNT2 for each of the cell lines. (B and C)
Fold induction of luciferase when the designated constructs were transfected into
the indicated cell lines and treated with TCDD (2nM). Each data point is the
mean of at least three different samples. ZFL = p-2699/+71, ZFA= p2608/−2100Ur, MFL= mouse-1647/+57, MMA= Mm-1315/−819Uf.
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containing the zebrafish CYP1A promoter/enhancer (ZFL and ZFA), were more
responsive in the Hepa-1, B19, and A498 cell lines than the constructs containing the
mouse CYP1A1 regions (Fig. 2.13 B and C). In contrast, the hRPE, TCM, C2C12, and
HepG2 cell lines significantly favor the full-length mouse promoter/enhancer over the
constructs containing the zebrafish regions. The data presented in Figure 2.13B also
supports previously detailed results which show that the zebrafish region -2100 to -2608
conveys an approximately 2-fold higher level of induction than does the mouse CYP1A1
region between -819 and -1316. It was previously detailed in this report that p-2608/2100Ur construct exhibited increased levels of luciferase activity and fold-induction over
the full-length p-2699/+71 construct. The data presented in Figure 2.13 supports these
findings although it is interesting to note that the increase is significantly more dramatic
in the cell lines which favor the zebrafish constructs (Fig 2.13B) versus those which favor
the full-length mouse construct (Fig 2.13C). Intriguingly, the contrary is observed in Fig.
2.13C wherein the full-length mouse construct, MFL, produced considerably greater
levels of induction than both p-2727/-2100Ur and p-2699/+71. It is also important to
recognize that the mouse enhancer region between -819 and -1316 yielded significantly
less activity when driving the zebrafish CYP1A promoter (MMA) than the full-length
MFL in these four cell lines. The molecular basis for the differences in response of the
various reporters in the different cell lines is currently unclear. However, there does not
appear to be a correlation to the level or species of AHR protein, the tissue type, or level
of expression of ARNT2. The findings presented above suggest that the differences
observed between the transcriptional activities in various cell lines may be due, in part, to
interactions between the enhancer and promoter regions. It is possible that differences in
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the expression, binding affinities, or transactivation domains of cell specific factors may
contribute to the observed results.

Analysis of the zebrafish CYP1A Proximal Promoter
Since the different levels of response exhibited between the mouse and zebrafish
regulatory regions may be due, in part, to their respective proximal promoters, it was of
interest to characterize the zebrafish CYP1A promoter region. To do this, successive
truncations of the zebrafish CYP1A promoter region were cloned upstream of pGL3
Basic, transfected into Hepa-1 cells treated with either DMSO or TCDD, and assayed for
luciferase activity. The results shown in Figure 2.14 indicate that up to three regions are
required for maximal promoter function while one region may have an inhibitory effect
on transcription. The loss of the region between -580 and -490 resulted in a 40%
decrease in activity while further truncation down to -439 results in an additional 10%
loss. Transcription Element Search Software (TESS) identified two Sp1 binding sites and
a CTF/NF1 binding site within these regions which may be responsible for the decrease
in activity. Interestingly, loss of the region between -439 and -398 caused an increase in
activity back to the levels yielded by p-580/+71 Basic suggesting that an inhibitory
element may reside within this region. In silico analysis identified an Sp1 site
overlapping a USF1 site within these 40 bases which are possibly involved in the
observed inhibition. Further truncation down to -206 resulted in another 50% decrease in
activity which may be due to the loss of putative ERα and HNF-3γ sites located within
the lost region. CTF/NF1 sites and G-boxes have both been implicated in the control of
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Figure 2.14. Analysis of the Zebrafish CYP1A Proximal Promoter

Fig. 2.14. Analysis of the zebrafish CYP1A proximal promoter. The indicated
plasmids were transfected into Hepa-1 cells and treated with TCDD (2 nM) or
DMSO (0.05%) for 15 h. Luciferase activity was measured using a Turner
Instruments luminometer and β-galactosidase activity was determined by
spectrophotometry (OD 420). The normalized relative luciferase units are shown
for the indicated plasmids. Open bars represent control treated cells while black
bars indicate TCDD treated cells. Each bar = mean±S.E. from three independent
experiments. The schematics to the left represent the portions of the promoter
contained within the respective construct. Shaded circles = TATA box;
Rectangles = CTF/NF1 sites; Triangles = ERα sites; Diamonds = Sp1 sites.
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the mouse CYP1A1 promoter as well as the existence of a possible inhibitory region.
(Jones and Whitlock, 1990) Further studies will have to be performed to characterize the
importance of these elements in the zebrafish CYP1A promoter.
Functional analysis of XRE flanking sequence
Previous results suggest that just the presence of a core 5’-GCGTG XRE
sequence is not sufficient to ascribe function to a putative XRE in vivo (Denison et al.,
1988). For example, zfXRE5 has the same orientation and core sequence as zfXRE4, but
does not associate with AHR/ARNT dimers in vitro and does not appear to participate in
AHR-mediated regulation of zfCYP1A in cell culture. Thus, it was of interest to
determine whether nucleotides flanking XRE5 contribute to the lack of function of this
sequence in cell culture and in vitro. To gain some insight into this question, the
sequences of all eight zfXREs as well as the six XREs present in the mouse CYP1A1
were aligned and compared (Fig. 2.14). As previously detailed by Swanson et al.
(Swanson et al., 1995) and others, it can be observed that all XREs contain the 5’GCGTG
core at positions −2 through +3, however, those XREs with defined activity in vivo also
show consensus residues at positions 4, 5, 6 and 8. In contrast, XRE1, XRE2, XRE3,
XRE5 and XRE6 as well as mouse XRE C that lack function in vivo, do not fit the
consensus at residues 6 and 8. Thus, in vitro mutagenesis was used to change T >A at
position 6 and T >G at position 8 in XRE5 so that it more resembled XRE4 (termed
XRE5 > 4). In addition, the converse changes were made in XRE4 to convert it to XRE5
(termed XRE4 > 5). To assess whether the changes affected the ability of AHR/ARNT
dimers to associate with the sequences in vitro, EMSA was utilized. The results in Figure
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Figure 2.15. Comparison of Mouse and Zebrafish XRE Flanking Regions

Fig. 2.15. Comparison of mouse and zebrafish XRE flanking regions.
Core XREs and flanking sequences from zebrafish CYP1A (XREs: 1–8) and
mouse CYP1A1 (XREs: A–F) were aligned. Shaded region indicates
conserved nucleotides. Nucleotide positions are numbered below and ability of
the XRE to bind in vitro or function in cell culture is indicated to the right, Y:
yes, N: no. Nucleotides in non-functional XREs which diverge from conserved
bases are circled.
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2.15A confirm that XRE5 does not associate with AHR/ARNT dimers with the same
efficiency as zfXRE4 and the XRE4 > 5 mutations at positions 6 and 8 do not appear to
affect binding in vitro. In contrast, when the binding of XRE5 > 4 is compared to that of
XRE5, there is an approximate 50% increase in association with AHR/ARNT. It was
next pertinent to determine whether the various nucleotide changes results in increased or
decreased ability to drive luciferase expression in cell culture. Thus, the various
constructs were introduced into Hepa-1 cells and the overall level of TCDD-induced
luciferase activity compared. Interestingly, mutation of XRE4 > 5 slightly reduced the
level of luciferase induction in comparison to p-2608/−2100Ur(−78), but the level of
change was not significant over several experiments. (Fig. 2.15B) Likewise, mutation of
XRE5 > 4, resulted in a slight elevation of the luciferase activity and overall level of fold
induction, but the elevation was never significant. Thus, the XRE5 > 4 mutation
functions like the XRE8, in that it can associate with AHR·ARNT dimers in vitro, but
does not appear to support higher levels of TCDD-mediated induction of luciferase in the
absence of other XREs. Collectively these results suggest that nucleotides within the 3’flanking sequence of the core XRE can influence association of AHR·ARNT in vitro, but
changes in culture may be too subtle to detect.
The role of nucleotides flanking the core XRE motif in binding of AHR/ARNT
dimers has been evaluated by a number of labs (Shen and Whitlock, 1992; Swanson et
al., 1995). For example, Swanson et al. (Swanson et al., 1995) have shown that binding in
vitro does not occur when a G is located at position 4. In addition, Shen and Whitlock
(Shen and Whitlock, 1992) have shown that an A or C must be present at position 4 and a
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Figure 2.16. Effect of Mutating Nucleotides Flanking XREs on AHR/ARNT
Binding In Vitro

Fig. 2.16. Effect of mutating nucleotides flanking XREs on
AHR/ARNT binding in vitro. (A) EMSA autoradiograph shows the
ability of in vitro translated zebrafish AHR2 and rainbow trout ARNTb
to bind synthetic double-stranded oligonucleotides containing zebrafish
XRE4 (4), zebrafish XRE5 (5), XRE4 with mutations at positions 6 and
8 (4 > 5), or XRE5 with mutations at positions 6 and 8 (5 > 4). Arrow
indicates the AHR·ARNT·DNA complex. (B) The indicated plasmids
were transfected into Hepa-1 cells and treated with TCDD (2 nM) or
DMSO (0.05%) for 15 h. Luciferase activity was measured using a
Turner Instruments luminometer and β-galactosidase activity was
determined by spectrophotometry (OD 420). The normalized relative
luciferase units are shown for the indicated plasmids. Open bars
represent control treated cells while black bars indicate TCDD treated
cells. Each bar = mean±S.E. from three independent samples. The
number in parentheses indicates the fold-change for TCDD samples
compared to DMSO treated controls. a. Statistically different from p2608/−2100Ur (p < .001).
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G or C must be present at position 5 for function in cell culture. These investigators also
suggested that a G abolishes function at position 6 (Shen and Whitlock, 1992). These
rules partially explain why a number of the putative zfXREs are non-functional, as
zfXREs 1,2, 3, and 6, have T or G at position 4, and all have a T at position 6 (as does the
non-functional mouse XRE C). However, XRE5 is also non-functional yet matches the
consensus at positions 4 and 5. Importantly, when the residues at positions 6 and 8 were
changed to those found in the functional XRE4, there was a significant increase in the
binding to AHR/ARNT dimers in vitro, although the binding did not reach the level
associated with wild type XRE4. (Fig 2.15A) However, when these same mutations were
made at XRE5 in the p-2608/−2100Ur reporter construct, there was a slight, but not
significant elevation in TCDD-mediated induction of luciferase activity compared to
controls. (Fig. 2.15B) Thus, it appears that bases at positions 6 and 8 may play a role in
DNA binding in vitro, but the changes do not support function in the model system used
to assess activity. This hypothesis is supported by the correlate studies that changed the
bases at positions 6 and 8 in the functional XRE4 so they mimicked those of XRE5. In
this case, the changes did not affect either the in vitro binding or activation in cells.
Indeed, others have suggested that function is abolished when an A is located at position
5 (Shen and Whitlock, 1992), however, zebrafish XRE4 binds AHR/ARNT and is
functional yet has an A at position 5. Thus, to truly assess the function of individual
XREs, it will be necessary to determine binding to specific sites at the endogenous gene.
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Identification of additional cis-regulatory regions which impact the induction of
zfCYP1A
Since not all of the putative XREs in the zfCYP1A regulatory region were
functional and since the pattern of expression varied in different cell lines, it was of
interest to determine whether additional cis-regulatory regions were involved in the
TCDD-mediated induction of the CYP1A gene. Analysis of the zfCYP1A enhancer by
Transcription Element Search Software (TESS) revealed an extensive list of putative
binding sites within the distal 500 bp enhancer region which contains XREs 4-8. To pare
down the number of sites to a more manageable list, TESS was used to evaluate the
mouse CYP1A1 enhancer and identify common sites that shared similar relative positions
within the enhancers of both genes. A summary of sites identified is shown in Figure
2.16. To begin to assess the function of the various sites, in vitro mutagenesis was used
to modify an Sp1 site located at −2474, HNF-3 sites located next to XRE7 and XRE5, an
AP2 site, and a CREB site. Each site was mutated within the wild type p-2608/−2100Ur
construct and evaluated for TCDD-inducible activity in the Hepa-1 cell line.
Interestingly, mutation of the AP2, Sp1 and proximal HNF3 sites did not cause a change
in either the magnitude or level of induction (Fig. 2.17). In contrast, mutation of the
putative CREB binding site caused a modest reduction in the both the basal and TCDDinduced luciferase activity. Similarly, mutation of the HNF-3 binding site located at
position −2547 caused an even more dramatic reduction in both the basal and TCDDinduced luciferase activity that was reduced 10-fold below the level of the p-580/+71
construct. This finding is intriguing as it suggests that the removal of the site acts to
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Figure 2.17. Putative Transcription Factor Binding Sites Within the zfCYP1A
Regulatory Region That Are Common to Both Mouse and Zebrafish

Fig. 2.17. Putative transcription factor binding sites within the zfCYP1A
regulatory region that are common to both mouse and zebrafish. Putative
transcription factor binding sites identified by TESS within the zfCYP1A
enhancer that are common to both mouse and zebrafish. Specific binding regions
are boxed and labeled. Binding sites that were targeted for mutagenesis studies
are double boxed.
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Figure 2.18. Analysis of cis-regulatory Elements Within the zfCYP1A Enhancer

Fig. 2.18. Analysis of cis-regulatory elements within the zfCYP1A enhancer.
The indicated plasmids were transfected into Hepa-1 cells and treated with TCDD (2
nM) or DMSO (0.05%) for 15 h. Luciferase activity was measured using a Turner
Instruments luminometer and β-galactosidase activity was determined by
spectrophotometry (OD 420). Open bars represent control treated cells while black
bars indicate TCDD treated cells. *Bar is statistically different from p2608/−2100Ur. The transcription factor denoted in the construct name indicates that
the specific transcription factor binding site has been mutated in that construct. –
HNF-3(5) and –HNF-3(7) indicates HNF-3 binding sites flanking XRE 5 and XRE
7, respectively. The fold induction is shown in the graph on the right and was
determined by dividing the normalized RLU of samples treated with TCDD by the
normalized RLU of control treated samples. *Statistically different from p2608/−2100Ur (p < .001).
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repress the overall activity of the construct. Indeed, HNF-3 has been implicated in
chromatin remodeling functions (Roux et al., 1995), nucleosome positioning (Shim et al.,
1998), and has a supportive role in xenobiotic-mediated transcriptional regulation
(Bombail et al., 2004; Rodriguez-Antona et al., 2003). It is quite possible that in the
absence of protein binding to this site, the nucleosome is shifted toward the promoter
and thereby blocks access of the transcriptional machinery from assembling. Another
possibility is that mutation of this site causes a bending of the DNA such that the
enhancer itself contacts the promoter blocking both assembly of transcriptional
machinery as well as AHR/ARNT from accessing the XREs. Furthermore, HNF-3 has
been shown to work cooperatively with C/EBP (Christoffels et al., 1998) and NF1/CTF
(Jackson et al., 1993) in regulating the carbamolyphosphate synthetase I (CPS) and serum
albumin genes, respectively. Since both C/EBP and NF1/CTF binding sites can be found
in the zfCYP1A promoter/enhancer as determined by in silico analysis, it is interesting to
speculate that such cooperative interactions with HNF-3 occur in this system as well.
To determine what effect the HNF-3 mutation had on a construct containing the
full-length zfCYP1A regulatory region, the p-2608/+71(-HNF-3(7)) construct in which
the PCR amplified region between -2100 and -2608 from p-2608/-2100Ur(-HNF-3(7))
was used to replace the same region of the p-2699/+71 construct was transfected into
Hepa-1 cells and evaluated for luciferase activity. The results in Figure 2.18 indicate that
contrary to the mutation in the p-2608/-2100Ur construct which resulted in ablation of
both basal and inducible activity, the mutation in the p-2608/+71 construct resulted in a 6
and 8-fold increase in basal and inducible activity, respectively. The overall foldinduction between p-2608/+71 and p-2608/+71(-HNF-3(7)), however was consistent.
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Figure 2.19. Effect of HNF-3 Mutation on the Full-length p-2699/+71 Construct

Fig. 2.19. Efect of HNF-3 mutation on the full-length p-2699/+71 construct.
The indicated plasmids were transfected into Hepa-1 cells and treated with TCDD
(2 nM) or DMSO (0.05%) for 15 h. Luciferase activity was measured using a
Turner Instruments luminometer and β-galactosidase activity was determined by
spectrophotometry (OD 420). Open bars represent control treated cells while
black bars indicate TCDD treated cells. Each bar = mean±S.E. from three
independent samples. The fold induction was determined by dividing the
normalized RLU of samples treated with TCDD by the normalized RLU of
control treated samples.
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This data supports a role for HNF-3 in maintaining the position of the nucleosome as, if
the loss of the site in the context of p-2608/-2100Ur results in a shifting of the
nucleosome 3’-ward such that it blocks assembly at the promoter then the loss of the site
in the full-length construct may shift the nucleosome into the 1.7kb AT-rich region which
lacks any transcription factor binding sites. Positioning of the nucleosome within this
region may open up the upstream enhancer region leading to the enhanced activity
observed. While the mechanisms behind the observations at this site are unclear, the
results clearly suggest that binding of AHR/ARNT alone is likely not sufficient to obtain
a full transcriptional response and other binding proteins are required. This may explain
the large differences in overall level of luciferase induction of the various reporters in the
different cell lines and the need to assess gene regulation in the proper cellular context.
Future studies should be designed to assess the binding of additional factors to the
CYP1A enhancer in genomic DNA. The large distance between the enhancer and
promoter regions of the zebrafish CYP1A gene make this ideal for procedures such as in
vivo footprinting and ChIP analyses as binding at the two regions should be easily
differentiated. It is anticipated that the future analysis of the zfCYP1A gene will provide
significant informa tion on how the AHR mediates gene regulation in both aquatic and
mammalian organisms.
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Chapter 3
Discussion of Impact, Relevance, and Future Direction

The data presented herein confirms the isolation of the upstream regulatory region
for a dioxin-inducible CYP1A gene in zebrafish. The identified region, which was
sequenced approximately 2.8 kb upstream of the transcriptional start site, contains eight
XREs and several other elements indicative of previously characterized CYP1A
regulatory regions including a TATA box positioned at -31. Sequence analysis revealed
that the XREs were organized into two distinct clusters. The proximal cluster of XREs
(XREs 1-3) was incapable of conveying TCDD-mediated induction to a luciferase
reporter gene while the distal cluster, containing XREs 4-8, enhanced luciferase
expression in the presence of dioxin more than 20 fold. As determined by electrophoretic
mobility shift assays, only a sub-set of the eight XREs were capable of binding
AHR/ARNT in vitro. Surprisingly, XRE1 and XRE3 were bound by AHR/ARNT in
vitro in a TCDD-dependent fashion despite their inability to drive luciferase expression in
cell culture. The reason for the lack of function exhibited by these XREs is currently
unclear. Considering the region between -580 and -187 containing XREs 1-3 failed to
convey induction when cloned immediately upstream of an SV-40 promoter or in the
context of its native promoter, it is unlikely that the lack of functionality is promoter
specific. Additionally, when the region containing XREs 4-8 was cloned in the same
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position upstream of an SV-40 promoter, it was capable of conveying significant levels of
induction indicating that the distance from the promoter is also not responsible the
inability of XRE1 and 3 to function. It is possible that XREs 1 and 3 are capable of
binding protein in vitro but fail to function in cell culture due to chromatin condensation
causing inaccessibility of the binding sites. To assess this possibility, tandem repeats of
XRE1 or XRE3 along with several flanking nucleotides could be cloned upstream of a
luciferase cassette driven by an SV-40 promoter and analyzed for TCDD-mediated
luciferase induction. In such a scenario, the absence of additional native DNA which
may recruit histones or influence the structure of the DNA will allow for the assessment
of the XRE alone to enhance transcription. Others have characterized the mouse
CYP1A1 XREs and found that XREC was also capable of binding AHR/ARNT in vitro
but failed to function in vivo (Lusska et al., 1993). In these studies, tandem repeats of
each of the six XREs were placed upstream of an MMTV promoter controlled
chloramphenicol acyltransferase cassette and even in such a context, XREC still failed to
drive CAT expression. This suggests that in the mouse, chromatin inhibition of the XRE
is likely not responsible for the lack of function. Another possibility for the failure of the
XREs to contribute to gene induction may lay in the nucleotides flanking the core XRE
sequence. Previous experiments have shown that an A is required at position 6 (Fig.
2.14) for XRE function in the mouse but not for in vitro binding (Lusska et al., 1993;
Shen and Whitlock, 1992). These results would help explain the lack of function of
XRE1 and XREC, but not XRE3 which contains an A at that position. It is important to
note however that XREs 1 and 3 also diverge from the consensus suggested in Figure
2.14 at positions 4 and 8 as well. Although it has been previously shown through the use
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of ligation mediated PCR that the AHR/ARNT complex likely only interacts with three
or four guanine residues within the core XRE sequence, (Wu and Whitlock, 1993)
flanking nucleotides may affect the ability or degree to which the DNA bends or may
reinforce the stability of the bound AHR/ARNT complex and recruited cofactors.
Utilizing in vitro mutagenesis to alter the nucleotides at positions 4, 6, and 8 in XRE 1
and XRE3 within the p-580/+71 construct could shed light on the importance of these
flanking nucleotides on XRE functionality. Furthermore, in vivo footprinting and ligation
mediated PCR should be performed on the zebrafish CYP1A regulatory region to
determine whether or not protein interacts with the XREs in intact cells.
Nucleotides flanking the core XRE may also be implicated in the inability of
XREs 5 and 6 to bind AHR/ARNT in vitro or function in vivo. Inaccessibility of the
XREs due to chromatin structure is unlikely in the case of XREs 5 and 6 since it has been
previously established that AHR/ARNT binding at an XRE results in chromatin
relaxation spanning approximately 200 bases around the XRE (Okino and Whitlock,
1995). Knowing that activated AHR likely binds to both XRE4 and XRE7, XREs 5 and
6 should be free of any chromatin related constraints in the presence of TCDD.
Chromatin interference can further be ruled out by the fact that AHR/ARNT does not
bind double stranded oligonucleotides containing XREs 5 and 6 in vitro. Failure to bind
in vitro using in vitro translated AHR and ARNT also suggests that inhibition is not being
caused by competition or hindrances from additional proteins binding nearby the XRE.
The observations stated above suggest that any constraints set upon AHR/ARNT-XRE
interactions exist within the DNA sequence itself. Like XREs 1 and 3, mentioned
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previously, XREs 5 and 6 both possess a T at position 6 (Fig. 2.14). A T at this position,
however, has been implicated in loss of XRE function but has not been shown to affect
protein binding (Lusska et al., 1993). The alignment in Figure 2.14 shows that XRE6
also diverges from functional XREs at positions 4, 5, and 8 while XRE5 diverges only at
positions 6 and 8. Experiments described previously in this work suggest that mutations
of nucleotides at positions 6 and 8 can enhance the ability of XRE5 to bind protein in
vitro however the enhanced binding was not to the level observed by functional XREs.
Furthermore, the reverse mutations made to the functional XRE4 did not appear to affect
the level of binding observed in EMSA. These findings suggest that additional flanking
nucleotides may be involved in protein binding and is supported by the fact that
statistically significant changes in luciferase activity were not observed when the same
mutations were made in reporter constructs. Swanson et al. have previously
characterized XRE flanking nucleotides but their studies only examined in vitro
interactions using synthetically generated oligonucleotides (Swanson et al., 1995). Wu
and Whitlock have also characterized the role of flanking nucleotides in mouse XREs but
their studies did not examine nucleotides extending beyond four bases around the core
XRE (Wu and Whitlock, 1993). Utilizing a combination of synthetically generated
double stranded oligonucleotides for EMSA and in vitro mutagenesis to alter flanking
nucleotides of XRE5 alone and in combination until they are identical to a functional
XRE may shed light on the precise nucleotide combination required for a functional
XRE. Species specificity could likewise be tested by performing the same experiments
on mouse CYP1A1 XREs and by using mouse AHR and mouse ARNT1 in EMSA
experiments. Determination of specific nucleotide sequences required for AHR function
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in transcriptional regulation could be greatly beneficial in the search for novel AHR
target genes which contain bona fide, functional XREs within their regulatory regions.
It is also of interest to note that the XRE5 exhibits weak binding to AHR/ARNT
in EMSA experiments after prolonged exposure. Characterization of the mouse CYP1B1
promoter has previously revealed that three of the five XREs located therein bound a
non-AHR/ARNT complex which ran identically to AHR/ARNT on EMSA (Zhang et al.,
1998a). These XREs diverged from AHR/ARNT binding XREs within the same region
only at positions 6 and 7. While XRE5 in the zfCYP1A regulatory region does not share
the same nucleotide sequence at these two positions, it would be of interest to repeat the
EMSA of XRE5 with anti-AHR antibodies to ensure that the observed binding is indeed
AHR/ARNT and not another protein present in the reticulocyte.
XRE4, XRE7, and XRE8 were capable of both binding in vitro and functioning to
induce luciferase in TCDD treated cells transfected with luciferase reporter constructs.
While all three of these XREs appear to be necessary for maximal induction, their
contributions do not appear to be equal. When luciferase reporter assays were carried out
using p-2608/-2100Ur constructs bearing mutations at each of the individual XREs, it
was observed that the loss of XRE4 resulted in an approximately 50% reduction in
activity compared to the non-mutated control while loss of XRE7 yielded a 70% loss of
activity and the mutation of XRE8 only decreased activity by approximately 30%. These
findings are contrary to previous studies which suggested that each of the mouse XREs
contribute equally to maximal induction (Fisher et al., 1990). Later studies by Lusska et
al. showed that when duplicate copies of each of the six mouse XREs, A-F, were placed
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upstream of an MMTV promoter driven CAT reporter, XREC failed to respond to TCDD
and XREA exhibited a considerable reduction in responsiveness compared to XREs B, D,
E, and F (Lusska et al., 1993). Unfortunately, the experiments utilized by the
investigators in these studies did not consider the enhancer elements within their native
environment nor did they evaluate cooperation between the XREs. Mutations of
individual mouse XREs in the context of the full-length mouse CYP1A1 regulatory
region have not been made, thus it is unknown what contributions mouse XREA and
XREC make toward maximal induction of that gene. The results presented in this report,
however, show that in the absence of additional functional XREs, XREs 4 and 7 can
contribute 25-30% of the induced activity observed in the non-mutated p-2608/-2100Ur
while XRE8 is incapable of functioning alone. This is the first time it has been shown
that an XRE regulating a cytochrome P-450 was required for maximal gene induction but
incapable of functioning in the absence of additional functional XREs. The reasons
behind this observation are currently unknown. It is possible that the sequence flanking
the XRE is responsible for the inability of XRE8 to function alone although this is
unlikely due to the fact that XRE only diverges from XRE7 at positions 4, 7, and 8. The
nucleotides found at these three positions within XRE8 are also found at the same
positions in other functional mouse and zebrafish XREs. It is additionally possible that
XRE8 is inaccessible to AHR/ARNT due to the presence of chromatin prior to chromatin
relaxation caused by AHR/ARNT binding at XRE4 or XRE7. In order to test these
hypotheses, duplicate copies of XRE8 should be cloned upstream of an SV-40 or MMTV
promoter driven luciferase promoter and assayed for TCDD-mediated induction.
Additional inhibitory factors such as chromatin should not be present in such a construct
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and if the XRE sequence is sufficient to regulate transcriptional activity, TCDD should
mediate induction of the reporter. Alternately, mutation of the nucleotides at positions 4,
7, and 8 within XRE8 in the context of p-2608/-2100Ur(-47) such that they are identical
to XRE7 should shed light on the importance of nucleotide specificity. The converse
mutations should also be made to XRE7 in the context of p-2608/-2100Ur(-48). If
sequence is important, the XRE7 mutant should lose functionality while XRE8 should
gain the ability to function alone. Finally, analysis of the p-2608/-2100Ur XRE mutants
should be revisited in Hepa-1 cells treated with a histone deacetylase inhibitor such as
trichostatin-A. These studies should lessen or eliminate any inhibition chromatin has on
the ability of AHR/ARNT to bind XREs within the reporter constructs.
Another observation made throughout the course of these studies is that
XRE reporter constructs behave differently in different cell lines. When various reporter
constructs containing regulatory regions from zebrafish CYP1A and mouse CYP1A1
were transfected into various cell lines from different species and tissues, a distinct
pattern of transcriptional regulation was observed. For instance, when the zebrafish p2727/+71 construct was transfected into the human A498 kidney cell line it yielded
approximately 20-fold induction when treated with TCDD. By comparison the mouse 1647/+57 construct yielded less than 10-fold induction under the same conditions.
Surprisingly however, in the C2C12 mouse myoblast cell line, transfection of p-2727/+71
led to only an approximately 10-fold induction of reporter while a 60-fold induction was
observed in cells transfected with the mouse p-1647/+57. This overall trend was
observed in several cell lines with the zebrafish constructs yielding considerably higher
79

levels of induction in the Hepa-1, A498, and B19 cells while the mouse constructs were
favored in the C2C12, TCM, HepG2 and hRPE cell lines. The reasons behind this
observation are unclear, however it does not appear to correlate with the AHR allele, the
species or tissue of origin, or the presence or absence of ARNT2. Importantly, the data
suggests that the differences observed may be dependent upon the proximal promoter.
Each of the cell lines were also transfected with the pMm-1315/-819Uf construct which
contains the indicated mouse CYP1A1 enhancer region immediately upstream of the
zebrafish CYP1A promoter region, -580/+71. In the Hepa-1, B19, and A498 cells which
appear to favor the zebrafish full-length construct over the mouse, pMm-1315/-819Uf
yielded approximately 20% less induction than the full length mouse, p-1647/+57, in the
same cell lines. These results are expected considering the full-length mouse construct
contains two additional functional XREs not present between -1315 and -819 which
should result in a 20% reduction if all 5 XREs contribute equally as reported previously.
(Fisher et al., 1990) In the cell lines which appear to favor the mouse constructs,
however, pMm-1315/819Uf exhibits >50% reduced fold-induction compared to p1647/+57. This difference is most noticeable in the C2C12 and HepG2 cell lines which
exhibit greater overall levels of activity. To better understand the role the proximal
promoter plays in these observed differences, additional constructs should be made which
contain the zebrafish -2608/-2100 enhancer region immediately upstream of the mouse
proximal promoter region and the mouse enhancer region between -1315 and -819
upstream of the mouse proximal promoter. A comparison of the luciferase activity
exhibited by these constructs as well as p-2608/-2100Ur and pMm-1315/-819Uf should
confirm the importance of the promoter region in begetting these differences.
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The mouse CYP1A1 promoter region has been previously characterized by others
(Jones and Whitlock, 1990). The results of these studies revealed that the mouse
proximal promoter region contains a TATA box located at position -30, two CTF/NF1like sites located at positions -59 and -136, and a G-box located at position -130.
Mutation analyses showed that loss of either the TATA-box or the proximal CTF/NF1
sequence resulted in an 80% decrease in promoter function. Additionally, simultaneous
loss of the distal CTF/NF1 site and the G-box resulted in a 50% decrease of promoter
function while individual mutations of these elements had little or no effect. Truncation
experiments also suggest that there may exist inhibitory elements located between
positions -419 and -246. Transcription Element Search Software (TESS) was used to
identify putative transcription factor binding sites within the zebrafish CYP1A proximal
promoter region. A TATA-box was identified at position-31 along with several pertinent
sites including putative CTF/NF1 sites, G-boxes and Sp1 sites. A proximal CTF/NF1 site
was identified by TESS at position -54 and it is likely that the zebrafish promoter is
similar to the mouse CYP1A1 promoter and also contains a distal CTF/NF1 site and a Gbox which are required for maximal promoter function. Luciferase reporter vectors
containing successive truncations of the zebrafish proximal promoter suggest that two
distal CTF/NF1 sites and two distal Sp1-like sites may be important for the
transcriptional activity of the downstream gene.

Additionally, the data suggests that

another element lies between bases -398 and -206 which is also required for full promoter
activity. TESS identified a putative ERα binding site at position -330 and a putative
HNF-3 binding site at position -225 both of which have previously been implicated in the
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transcriptional regulation of cytochrome containing xenobiotic metabolism enzymes
(Bombail et al., 2004; Gibson et al., 2002; Matthews et al., 2005; Rodriguez-Antona et
al., 2003). Finally, the data suggests that an inhibitory element may exist between bases 439 and -411. An Sp1 site was identified overlapping a USF1 site within this region by
in silico analysis and may have a role in transcriptional inhibition of the gene.
Overall, the zebrafish CYP1A proximal promoter greatly resembles the
previously characterized mouse CYP1A1 promoter. Many additional studies still need to
be performed to better characterize this region, however. In vitro mutagenesis needs to
be utilized to mutate target binding sites within the promoter region both alone and in
combination to assess the function of the sites since truncation analyses alter the physical
characteristics of the DNA and cannot, therefore, be reliable. Mutations should also be
carried out in the context of p-2608/-2100Ur and assayed in TCDD treated cells to obtain
greater levels of overall activity and thus, more substantial differences between mutants
and control samples. EMSA should be performed to identify the ability of the pertinent
elements to bind protein in whole cell lysates and nuclear extracts from both DMSO and
TCDD treated cells. It is possible that the different patterns of regulation observed
between the constructs containing mouse and zebrafish elements is due to differential
binding to elements within the proximal promoters. In order to assess this, EMSA can be
performed using oligonucleotides containing elements of interest from both mouse
CYP1A1 and zebrafish CYP1A and nuclear extracts from each of the seven cell lines
used previously to determine differences in relative protein/DNA binding affinities
between the cell lines. DNAse in vitro footprinting should be performed as well using
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nuclear extracts from the seven cell lines of interest to further characterize differences in
protein binding at the two promoters. In vivo footprinting and LMPCR should ideally be
performed in ZFL cells to confirm protein binding at the zfCYP1A promoter in intact
cells.
TESS was also used to identify putative transcription factor binding sites which
were common between the mouse CYP1A1 and zebrafish CYP1A distal enhancers. In
vitro mutagenesis of selected sites within p-2608/-2100Ur and subsequent luciferase
assays identified both a CREB and HNF-3 sites which were important to the
transcriptional activity of the downstream gene. Previously, no additional proteins have
been implicated in binding at the enhancer other than AHR/ARNT and Sp1 (Fisher et al.,
1990) however mutation of the CREB binding site results in modest reductions of both
basal and induced reporter activity. Even more surprising was the finding that mutation
of an HNF-3 site located at position -2547 completely ablates both basal and inducible
transcriptional activity. This finding suggests that loss of the putative HNF-3 site
somehow inhibits the assembly of the transcriptional machinery at the promoter in the
presence or absence of TCDD. To investigate the role of the site in more detail, the
mutation of the HNF-3 site was assessed in the context of the full-length, p-2608/+71
construct. Unexpectedly, mutation of the HNF-3 site in this construct resulted in a
significant 6-fold increase in both basal and induced activity while only slightly elevating
the overall fold induction. The conflicting results obtained from the experiments using
the two different constructs led to the formulation of a hypothesis that HNF-3, or an
HNF-3-like protein is responsible for the positioning of a nucleosome at the CYP1A
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enhancer. In such a scenario, it can be envisioned that the nucleosome is shifted 3’-ward
such that in the case of p-2608/-2100Ur, the nucleosome blocks assembly at the promoter
while in p-2608/+71, the nucleosome is shifted into the 1 kb AT-rich region located
between the proximal promoter and the enhancer region, opening up enhancer and
leading to super-induction. Indeed, HNF-3α has been implicated by others in the
positioning of the nucleosome (Shim et al., 1998) and in chromatin remodeling, (Roux et
al., 1995) supporting this hypothesis. Fascinatingly, two similar binding motifs can be
found in the mouse CYP1A1 regulatory region; both of which exist centrally within 200
bp spans known to undertake a nucleosomal configuration. HNF-3 is known to bind
nucleosomal DNA (Shim et al., 1998) and this may explain why these sites may have
been protected from DNaseI digestion in footprints of the mouse CYP1A1 promoter and
enhancer regions (Okino and Whitlock, 1995; Shen and Whitlock, 1992). To test this
hypothesis, reporter assays using p-2608/-2100Ur and p-2608/+71 HNF-3 mutants should
be repeated in cells treated with a chromatin inhibitor such as Trichostatin A. If the
nucleosome is responsible for the effects observed in HNF-3 mutants then Trichostatin-A
treatment should reduce or eliminate the inhibition observed in p-2608/-2100Ur HNF-3
mutants while super-induction should be observed in the non-mutated p-2608/+71.
Additionally, EMSA using oligonucleotides containing the putative HNF-3 binding site
and Hepa-1 nuclear extracts could be utilized to confirm binding at the site in vitro while
super-shifting with antibodies against HNF-3α could confirm that is the protein
responsible for binding the element. These experiments may not be successful, however,
since the forkhead region of HNF-3α interacts directly with histones which would be
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absent in an EMSA. In vivo footprinting could also be utilized to detect the nucleosome
in ZFL cells treated with control or HNF-3α siRNA.
Overall, the structure and function of the zebrafish CYP1A regulatory region
appears to be similar to that which has been reported for other piscine and mammalian
CYP1As. Several novel findings have been identified for this model organism, however.
Within this report, it has been shown that there exists an inequality of the contribution
toward maximal induction exhibited by the functional XREs within this regulatory region
which contradicts what has been previously established in the mouse. Furthermore,
previous studies have not identified an XRE which is required for maximal induction yet
which fails to function in the absence of additional functional XREs as was observed for
the zebrafish XRE8. These findings are significant in that they support a better
understanding of the mechanisms of AHR/ARNT-XRE binding and subsequent gene
regulation. Also within this report, it has been established that the degree of regulation
mediated by CYP1A regulatory regions from different organisms is inconsistent between
cell lines. The data suggests that these inconsistencies may be due, at least in part, to
selective binding of proteins at the promoter. This novel finding may help elucidate how
AHR target genes are differentially expressed in various tissues and organisms;
especially as pertains to the application of findings obtained using cell culture and model
organisms to human health. Finally, a putative HNF-3 binding site was identified within
the zebrafish CYP1A enhancer region which may have a role in nucleosome positioning
based on mutational analyses. Chromatin reorganization is a fundamental aspect of
CYP1A regulation and an understanding the molecular mechanisms of nucleosome
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arrangement in this regulatory region is essential to discerning the AHR-mediated control
of this gene.
The characterization of the zebrafish CYP1A regulatory region was an important
step toward using Danio as a model organism for the study of AHR-mediated signaling
and TCDD-toxicity. Apart from the numerous benefits this organism offers for
developmental studies, the zebrafish CYP1A gene may be useful for future studies of
AHR-mediated regulation of target genes. Importantly, the distance between the
promoter and enhancer regions in zebrafish CYP1A is far greater than observed in
previously characterized organisms, thus making it ideal for procedures such as ChIP
assays in that binding can be easily differentiated between the two regions. Additionally,
the zebrafish can be used as a bio-detector of environmental pollutants such as TCDD by
the creation of transgenic fish which can produce a fluorescent signal in the presence of
such chemicals at a dose dangerous to human health. Such methods would be far more
accurate and reliable than bio-chemical testing which is often inaccurate and incapable of
knowing precisely the doses which may pose a threat to human health.
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Chapter 4
Materials and Methods

Materials
TCDD (98% stated chemical purity) was obtained from Radian Corp. (Austin, TX) or
Cambridge Isotope Laboratories and was solubilized in dimethylsulfoxide (DMSO).
Buffers
PBS is 0.8% NaCl, 0.02% KCl, 0.14% Na2HPO4, 0.02% KH2PO4, pH 7.4. Lysis buffer
is 60 mM Tris, pH 6.8, 2% SDS, 15% glycerol, 2 mM EDTA, 5 mM EGTA, 10 mM
DTT, 5% NP-40, 20 mM sodium molybdate, 0.005% bromphenol blue. TBS is 50 mM
Tris, 150 mM NaCl, pH 7.5. TTBS is 50 mM Tris, 0.2% Tween 20, 150 mM NaCl, pH
7.5. TTBS_ is 50 mM Tris, 0.5% Tween 20, 300 mM NaCl, pH 7.5. BLOTTO is 5% dry
milk in TTBS. Gel Shift Buffer is 50 mM Hepes, pH 7.5, 15 mM MgCl2, 50% glycerol.
Cells and growth conditions
Wild-type Hepa-1c1c7 (Hepa-1), were a generous gift from Dr. James Whitlock, Jr.
(Department of Pharmacology, Stanford University). These cells were propagated in
DMEM supplemented with 10% fetal bovine serum (FBS). Stable cell lines expressing
the Ahb-2 AHR in the Hepa-1 background (B19) were propagated as detailed previously
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(Pollenz and Dougherty, 2005). ZFL cells were obtained from ATCC (Manassas, VA)
and propagated in a 0.5/0.35/0.15 mixture of L15:DMEM:Ham-F12 supplemented with
bovine insulin (10 mg/L), EGF (20μg/L) and heat-inactivated FBS (5%) at 28 °C. Human
HepG2, human ARPE-19, human A498 cells, mouse TCM cells and mouse C2C12 cells
were purchased from ATCC and propagated as detailed by the manufacturer. All cells
were passaged at 1-week intervals and used in experiments during a 3-month period at
approximately 70% confluence. For treatment regimens, TCDD was administered
directly into growth media for the indicated incubation times. DMSO was used as the
vehicle control and the final concentration present in the culture media was between 0.05
and 0.1%.
Antibodies
Specific antibodies against the zfAHR2 (zf-4) and rtARNTb (rt-84) are identical to those
described previously. (Pollenz et al., 1996; Wentworth et al., 2004) All antibodies are
affinity-purified IgG fractions. Antibodies specific to the zfARNT2b were purchased
from Santa Cruz (Santa Cruz, CA). For Western blot analysis, goat-anti-rabbit antibodies
conjugated to horseradish peroxidase (GAR-HRP) or rabbit anti-goat antibodies
conjugated to horseradish peroxidase (RAG-HRP) were utilized (Jackson
Immunoresearch, West Grove, PA).
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Isolation of PAC clones containing the zfCYP1A gene
Oligonucleotide primers:
zfCYP1A1-UTR-upstream: 5’CTGGAAAGTATCCACTCGATCG3’
zFCYP1A1-ORF-downstream: 5’CCAGGACATTTCCGATAATCGG3’
were generated to the 5’UTR and ORF of the putative zfCYP1A mRNA (GenBank
accession #BC094977). These primers were use to screen superpools of zebrafish
genomic PACs, (Amemiya and Zon, 1999) by PCR. Two superpools displayed positive
PCR products when visualized on a 2% agarose gel. The PAC 133 and 150 were then
robotically dotted onto nitrocellulose filters and screened by colony hybridization using
the 312 bp zfCYP1A1 cDNA fragment. One positive clone was isolated from each of the
two superpools and termed #133 and #150. Southern blotting was used to identify
fragments corresponding to the CYP1A gene, and these were subcloned into pBluescript
SK- (Stratagene, Madison, WI) and sequenced. Sequence analysis and alignments were
carried out using Lasergene software (DNAStar, Madison, WI). Analysis of regulatory
elements was carried out using Transcription Element Search Software (TESS) freeware
available through the University of Pennsylvania (http://www.cbil.upenn.edu/ tess). The
sequence of the putative zfCYP1A promoter region (-2710 ± 65) that includes a portion of
the 5’UTR and the splice site for intron 1 has been entered into GenBank (Accession#
DQ182546).
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Generation of reporter constructs and site-directed mutagenesis
PCR was used to amplify the indicated regions of the zfCYP1A promoter/enhancer from
subcloned SpeI fragment of PAC #150. The PCR fragments were then ligated into
pGL3promoter (Promega), to generate p-2608/-2100Fup, p-2608/-2100Rup, p-2608/2100Fdown, p-2608/-2100Rdown, p-580/-187Fup, and p-580/-187F or ligated into
pGL3Basic (Promega) to generate p-580/+71Basic, p-2608/-2100Uf, p-2608/-2100Ur,or
p-2727/-2100Ur. Orientation was determined by restriction analysis. To generate
constructs containing the full-length promoter/enhancer, the 12kb SpeI fragment was
digested with SacI to yield a 2.7 kb fragment containing all of the previously examined
XREs but terminating at−42 and missing the TATA box and transcriptional start site. To
deal with this issue, the fragment was ligated into pSK- (Stratagene) and then cut out with
SacI and KpnI. This fragment was ligated into the SacI and KpnI sites of p-2727/−2100Ur
that had been cut to remove all but the +71 to −42 portion of the −2727/−2100Ur
fragment. The full-length promoter/enhancer construct was termed p-2699/+71. The
reporter vector containing the full promoter region from the mouse and the full promoter
region from rainbow trout (p-1897Om1A3luc) were generous gifts from Dr. Michael
Carvan (University of Wisconsin—Milwaukee) (Carvan et al., 1999). To generate Om1897/-1392Uf, Om-1897/-1392Ur,Mm-1315/-819Uf, and Mm-1315/-819Ur, the
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indicated regions were amplified by PCR and ligated into pGL3Basic (Promega)
upstream of the -580/+71 region of the zfCYP1A.
Site-directed mutagenesis of specific cis regions of the zfCYP1A was carried out
on the appropriate parental vectors using the Quikchange II XL site-directed mutagenesis
kit using the manufacturer’s protocol (Stratagene). The primer sets used are listed with
the specific base changes indicated in bold.
XRE1: 5’-CCATGTATGTGTGAGTGTGTTACATAC
5’- GTATGTAACACACTCACACATACATGG.
XRE3: 5’-CTCTCATTCACACTCACACTCATACAC
5’-GTGTATGAGTGTGAGTGTGAATGAGAG.
XRE4: 5’-CACACCTTTGCACTCGATGCTTTACCTGTTGC
5’-GCAACAGGTAAAGCATCGAGTGCAAAGGTGTG.
XRE7: 5’-CAGGTGCGCGCACTCGATGCTGTTTGATC
5’-GATCAAACAGCATCGAGTGCGCGCACCTG.
XRE8: 5’-CCTCCTCCAGCTCACTCAACGTGGCCAATC
5’-GATTGGCCACGTTGAGTGAGCTGGAGGAGG.
Sp1: 5’-CTTCCCATAAACCAACCGCAGAACAAAC
5’-GTTTGTTCTGCGGTTGGTTTATGGGTAG.
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HNF-3(7): 5’-GCACGCGATGCTGTGGGATCAGTTTATCGTAGC
5’-GCTACGATAAACTGATCCCACAGCATCGCGTGC.
HNF-3(5): 5’-CGCACGCACATACTCTCACAC
5’-GTGTGAGAGTATGTGCGTGCG.
AP2: 5’-CCAATCTTTAACCAGCGCTACAGGTGC
5’-GCACCTGTAGCGCTGGTTAAAGATTGG.
CREB: 5’-CGACGGCCACGCGCTTATACCCCATTCTGC
5’-GCAGAATGGGGTATAAGCGCGTGGCCGTCG.
XRE4(6/8): 5’-CACACACACACACTTATGACAGCGATG
5’-CATCGCGTGCATAAGTGTGTGTGTGTG.
XRE5(6): 5’-GCAGCGGTTCACCATCGCACGCACAC
5’-GTGTGCGTGCGATGGTGAACCGCTGC.
XRE5(8): 5’-GCAGCGGTTCACCATCGCACGCACAC
5’-GTGTGCGTGCGATGGTGAACCGCTGC.
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Transfection and reporter assays
Approximately 2×105 cells were plated into 35mm culture dishes and incubated at 37°C
for 16–24 h. Transfection cocktails were set up so that multiple dishes could be
transfected with aliquots of the same sample. This was accomplished by mixing the
reporter plasmid and pSV-β-galactosidase in OptiMEM media (Gibco) and then
incubating the mixture with either LipofectAMINETM or LipofectAMINE 2000TM
(Gibco) as specified by the manufacturer. Aliquots were
then applied to the appropriate plates and after 24 h; the cells were exposed to TCDD or
DMSO (0.05%) for 6–16 h. When multiple reporter plasmids were tobe used in an
experiment, the concentration of DNA utilized was the same and was verified by OD260
readings as well as agarose gel electrophoresis. Cells were harvested from plates by
scraping directly into 200–400μl Reporter Lysis Buffer as specified by the manufacture
(Promega). Luciferase activity was measured using identical sample volumes for 30 s in a
Turner Instruments luminometer. β-Galactosidase activity was measured using the βgalactosidase assay kit as specified by the manufacturer (Promega). Typically, each data
point was evaluated in triplicate and luciferase values were normalized by dividing the
relative luciferase units (RLU) of each sample by the corresponding level of βgalactosidase activity (OD420 reading). In most experiments, the relative transfection
efficiency for all plasmids was similar in a given cell line, although the level of
transfection efficiency across cell lines was different. Results are presented as
normalized luciferase units (raw) as well as fold-change between control and treated
samples.
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In vitro expression of protein
Recombinant protein was produced from zfAHR2, rtARNTb, and zfARNT2b expression
plasmids using the TNT™ Coupled Rabbit Reticulocyte Lysate Kit essentially as detailed
by the manufacturer (Promega). Upon completion of the 90 min reaction, samples were
either combined with an equal volume of 2X gel sample buffer and boiled for 5 min, or
stored at -80°C for use in functional studies. The actual concentration of protein
expressed in each reaction is estimated to be 6ng/μL, based on previous studies.
In vitro activation of AHR:ARNT complexes and electrophoretic mobility shift assay
The following oligonucleotides containing the core zfXRE sequences (bold) and 5’GG3’
overhangs (underlined) were synthesized by IDT (Coralville, IA).
zfXRE1: 5’GGTGTAACACACGCACACATAC3’
zfXRE2: 5’GGGGAAACCCACGCCATGCAAA3’
zfXRE3: 5’GGATGAGTGTGCGTGTGAATGA3’
zfXRE4: 5’GGTAAAGCATCGCGTGCAAAGG3’
zfXRE5: 5’GGAGAGTGTGTGCGTGCGTTTG3’
zfXRE6: 5’GGTGTGAAACACGCTACGATAA3’
zfXRE7: 5’GGAACAGCATCGCGTGCGCGCA3’
zfXRE8: 5’GGGGCCACGTTGCGTGAGCTGG3’
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Duplex DNA was produced by mixing each oligonucleotide with its complementary
strand, heating to 95°C and cooling to 25°C. Duplex DNAs were labeled with [32P]dCTP
by Klenow fill in. In vitro binding assays and EMSA were carried out by combining
approximately 25 ng of in vitro translated AHR and ARNT protein with 60 μL of MENG
and incubated for 2 h at 30°C in the presence of TCDD (16 nM) or DMSO (0.5%). 14 μL
of the activated sample was then incubated at 2°C for 15 min in 1X gel shift buffer
supplemented with KCl (80 mM) and polydIdC (0.1mg/mL). 4 ng of the labeled zfXRE
were added to each sample and incubated an additional 15 min at 22°C. The samples
were resolved on 5% acrylamide/0.5% TBE gels, dried, and exposed to film.
Western blot analysis and quantification of protein
Protein samples were resolved by denaturing electrophoresis on discontinuous
polyacrylamide slab gels (SDS-PAGE) and electrophoretically transferred to
nitrocellulose. Immunochemical staining was carried out with varying concentrations of
primary antibody in BLOTTO buffer supplemented with DL-histidine (20 mM) for 1–2 h
at 22°C. Blots were washed with three changes of TTBS+ for a total of 45 min. The blot
was then incubated in BLOTTO buffer containing a secondary antibody for 1 h at 22°C
and washed in 3 changes of TTBS+ as above. Bands were visualized with the enhanced
chemiluminescence (ECL) kit as specified by the manufacturer (Amersham, Arlington
Hts, IL). Multiple exposures of each set of samples were produced.
Statistical analysis
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Normalized RLU values were compared by ANOVA and Tukey-Kramer multiple
comparison tests using InStat software (GraphPad Software Inc. San Diego, CA). Results
are presented as mean ±SE. A probability value of ± 0.05 was considered significant.
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Appendix A

PAC 133 Sequencing Data

In order to obtain the sequence of the putative CYP1A regulatory region located
within the fragments obtained from PAC 133 via restriction enzyme digestion, the
12kb SpeI fragment and the 2.5kb and 0.5kb HindIII fragments were subcloned
into pBluescript ks- and sequenced. The initial sequencing was carried out using
the T7 and T3 primers native to the vector. Subsequent primers were designed
against the sequence retrieved from the initial sequencing (Figure AA1).

Since

the completion of this work, the zfCYP1A gene has been identified in the Sanger
zebrafish genome project database. The zfCYP1A has been assigned to
chromosome 18. The closest neighboring genes are the transient receptor
potential cation channel, subfamily M, member 7 (trpm7), approximately 150 kb
5’-ward of CYP1A and fibroblast growth factor 7 (fgf7), approximately 50kb 3’ward. The sequence obtained from the sequencing outlined above follows in this
appendix. Directly sequenced nucleotides are capitalized. Sequence obtained in
silico from other sources is represented by lowercase characters. Introns are
italicized. Splice donor/acceptor sites are bold faced. The TATA box is
underlined. SpeI and HindIII restriction enzyme sites are bold faced. XREs are
bold and underlined. Numbering is relative to the transcriptional start site such
that -1 is immediately 5’ of the transcriptional start site and +1 is immediately 3’.
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Appendix A continued
Figure AA1. Schematic Overview of Sequencing Strategy

Fig. AA1. Schematic overview of sequencing strategy. Visual representation of
the sequencing strategy employed on the subcloned constructs containing the region
upstream of the zfCYP1A. The 12kb SpeI fragment as well as the 2.5kb and 0.5kb
HindIII fragments were subcloned into pBluescript ks- and sequenced using T7 and
T3 primers. Subsequent primers were generated based upon the sequence retrieved
from the initial sequencing. Primers and direction are indicated by arrows. The
shaded region indicates the relative location of the HindIII fragments within the
larger SpeI fragment. The positions of the 5’ untranslated region, the translational
start codon, open reading frame, and splice donor/acceptor sites are labeled.
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Appendix A continued
>Danio rerio Cytochrome P4501A 5’ Regulatory Region, 5’-UTR, and Intron 1

-3359
-3294
-3229
-3164
-3099
-3034
-2969
-2904
-2839
-2774
-2709
-2644
-2579
-2514
-2449
-2384
-2319
-2254
-2189
-2124
-2059
-1994
-1929
-1864
-1799
-1734
-1669
-1604
-1539
-1474
-1409
-1344
-1279

gttcataccattgtgaatgcataatctgtctatacaacaaaaaaagtcagtcaacagtctgaaac
tggcagatttagagcaccgtaagagttcacaaaaaatagctgtttgtttctacatagactaaaag
taaactaaaagtaaattagatgcatggagtgtatagtttgagctaaggtaagcctatgtaagtca
gaatacactaatttgcctatccctatctctcagaaaacactgaaaacttaaacacatttcattaa
taaattagatgtcatttaattaaatacataactttgattaactgaagcatgtattacacaattct
catggggaaaattttaaatatatgtatatatttgtaatatttatttgtacaatttatttataatt
tcatgttagtaattatttgttgtgaatgataacaacttgtttgtaaagttttttttttccttaac
aacaaaactatagctgtagggttaatcaggctgagtgttaggacagggtttgtacatttgtaaag
tgttttaatgaagcaaaaaaatctgaaaaccaaataatgacatactttcctttacaaaacaactc
acagaaatcaaccatcgggccattttagtcatgtttgggatgaaatacttgcattcactgtattt
atgtttttatttcaaggtcagataatgtttctcttaggatgtcctacatataaagccgaacagga
gggtaaatagagcagaACTAGTGAACCTCTTCTCCTCCTCCAGCTCACGCAACGTGGCCAATCTT
TAACCCGCGCTACAGGTGCGCGCACGCGATGCTGTTTGATCAGTTTATCGTAGCGTGTTTCACAC
AGCGATAACAGTCTGAGGTCGCAGGAACTCTTCCCATAAACCCACCGCAGAACAAACACTCCGGC
TTTAACACTCCTCGTGCTTTTGTGCATGAACCGCTGACATGCACGCTCTCCGACGGCCACGCGCG
TCTACCCCATTCTGCCAGCTCTTCCTGTTGACAGTCAATGAGATGCATGAAAAATGTGTGAAGGA
ATCTGCAGCAGCGGTTCACAAACGCACGCACACACTCTCACACACACACACCTTTGCACGCGATG
CTTTACCTGTTGCTTAATGAGTTACGAGCGCGTGCCAGATCAGCAGAGACTCAAACATGCAGGCA
ATTATCGGATGTGTTGCAACAAACAATTTATTTAGTTCACATAATTGCCTAAACCATCACACTGA
TTTATGACACTTTAGCTTAGACAGCTTTAAAAGATAAATAAACATCTCGAGCATGCTGTTTAACT
TTTCATGATTTATATATTCTGATTTTATTGGGCTTATTTATTTCTCACATAATTATTATCCGCAT
TGAGTTTGCTGTATTAAGAGTTGTGATGAAATGTGGGATTGATTTCTCAGTTAATGCACGTCGCT
TTTGTCTACAAACTGTTCTGTAAATATTAACATTACATTACATAACATCAAAAAACACTGATAAG
CCCAGTTCTGCCTTAATTATAAAGGCTAATTAAGCGTCTCATTTATTAATTTATTTCATTTATTT
ATGTTTTAAATATATATTTGTTTACATATTGCAAATTTAGTTGGAAATGCATGTTAAAAATATTA
GTGCTGTATAATTATTACCCAATCAAAAATGTTGCATTTGTGTTAAATATTGACATATATATGAT
CACATTACATAAATATTGACATATATATGATTACAATACATAAATATTGACATATATATATATAA
TAATGTTACATAAATATTGACATATATGATTACGTTACATAAATATTGACATATATATAATTACT
TTACATAAATATTGATATATATATAATTACATTACATAAATATGAGCATATATATATAATTACAT
TACATAAATATTGACATATATATTTAATTACAATACATAAATATTGACATATATATAATTACATT
ACATAAATATTGACATATATGATTACATTACATAAATATTGACATATATAAGTACGTTACATAAA
TATTGAGATATATATATATAATTACAATACATAAATATTGGCATATATATAATTACGTTACATAA
ATATTGACATATATATATATATATATATATATATATATATATATATATATATATATATATATATA

125

Appendix A continued
-1214
-1149
-1084
-1019
-954
-889
-824
-759
-694
-629
-564
-499
-434
-369
-304
-239
-174
-109
-44
+21
+86
+151
+216
+281
+346
+411
+476
+541
+606

ATTACAATACATAAATATTGACATATATGATTACGTTACATAAATATTGACACATATATAATTAC
GTTACATAAATATTGACATATATATAATTACGTTTCATAAATATTGACATATATATAATAACGAT
ACATAAATATTGACATATATATGATTACAATACATAAATATTGGCATAATTAAAATGACATTACA
TAAATATTGACATATATATGACTATATTACAAAAATATTGACATATATATATATACACACACACA
CACATATATATATACAATTACGTTGAATCAATATTGACATATATATGAATGAATTACAAAAATAT
TGACATATATATAATAACGTTACATAAATATTGACATATATTTGATTTTATTAAATAAATATTGG
CATATATATAATTACATTACATAAATATTGACATATATATGATTACATTACATAAATATTGACAT
ATATATAATAACGTTACATAAATATTGACATATATTTGATTTTATTAAATAAATATTGGCATATA
TATGATTACATTACATAAATATTGACATATATATATATATATATATATATATATATATATATATA
TATATATATATATTTACTTTACATAAATATTGACATATTTGACTTAGTCCCTTTAATCAGGGGTC
GCCACTGCGGAATGAACCGCCAACTTATCCAGCATAGTTTTTACGCAGCAGATGCCCTTCCAGCT
GCAACCCAACACTGGGAAACACACATACCCTCTCATTCACACGCACACTCATACACTACGGCCAA
TTTAGTTCATCAGTTCCCCTAAAGTGCATGTGTTTGGACTGTGGAGAAAACCGGAGCACCCGGAG
GAAACCCACGCCATGCAAACTCCACACAGAAATGCCAGCTGACCCAGCTCGAACCAGCGATCGTG
CTACTCACTGCACTTTATAAATATATATTTTTCATTCATAACTTTTGTATACATTTTACATAGTC
TTTTGTACCATGTATGTGTGCGTGTGTTACATACATCAATCTCCTTCCCACAGTTTAGATATGTG
TGAGGTGAGTGTGTGTAATTACTCAGGGAGTTTACTCAGTGCAATCGATCAGCCTGTAATAAAAT
CTCAGCCCTTCTCAGCATCAAAGCCTCCTGCGCTCGGTGACGTCCGCGGAGGACAGCCAATCACG
GCGAGCTCTGCGCTATAAAAGATTTACCGCTGGAATAGTGCAGCACTCCTCTGGAGCTAATTGGC
ACTGGATAGAAACAGCTGAGAACTGGAAAGTATCCACTCGATCGCTCCGGGTGAGTCTGATGTCA
ATGGTTTTGTCTTATATTGAATATGTGATCATTGTGCAGGTGCTTTATGCAACTTTTAAACGTCA
AAACATTAACTTTCTTTACTTTTTCTACATGTTTTGCACAATATTGTACAGCTTAAATGGTGTGC
ATGTCACTTTTATAATAATTTTAGAGTTGAAAAAAAATGTATGTATAATATATATACTATAATTA
TATTATATATTATATTTTAATATCACTGTATTCCATTATAATGACATTTTTTGATTGCAAAGCAT
TTATTCATGCACCATTTTGCTCTTCATCATCAGTTTCAGTGCACATAAAGCCTATTTCCAGCTTT
TATATGAAGTTATATGGAGTATAGCGTGTGTATGTGTGTGTATATATAGGTTTTTCTAACTTTAG
AATTATTATTTATCATTGTTATTAATATAATTATTATTATTATTGGTTTGATGATGATTGTTAAT
TATTTATTGCTTTGAATACTCCATATGGTCATTTAAACCCTTTATTGTTTCCCCACTTCTTTATT
TGAAATCATACTTGAAAATGCTATAAGATTTATGCATATGGTTGATGTTCAGA

> Danio rerio Cytochrome P4501A Intron 1 partial sequence and Exon 1 partial sequence

…TATATATATATATATATATATATATATATATATATATATATATATATATATATATATATATATA
TATATATATATTTATATTTATATGTAGGTTGTAGGTTTTTATGTTGCTGCACAGTATGCATGTGT
GAGTATATCTTGCCTAATACAGGTGTGTGTGCATGTGCGTGTGTGTCTCAGATATGTGCTCTGAC
CTTGAGACAAATCACTCCATGTGTAGTTTATCATTAATGAATTTTGCAATTCAAATAACCAACCA
ATGCGCACTGGTTAAGCTGCACACTTATAGCATTTAGTTGCATAAAAACTCATGCATGTGCAGCA
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TTAATGACAGACAGGTTGCGGAAACACACACCTTTCTCAGTATCGTTCATCTAAGAAGTGTTACT
GTTAGACTTCTGCTGGCATCAAATTTACTTGTTGCAATTTATTGCTGAAGCTTGTAACTTGATAT
ATGGTGTTATCACAATAGACTGCAAAATAAACTACTTTAACAGGTATAGCAACAATAATACTTGT
ATTGATTTATCATTCAGGATAAACACATTTTTCAACTAAAATAAATTCTGAAAAAAATTATAAAG
TACAACAGGTAACACTTTACATTAAAGATGAGTTAACACTAATTAATGTATTAAAATCTACAGTG
ATAAAATGACATATTATGGTTGTGTTAAAGAAATATAAATAAATATTTTAAAATATCTTCTGTAA
AACAACCGTCCTGGATGTTCTTGATCCCACTTAATACAATCCAGCCACAAAACATAGAAATTAGA
CACAAACATTGTTCTGAACCGTAATAGTTTATTAAATCATTAAATAAATGCAAAGCTGACAGAGA
CTTAAACAGCTGATGGAGTATAAACTAACCTGCACATTATTCAGACACTAGATGGCGCTAAAAAC
AGTCAAAAACACAAAAGAAACTAAACAGCTGATGGAGTATACATTAACCTGCGCATTATTCACAC
ACTAGATGGCGCTAAAAACAGTCAAAAACACAAAGCTGACAGACACTAAAACAGCTGATGGAGTA
TACACTAACCTGCGCATTATTCAGACACTAGATGGCGCCAAACAGTCAAAAACACAACAGACACT
AAAACAGCTGATGGAGTATACACTAACCTGCGCATTATTCAGACACTAGATGGCGCCAAACAGTC
AAAAACACAACAGACACTAAAACAGCTGATGGAGTATGCACTAACCTGTGCATTATTCAGACACT
AGATGGCACTAAAACAGTCAAAAACACAAAGCTAAAAAAACACGAACAGCTGATGGAGTATACAC
TAACCTGCACATTATTCAGACACTAGATGGCGCTAAAAACAGTCAAAAACACAAAGCTGACAGAC
ACTAAAACAGCTGATGGAGTATACACTAACCTGTGCATTATTCAGACACTAGATGGCGCTAAAAA
CAGTCAAAAACACAAAGCTGACAGACACTAAAACAGCTGATGGAGTATACACTAACCTGCACATT
ATTCAGACACTA…
…TTCCATTTTCAGACACTAGATGGCGCCAACAGTCAAAACACACAAAAACACAACAGTTGATGGA
GTATACACTAACCTGTGCATTATTCAGACACTAGAAGGCGCCAAACAGTTAAAAACACAACAGAC
ACTAAAACAGCTGATGGAGTATACACTAACCTGCGCATTATTCAGACACTAGATGGCGCCAAACA
GTTAAAAACACAACAGACACTAAAACAGCTGATGGAGTATACACTAACCTGCGCATTATTCAGAC
ACTAGATGGCGCTAAACAGACAAAATCTGCAGTGTAAGTCAGCAGATACGTATAAACATGGACGT
GTATTTAAATTTTGACATATGTGAATCTCAGTTCCGGGATGAGTCTGTATTATCCTGCAGTTGTT
ATCTGTAAATAACATACCTTATTATTGTCACAACTGACCAATCAGAATCAAGTATTCTACACAAA
ACCATGTAATAATTTTTACTAACAACCACCTGAATGTACTTAATTCCGCTTATTACATGGCTACT
TACCACAAAGCATAAAAAAAGACTCAAAAATCAATTCAACAGTATATATTTAATAACTGATGGTG
ATAATTACTGATATTCCCTCTCTAATACCTCATTTATGTCTGCTTCCTTCTAAACAGGTTATTAA
ATCAGCAATGGCTCTGACTATTCTTCCAATATTGGGTCCGATTTCTGTGTCTGAGAGTCTCGTGG
CCATTATAACAATATGTTTGGTGTATCTGCTCATGCGCCTAAACCGCACGAAAATCCCAGACGGG
CTACAGAAGCTT
> Danio rerio Cytochrome P4501A Exon 1 partial sequence

AAGCTTCCCGGCCCGAAGCCTCTGCCGATTATCGGAAATGTCCTGGAAATCGGAAACAACCCACA
TTTGAGTCTGACGGCCATGAGTAAGTGCTATGGCCCGGTTTTTCAGATCCAGATCGGCATGCGTC
CTGTTGTCGTACTCAGTGGGAATGATGTGATCCGACAGGCGCTCCTAAAACAGGGCGAAGAGTTT

127

Appendix A continued
TCCGGACGTCCAGAATTGTACAGCACCAAGTTCATCAGTGATGGAAAGAGTCTGGCGTTCAGTAC
GGATCAAGTCGGAGTCTGGAGAGCACGCCGAAAGCTGGCGCTCAATGCCCTGCGAACATTTTCAA
CGGTGCAGGGAAAGAGTCCCAAATATTCCTGCGCCCTAGAGGAGCACATCAGTAATGAGGGTTTA
TATTTGGTCCAGAGGCTGCACTCTGTTATGAAAGCCGATGGAAGCTTTGATCCATTCAGACATAT
CGTAGTATCCGTGGCTAACGTAATCTGCGGGATCTGTTTCGGACGCCGGCATAGTCATGATGATG
ATGAACTGGTGCGACTGGTTAATATGAGCGATGAGTTCGGGAAGATCGTGGGCAGCGGAAACCCT
GCCGATTTCATCCCTTTCCTGCGCATTCTGCCGAGCACGACGATGAAGAAGTTCCTGGATATCAA
CGAACGCTTCAGTAAATTCATGAAGAGGCTGGTGATGGAGCATTACGATACGTTCGATAAGG

> Danio rerio Cytochrome P4501A Intron 2 partial sequence and Exon 2 partial sequence

TGGGGTGGGTTACGTTTGTGTGTGAGCTTATAGGAACATTCATTCATTCATTTTCGGCTTAGTCC
CTTTATTAATCAGGGGTCACCACAGCAGAATGAACCACCAACTTATCCAGCACATGCTTTATGAA
GCGCATGCCCTTCCAGCCGCAACCCATCACTGGGAAACACCCACACACTCTCATTCACACTCACA
CACTACGGACAATTTAGCCTACCCAATTCCCCTACACCGCATGTGTTTGGACAGTGGGGGAAACC
GGAGCACCCGGAGGAAACCCACACGAACGCAGGGAGAACATGCAAACTCCACACAGAAACACCAa
ctgacccagctgaggatcgaaccagcaaccttcttgctgtgatgcgacagaagtacctactttta
taatctttttatttattcaggagcagttttagcttagcttagcatccatcattgaatcagattag
accattagcatctctctcaaaatattcaaaagttagactcttccatagtcgtgtatttattagtc
acactggatcaataaaagcgggctgcacggtggcgtagtgggtagcacattcacctcacagcaag
aaggtggctggttcgagcctcggctgggtcaggtggcgtttctgtgtggattttgcatgttctcc
ctgtgtttgcgtgggtttcctccaggtgctccggtttcccccactgtccaaacgcatgtggtata
ggtgaattgggtaggcgaaatgtgtgtgaataagtgtgtatgaatgattcccagtgatgggttgc
agttggaagggcatccactgcataaaacatatgatgaataggttggtggttcattccgctgtggc
gactccagattaatagagggacaaacctctagcttagcttagcttagcatagttcattgaatcag
attagaccattagcatctctttcaaaaatgattatcaaagagttttgatgatttttctgactcct
caagctttgaataggaaaataatccaaacaccttttacagttttttttagcaagatgctaatggt
ctaatccgattcaatggtctatgctaagctaagttataagtcctccggccaaacttggagatcgg
ctgaataaatccaataatgaaaaactcaaccgttaaactttagatctggggtgtccaaactcggt
cctggagggctgttgtcctgcagattttagctccaacttgcctcaacacacctgcaaggatgttt
ctagcttgttaaacagtggagtgtatcggtacttcacccaaaaatgtaaattctgtatataatta
gttactcatcctcatttttaatccatcaccctaaaagcgacaatttgaatttattttaaaaaata
gtaaatctgttgtaacttaaaagagttgacttaatttctaagttaatagtattttaaaaataaca
gttatgcacacagtttttatttctattgtttattaagatccccattggccacaatattcctgggg
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tccgacaaatgaaatgacaagtttagattaattcatcattaaaaacaataacaaaaaagctaatt
taaattaaaataaaacaatagaaactttaaaaaaacacagaaaaaggctaattcacactaaacac
aacaatagacatcaaaaccacaaccaactaaagacaaataagcattaaattacaaaaccaacaca
ataaaacacactgtttcaatcatttgaaactatttatttaatttcaaggcaacgcattactcaaa
ttttattgcatttattttagtttgatctccacatagataaacgatcttaaaaataggtcatttta
aatagtgtttctctatcaggcaaatgtaatgttgcaagtttttccagtgtcgtgtggctcttcgt
agctcattgtctgttaaatttttttcaggACAACATCAGAGACATCACCGACTCTCTTATCAACC
ACTGCGAAGACCGAAAACTGGACGAAAACTCCAACCTGCAAGTGTCCGATGAGAAGATCGTAGGA
ATCGTCAATGACCTATTCGGAGCCGGTTTCGACACTATCAGTACGGCTCTGTCCTGGGCGGTTGT
CTATCTAGTGCACTACCCAGAGGTCCAGGAGCGACTGCAAAGAGAATTGGATGAAAAGATCGGGA
AGGATCGCACACCACTGTTATCTGACAGGGCGAACCTGCCGCTTCTGGAGTCCTTCATTCTGGAG
ATCTTCCGTCATTCATCCTTCCTTCCCTTCACCATTCCTCACTGCACATCCAAAGACACGTCACT
CAATGGCTATTTTATTCCCAAAGACACCTGCGTGTTTGTAAACCAGTGGCAAGTCAACCATGACC
CGTAAGTTTCTCGTTATTAATCTGGTCTGATTTACAATGCTTTCTCAACACATTAAAAATACTGT
AGTACTTACATACTATAGTCTATAAGTAACCATACCATAGTTTAGTTCTTGAACTGTTGTGGTGA
TTCTACAGTTGCTATGGTAACACAACAACTTCAGTAATTAATCCATTGTGGCGATTGTACAGTTG
CTATGGAAACACAATGACTAGAGTAATTGAGTTGTGGTGATTATACAGTTGCTATGGTAACAACA
ACTATAGTAATTAATCTGTTGTGGTGATTCTACAGTTGCTATGGAAACACAACAACTATAGTAAT
TGAGTTGTTGTGGTGATTCTACAGTTGCTATGGTAACACAACAACTATAGTAATTAATCCGTTGT
GGTGATTCTACAATTGGTATGGAAACACAATGACTACCGTAATTGAGTTGTTGTGGTGATTCTAC
AGTTGCTATGGTAACTCAACCACGATTGTAATTGATTGTTGTGGTTATTCTACAGTTGCTATGGT
AACACAACAACTATAGTAATTAATCTGCTTTGATGATTCTAAAGTTGCTATGGTGACACAACAAC
TATAGTATTTAATCCGTTGTGGTGATTCTACAGTTGCTATGGTAACACAACAACTATAGTTAATG
ATCTGCTTTGATGATTCTATAGTTGCTATGGTAACACAACAACTGTACTATTATAAACAAATGAT
CCAATACTGTAGTTTTCTACAACTATAGGGTATATTATACTACACTACATCACAGTGTACTAGTa
aaaaaggagtatgttacagtatttattataatttatcaggtcactgttgttaaactacagtatac
tggaacattcattaacaaagtgttgtaaaaactataatatatatatgatattttacactttacta
cagtatggttcacaaacactacagtattcaccatggatgaattgatatttaatttgtgactgata
ccattagccgatgacttttaaaatttggagggtgttatctgatatataggccaatcaatgtgaat
aataacatttctgcttgattgctaaaccaaaaggcaaacacatacagagaacaactctgaaatta
atttatttagcaactattcatttctatggccagctttgctttcatataaaggaaatctattgaca
aaaaacaacaacaacaaagcaataaagccattgaaaaagtggcacgcagcaagcatgtaaaatgg
ctaaaccagaagaaataatacatctttaatcagcttattgaaccgataacaataatattaaatat
agcgtataagactgtacattaatttagttaagcatttcatttgtgatttaacagtctttttatta
atatgcagttttgcttattcattgtttttatcgtagtgtgatttattattgtgatctgattatgc
ataagatgcaaatatatccacttaattctgttattggagctacaataatattacaaatagcattt
atcagctgatattcatatggccactatcatgaatccccagtatttactataaattactgcacatt
tatatgtgagtcaaaccaagctgaacctgttatttgtgtttgcagAGAACTGTGGAAGGATCCCT
CGTCTTTTATTCCCGACCGGTTCCTCACTGCGGACGGTACTGAACTGAATAAGTTGGAAGGCGAG
AAGGTGTTGGTTTTCGGTTTGGGAAAGCGCCGCTGCATTGGAGAGTCCATCGGACGCGCTGAAGT
CTTCCTGTTCCTGGCCATCCTGCTGCAAAGGTTAAAGTTCACCGGGATGCCAGGAGAAATGCTGG
ATATGACCCCAGAGTACGGGTTGACCATGAAACACAAGCGGTGTCTTCTTCGGGTCACACCACAG
CCTGGGTTCTAGATCCAGAACTCCTCATCATGATCCAAAAATCAAAGATTGAGCCCCTGAAATCC
AGGAAAACTGGCCAGCAGGTGGAGATGCTGAATATTAGAGATGTTTGTTCGCAGGTCAAAGCATC
CGATGCATTCTGATGCAAGCACACTGCAAAATATATGCTATTATTACTTACTATTAGAGTTTTTG
TCTTGCTTCTAGTCCAAATATCTCAAACGTCATTAATCAAGAAGCATTTTGTTGGCAAGTGAAAC
ATCTTGTCTTGTTTTCAAATATAATGAGTGAAAATTAAATGACGTTTTCCGTAAAACAAGCAAAA
TAATCTGCTTGCTCTGTTTAAAAAACTCTGTTAAACAGCTCTTTGGTAAGGAACTTTAATAATTG
GATAGTTTTGTTGTAAATTGTGCATATATGCATATCAGATGCACGCTTGCATGGCCTTGTCCTTT
CAAAACTGGAATGCTGATAATGTATTTGTGCTTTCAAACATACCGCGGTAAAGCACAGATCAGGA
TGAAGAGTGCCTGTTTTAGCTGCGGTTTAGCTGTCTATCAAAGCAATGCCTTCTGTCTTCATAAG
CTTAATGCAGATTCATCTGCCTGTCGACATACACTGATGCTGTTTTCTAATTGATGATGATCCCC
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GAATGTGATCCACATGTAAATACGCAGCGGCTGTTTCAATATGCACATTTTTTTTCCCATGTGCC
TGATTTTACTTGTGTACAGATTTGTAATATCTACTTTTTGTATTTATCAAAGTGCTTAATCAGAT
GTTTATTTCCTTGAGATATCGTGTCTGTGACCTGCTGAAACTCTTCGCAGGTGCTCATAATTGTA
TTATGAAGGAATTCTGAAGTACTACTGCTATAATTAATTCATGCTAACATGGTCTCCAATGGCAG
TTTGTTGTTGCATAGCATATTTATGATGTTGGCAAAATAAATAATAAAACTTCTACTGCTG
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Appendix B

Construct Maps

This appendix contains maps of constructs uses in the experiments outlined in
this report. The names and size of the constructs in base pairs are indicated. Pertinent
restriction enzyme sites are noted along with their numerical positions. Bold faced
numbers represent the position of the indicated DNA insert relative to the transcriptional
start site. The diagrams below the maps represent the portion(s) of the regulatory region
within the construct. XREs are shown as shaded rectangles. The XRE designation and
its position relative to the transcriptional start site are indicated.
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Figure AB1. p-2608/-2100Fup
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Figure AB2. p-2608/-2100Rup
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Figure AB3. p-2608/-2100Fdown
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Figure AB4. p-2608/-2100Rdown
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Figure AB5. p-580/-187Fup
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Figure AB6. p-580/-187Fdown
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Figure AB7. P-580/+71Basic
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Figure AB8. p-2608/-2100Uf
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Figure AB9. p-2608/-2100Ur
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Figure AB10. p-Om-1897/-1392Uf
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Figure AB11. p-Om-1897/-1392Ur
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Figure AB12. p-Mm—1315/-819Uf
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Figure AB13. p-Mm-1315/-819Ur
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Figure AB14. p--2699/+71
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Figure AB15. p—2608/+71
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Appendix C

Additional Studies

Generation of destabilized EGFP and EYFP constructs
In order to gain a better understanding of the timecourse of AHR-induced
genes, constructs were generated which contain a gene encoding a destabilized enhanced
green fluorescent protein (dEGFP) under control of the zfCYP1A regulatory region. The
purpose of destabilizing the EYFP was to ensure that the fluorescent signal produced is
not persistent and can be representative of transcriptional activity over time without
protein accumulation from earlier transcriptional activity. To produce a destabilized
EGFP, the degradation domain of the mouse ornithine decarboxylase gene was fused to
the EGFP coding sequence. Additionally, a 3x nuclear localization signal was fused to
the amino terminus of EGFP to generate a nuclear fluorescent signal which would be
easier to view via fluorescent microscopy. PCR was utilized to make the constructs such
that primers were synthesized which amplified both the 3xNLS and the dEGFP with
overhangs respectively complementary to each other. An additional PCR cycle was run
using both products as template, the forward NLS primer, and the reverse dEGFP primer.
A non-destabilized EGFP was also generated by using a reverse EYFP primer which
precedes the ornithine decarboxylase degradation domain and includes a stop codon. The
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3xNLS template was purchased as a double stranded oligonucleotide. The pd2EGFP
vector (Clontech) was used as a template for the dEGFP.
The primers used are listed below. Indicated restriction enzyme sites are
underlined.
3xNLS double stranded oligonucleotide:
5’- CCGAGATCCGGTGGATCCCACTCTTTTCTTTTTGGGGTCCACCCTTTTTTTTTTT
3’- GGCTCTAGGCCACCTAGGGTGAGAAAAGAAAAACCCCAGGTGGGAAAAAAAAAAA

GGGTCAACCCGCTTCTTCTTAGGATCCATGGTGGGATATCTGAC -3’
CCCAGTTGGGCGAAGAAGAATCCTAGGTACCACCCTATAGACTG -5’
P1 FOR 3XNLS EcoRV – 5’- ATCGTCAGATATCCCACCATGGATCC
P2 REV 3XNLS –5’ - CAGCTCCTCGCCCTTGCTCACCATCCGAGATCCGGTGGAT
CCCACTCT
P3 FOR GFP – 5’- AGAGTGGGATCCACCGGATCTCGGATGGTGAGCAAGGGCG
AGGAGCTG
P4 REV GFP XbaI – 5’- CCTCCATCTAGACTACACATTGATCCTAGCAG
After creating the recombinant GFP inserts they were ligated into the multiple
cloning site of pcDNA 3.1 (Clontech) and termed p-EGFP and p-dEGFP. Transfection of
the constructs into Hepa1c1c7 cells, however failed to produce fluorescence. The reason
for the failure of the constructs to work is unknown. To allow for the problem lying
within the GFP, additional constructs were made containing the coding sequence for an
enhanced yellow fluorescent protein (EYFP) known to work previously. These
constructs were assembled modularly such that PCR was utilized to amplify the ODC and
NLS from p-dEGFP with primers containing restriction enzyme sites integrated into
them. EYFP was amplified from p-EYFP-C1 (Clontech) using primers with
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Figure AC1. Strategy for Generating EYFP Constructs

Fig. AC1. Strategy for Generating EYFP Constructs. Schematic
representation of the EYFP inserts used to generate EYFP constructs.
EYFP = Enhanced yellow fluorescent protein. NLS = 3x nuclear
localization signal. ODC = ornithine decarboxylase degradation domain.
Restriction sites and the PCR primers within which they are integrated are
indicated
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corresponding restriction enzyme sites. To ensure the lack of function exhibited by pdEGFP was not due to the ornithine decarboxylase cassette or the nuclear localization
sequence, the new constructs were assembled containing only the EYFP cassette, (pEYFP), the EYFP cassette with the ODC degradation domain, (p-dEYFP), the EYFP
cassette with the 3xNLS, (p-NLSEYFP), and the EYFP with both the ODC and NLS, (pNLSdEYFP). A schematic overview of the modular assembly of the EYFP constructs is
shown in Figure AC1. The primers used for the creation of the EYFP constructs follow.
3xNLS double stranded oligonucleotide:
3xNLS – 5’- CTAGCCCCACCATG CCA CCT AAG AAA AAA AGA AAG GTT
3’GGGGTGGTAC GGT GGA TTC TTT TTT TCT TTC CAA
GAA GAT CCTGGTAC-3’
CTT CTA GGAC
-5’

P1 FOR 3xNLS NheI – 5’- ATCGTCAGCTAGCCCACCATGGATCC
EYFP IN NheI – 5’- TTTTGCTAGCCCACCATGGTGAGCAAGGGC
P4 REV EYFP HindIII – 5’- TTTTAAGCTTTCACTTGTACAGCTCGT
EYFP OUT FOR ODC – 5’- TTTTAAGCTTGTACAGCTCGTC
ODC IN HindIII – 5’- TTTTAAGCTTAGCCATGGCTTC
ODC OUT BamHI – 5’- TTTTGGATCCCTACACATTGATCCT

The appropriate modules were ligated into pcDNA 3.1 and the constructs were
once again transfected into Hepa1c1c7 cells. Fluorescence microscopy revealed that a
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Figure AC2. Constrct Maps of p-EYFP and p-dEYFP
NheI (1388)
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Fig. AC2. Construct maps of p-EYFP and p-dEYFP. Maps of the p-EYFP
and p-dEYFP plasmids. The size of the constructs in base pairs is shown.
Pertinent restriction enzyme sites are indicated. EYFP = enhanced yellow
fluorescent protein. NLS = 3x nuclear localization signal. ODC = ornithine
decarboxylase degradation domain.
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fluorescent signal was produced by all constructs. The cells transfected with pNLSEYFP and p-NLSdEYFP however, did not appear to localize to the nucleus and was
dispersed throughout the cells. Treatment of transfected cells with cycloheximide
additionally did not show a difference in the rate of degradation between p-EYFP and pdEYFP as expected.
To test whether or not the EYFP could be controlled by an AHR dependant
promoter, the recombinant EYFP inserts were cloned downstream of the zebrafish
CYP1A enhancer region (-2628/-2100) and the zfCYP1A promoter (-580/+71). Maps of
these constructs can be seen in Figure AC2. These constructs, termed p-2628/2100UrEYFP, p-2628/-2100UrdEYFP, p-2628/-2100UrNLSEYFP, and p-2628/2100UrNLSdEYFP were then transfected into Hepa1c1c7 which were treated with
vehicle dimethylsulfoxide or TCDD. The cells produced a fluorescent signal, however
the signal was produced even in the absence of TCDD to the same levels as TCDD
treated cells. The reason for the constitutive activity is unknown but may be due to
moderate basal levels exhibited by luciferase constructs bearing the same regulatory
region. As seen in previous experiments with p-EYFP, p-dEYFP, and p-NLSEYFP, the
signal did not localize to the nucleus or appear to degrade at an accelerated rate when
treated with cycloheximide. Sequencing of the constructs revealed that the inserts had no
aberrations. Further work will have to be done to design constructs capable of being used
to address the timecourse of AHR-induced genes.
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ARNT Domain Swapping
To assess the role the bHLH, PAS, and TAD domains of ARNT and ARNT2
have on their function, the coding regions of the human ARNT and mouse ARNT2 genes
were analyzed and a strategy to insert restriction enzyme sites between domains was
devised. PCR was utilized to alter nucleotides within the coding region to create unique
restriction sites which did not alter the amino acids being
encoded. The nucleotide and corresponding amino acid sequences of the human and
mouse ARNT and ARNT2 are listed below. Generated restriction enzyme sites are bold
faced. Mutated nucleotides are capitalized and underlined. A schematic overview of the
domains and the restriction enzyme sites can be seen in Figure AC3.
>C57/BL6 Mouse ARNT
3
63
123
183
243
303
363
423
483
543
603
663
723
783
843

I S T M A A T T A N P E M T S D V P S L
atctcgaccatggcggcgactacagctaacccagaaatgacatcagatgtaccatcgctg
G P T I A S G N P G P G I Q G G G A V V
ggtcccaccattgcttctggaaaccctggacctgggattcaaggtggaggagctgttgta
Q R A I K R R S G L D F D D E V E V N T
cagagggctattaagcgacggtcagggctggattttgatgatgaagtagaagtgaacact
K F L R C D D D Q M C N D K E R F A R S
aaatttttgagatgcgatgatgaccagatgtgtaatgacaaggagcggtttgccaggtcg
D D E Q S S A D K E R L A R E N H S E I
gatgatgagcagagctctgcggataaagagagacttgccagggaaaatcatagtgaaata
E R R R R N K M T A Y I T E L S D M V P
gaacggcggcgacggaacaagatgacagcttacatcacagaactgtcagacatggtacct
T C S A L A R K P D K L T I L R M A V S
acatgtagtgccctggctcgaaaaccagacaagctaaccatcttacgcatggccgtttct
H M K S L R G T G N T S T D G S Y K P S
cacatgaagtccttgaggggaactggcaacacatctactgatggctcctacaagccatct
F L T D Q E L K H L I L E A A D G F L F
ttcctcactgatcaggaactgaaacatttgatcCtCgaggcagcagatggctttctgttt
I V S C E T G R V V Y V S D S V T P V L
attgtctcctgtgagactggacgggtggtgtatgtctctgactcagtgactcccgttttg
N Q P Q S E W F G S T L Y D Q V H P D D
aaccagccacagtctgaatggttcgggagcacactgtatgatcaggtgcacccagatgat
V D K L R E Q L S T S E N A L T G R V L
gtggataaacttcgagagcagctctctacatcagaaaatgccctaacagggcgggtcctg
D L K T G T V K K E G Q Q S S M R M C M
gatctgaagactggaacagtgaaaaaggaaggccagcagtcttccatgaggatgtgcatg
G S R R S F I C R M R C G T S S V D P V
ggctcacgaaggtcgttcatctgccgcatgaggtgtggtactagctccgtggaccctgtt
S M N R L S F L R N R C R N G L G S V K
tccatgaatagactgagctttttgaggaacagatgcaggaatgggcttggctctgtgaag
E G E P H F V V V H C T G Y I K A W P P
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182
242
302
362
422
482
542
602
662
722
782
842
902

Appendix C continued
903
963
1023
1083
1143
1203
1263
1323
1383
1443
1503
1563
1623
1683
1743
1803
1863
1923
1983
2043
2103
2163
2223
2283
2343
2403
2463
2523
2583

gaaggagaacctcactttgtggtagtccactgcacCggTtacatcaaggcctggccacca
A G V S L P D D D P E A G Q G S K F C L
gcaggtgtctccctcccagatgatgacccagaggctggccaggggagcaaattctgccta
V A I G R L Q V T S S P N C T D M S N I
gtggccattggcaggctgcaggtaactagttctcccaactgtacagacatgagtaacatt
C Q P T E F I S R H N I E G I F T F V D
tgtcagccaacagagttcatctcccgacacaacattgaagggatattcacttttgtagac
H R C V A T V G Y Q P Q E L L G K N I V
catcgttgtgtggctactgttggctaccagccacaggagctcttagggaagaatattgta
E F C H P E D Q Q L L R D S F Q Q V V K
gaattttgtcatcctgaagaccaacaacttctaagagacagctttcagcaggtggtgaaa
L K G Q V L S V M F R F R S K T R E W L
ttaaaaggtcaggtgctgtccgtcatgttccgattccgatctaagacccgagaatggctg
W M R T S S F T F Q N P Y S D E I E Y I
tggatgagaacgagctcctttaccttccaaaacccttattcagatgaaattgagtatatt
I C T N T N V K N S S Q E P R P T L S N
atctgcaccaacaccaatgtgaagaactctagccaggaaccacggcctacactgtccaac
T I P R S Q L G P T A N L S L E M G T G
accatcccaaggtcacaactaggtccgacagccaatttatccctagagatgggtacaggg
Q L P S R Q Q Q Q Q H T E L D M V P G R
cagctgccatcTagAcagcagcagcagcagcacacagaactggatatggtaccaggaaga
D G L A S Y N H S Q V S V Q P V A S A G
gatgggctggccagctataatcattcccaggtttctgtccagcctgtggcaagtgcagga
S E H S K P L E K S E G L F A Q D R D P
tcagaacacagcaagccccttgagaagtcagaaggtctctttgcacaggacagagatcca
R F P E I Y P S I T A D Q S K G I S S S
aggtttccagaaatctatcccagcatcactgcagatcagagtaaaggcatctcctccagc
T V P A T Q Q L F S Q G S S F P P N P R
actgtccctgccacccaacagctgttctcccagggcagctcattccctcctaacccccgg
P A E N F R N S G L T P P V T I V Q P S
ccggcagagaatttcaggaatagtggtcttacccctcctgtaaccattgtccagccatca
S S A G Q I L A Q I S R H S N P A Q G S
tcttctgcagggcagatactggcccagatttcacgtcactccaaccctgcccagggatca
A P T W T S T S R P G F A A Q Q V P T Q
gcgccgacctggacctctacgtcccgcccaggctttgccgcccagcaggtgcccacccag
A T A K T R S S Q F G V N N F Q T S S S
gctacagccaagactcgttcttcccaatttggtgtgaacaactttcagacttcttcctcc
F S A M S L P G A P T A S S G T A A Y P
ttcagtgctatgtctcttccgggtgctcccactgcctcatctggtactgctgcctaccct
A L P N R G S N F P P E T G Q T T G Q F
gctctccccaaccgtggctccaactttcctcctgagactggacagaccacaggacagttc
Q A R T A E G V G V W P Q W Q G Q Q P H
caggcccggacagcagagggcgtgggggtctggccacagtggcagggccagcagccccat
H R S S S S E Q H V Q Q T Q A Q A P S Q
catcggtctagttccagtgagcagcatgttcagcagacacaagcacaagcacctagccag
P E V F Q E M L S M L G D Q S N T Y N N
cctgaggtctttcaagaaatgctgtccatgctgggagaccaaagcaacacctacaacaat
E E F P D L T M F P P F S E * N Y W G E
gaagaatttcctgatctaactatgtttccccccttttccgaatagaactattggggtgag
D K G G G K S L F V F K S K S F V N R I
gataagggtggggggaaatcactgtttgtttttaaaagcaaatcttttgtaaacagaata
K V L S L R S S P F P S L T P D M Y P F
aaagtcctctccctccgttcctctcccttcccttccctcacccctgatatgtaccctttc
P P P * L A E E T Y R R N * M N F P G F
ccacccccttgacttgctgaagaaacgtatagaagaaattaaatgaatttcccaggcttt
* D P L K F * G * V R P E
taggatcctctgaaattttgaggataggtgaggcctgaatc 2623
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Appendix C continued
>C57/BL6 Mouse ARNT2
3
63
123
183
243
303
363
423
483
543
603
663
723
783
843
903
963
1023
1083
1143
1203
1263
1323
1383
1443
1503
1563
1623
1683
1743
1803

P A L R S L P G K M A T P A A V N P P E
ccggcgctccggtcccttcccggcaagatggcaaccccggccgccgtcaaccctccggag
M A S D I P G S V A L P V A P M A A T G
atggcgtcagacataccaggatctgtggccttgcctgttgcccccatggcagccaccgga
Q V R M A G A M P A R G G K R R S G M D
caggtgagaatggcaggggccatgcctgcccgaggaggaaagcgtcgatccggaatggac
F D D E D G E G P S K F S R E N H S E I
ttcgatgacgaagatggtgaaggtcccagtaaattctcaagagagaaccacagtgagatt
E R R R R N K M T Q Y I T E L S D M V P
gagcggcgcaggcggaacaagatgactcaatatattacggaactctccgacatggttccc
T C S A L A R K P D K L T I L R M A V S
acctgcagtgcactggctaggaagccagacaagctgaccatcctgcgcatggcggtctcg
H M K S M R G T G N K S T D G A Y K P S
cacatgaagtccatgaggggcaccggcaacaaatcgactgacggcgcctacaagccttcc
F L T E Q E L K H L I L E A A D G F L F
ttcctcactgagcaggaactgaagcatctcatcctCgaGgccgctgatggatttctgttt
V V A A E T G R V I Y V S D S V T P V L
gtggtggcagctgagacagggagagtcatctacgtgtctgattcggtcactcctgtcctg
N Q P Q S E W F G S T L Y E Q V H P D D
aaccagccacagtcagagtggtttgggagcacgctttatgagcaggtgcaccctgatgac
V E K L R E Q L C T S E N S I T G R I L
gtggagaaactgagggaacagctgtgcacttcggaaaactccattacaggccgcatcctg
D L K T G T V K K E G Q Q S S M R M C M
gacctgaagactgggacagtgaagaaggagggacagcagtcatccatgcgcatgtgtatg
G S R R S F I C R M R C G N A P L D H L
ggctctcggcgctccttcatctgtaggatgaggtgtggaaacgctcccttggaccacctg
P L N R I T T M R K R F R N G L G P V K
cctttgaacagaataaccaccatgaggaaaaggttcaggaatggccttggccctgtgaaa
E G E A Q Y A V V H C T G Y I K A W P P
gaaggagaagcccagtatgctgtggtccactgcacCggttacatcaaggcttggccacca
A G M T I P E E D A D V G Q G S K Y C L
gcaggaatgaccatacccgaagaagatgctgatgtcggacaaggcagtaaatattgcctc
V A I G R L Q V T S S P V C M D M S G M
gtggcaattgggaggctccaggtgaccagctctcctgtgtgcatggacatgagcggcatg
S V P T E F L S R H N S D G I I T F V D
tcagtgcccacagagttcctgtcacggcacaactctgatgggattatcacgtttgtggac
P R C I S V I G Y Q P Q D L L G K D I L
cccagatgcatcagtgtgattggctaccagccccaggaccttctgggaaaggatattttg
E F C H P E D Q S H L R E S F Q Q V V K
gaattttgccaccctgaggatcagagccacctacgggagagcttccaacaggtggttaag
L K G Q V L S V M Y R F R T K N R E W L
ctgaagggccaagtgctgtcggtcatgtatcggttccgcaccaagaaccgggagtggctg
L I R T S S F T F Q N P Y S D E I E Y V
ttgatccgtaccagcagcttcaccttccagaacccctactctgatgagatcgagtacgtc
I C T N T N V K Q L Q Q Q Q A E L E V H
atctgcaccaacaccaatgtcaagcaacttcagcaacagcaggcagaactggaggtacat
Q R D G L S S Y D L S Q V P V P N L P A
cagcgagatgggctgtcgtcatatgacttatctcaggtcccagtacccaacctacccgct
G V H E A G K S V E K A D A I F S Q E R
ggtgttcacgaggccgggaagtctgtggaaaaggcagatgcaatcttctcccaagagaga
D P R F A E M F A G I S A S E K K M M S
gaccctcgttttgctgagatgtttgcaggcatcagtgcatctgagaagaagatgatgagc
S A S A S G S Q Q I Y S Q G S P F P A G
tcagcctcagcatcaggcagccagcagatctactcccaaggaagtccattccctgccggg
H S G K A F S S S V V H V P G V N D I Q
cactcgggcaaggccttcagctcttccgtggtccatgtgcctggagtgaatgacattcag
S S S S T G Q N I S Q I S R Q L N Q G Q
tcctcctcctcaacgggacagaacatatcccagatctctAgAcagctgaaccagggccag
V A W T G S R P P F P G Q P S K T Q S S
gtggcatggacaggcagccgtccaccgttcccagggcagcccagcaagacgcagtcatct
A F G I G S S H P Y P A D P S S Y S P L
gccttcggaattggatcaagccacccttacccggctgacccttcatcctacagtcctctc
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1863
1923
1983
2043
2103
2163
2223
2283
2343
2403

S S P A A S S P S G N A Y P S L A N R T
tccagcccagctgcctcctcaccaagtggaaacgcataccccagtcttgccaacaggact
P G F A E S G Q S G G Q F Q G R P S E V
ccagggtttgctgagagtggacagagtggcgggcagttccagggccggccctcggaggtc
W S Q W Q S Q H H G Q Q S G E Q H S H Q
tggtcccagtggcagagccagcatcacggacagcagagcggtgagcagcactcgcatcag
Q P G Q T E V F Q D M L P M P G D P T Q
cagcctggccagactgaagtgttccaggacatgctacccatgccgggcgacccgacgcag
G T G N Y N I E D F A D L G M F P P F S
gggactggcaactataacatcgaggactttgctgacctgggcatgttccctccattttct
E * L Q A K P G F Y C P D A I I M P * M
gagtagcttcaggcaaagccaggcttctactgcccagacgctattatcatgccatagatg
P M F K E G P P H P A C P A V E P P E I
cccatgttcaaagagggtccccctcacccagcttgccctgctgtagaacccccagaaatc
S L I P H P P W T W H H L A L T H S P G
tcccttattccccatcctccctggacatggcatcacctggctctaacccacagccctggc
F L G L G S L Y L L Y F I C V L G R G P
ttcttgggtttgggatctttgtatttattgtactttatctgtgtgctcggaagggggccg
P G S * I P L * I I Y * W
ccagggtcttaaatcccattgtgaataatctattaatggac 2443

1922
1982
2042
2102
2162
2222
2282
2342
2402

>Human ARNT
3
63
123
183
243
303
363
423
483
543
603
663
723
783
843
903
963
1023
1083
1143

G G S S H W G G G G A A A V A S A A M A
ggcggctcctcccactggggggggggtggcgcggcggcggtggcatctgcggccatggcg
A T T A N P E M T S D V P S L G P A I A
gcgactactgccaaccccgaaatgacatcagatgtaccatcactgggtccagccattgcc
S G N S G P G I Q G G G A I V Q R A I K
tctggaaactctggacctggaattcaaggtggaggagccattgtccagagggctattaag
R R P G L D F D D D G E G N S K F L R C
cggcgaccagggctggattttgatgatgatggagaagggaacagtaaatttttgaggtgt
D D D Q M S N D K E R F A R S D D E Q S
gatgatgatcagatgtctaacgataaggagcggtttgccaggtcggatgatgagcagagc
S A D K E R L A R E N H S E I E R R R R
tctgcggataaagagagacttgccagggaaaatcacagtgaaattgaacggcggcgacgg
N K M T A Y I T E L S D M V P T C S A L
aacaagatgacagcctacatcacagaactgtcagatatggtacccacctgtagtgccctg
A R K P D K L T I L R M A V S H M K S L
gctcgaaaaccagacaagctaaccatcttacgcatggcagtttctcacatgaagtccttg
R G T G N T S T D G S Y K P S F L T D Q
cggggaactggcaacacatccactgatggctcctataagccgtctttcctcactgatcag
E L K H L I L E A A D G F L F I V S C E
gaactgaaacatttgatcCtCgaggcagcagatggctttctgtttattgtctcatgtgag
T G R V V Y V S D S V T P V L N Q P Q S
acaggcagggtggtgtatgtgtctgactccgtgactcctgttttgaaccagccacagtct
E W F G S T L Y D Q V H P D D V D K L R
gaatggtttggcagcacactctatgatcaggtgcacccagatgatgtggataaacttcgt
E Q L S T S E N A L T G R I L D L K T G
gagcagctttccacttcagaaaatgccctgacagggcgtatcctggatctaaagactgga
T V K K E G Q Q S S M R M C M G S R R S
acagtgaaaaaggaaggtcagcagtcttccatgagaatgtgtatgggctcaaggagatcg
F I C R M R C G S S S V D P V S V N R L
tttatttgccgaatgaggtgtggcagtagctctgtggacccagtttctgtgaataggctg
S F V R N R C R N G L G S V K D G E P H
agctttgtgaggaacagatgcaggaatggacttggctctgtaaaggatggggaacctcac
F V V V H C T G Y I K A W P P A G V S L
ttcgtggtggtccactgcacCggTtacatcaaggcctggcccccagcaggtgtttccctc
P D D D P E A G Q G S K F C L V A I G R
ccagatgatgacccagaggctggccagggaagcaagttttgcctagtggccattggcaga
L Q V T S S P N C T D M S N V C Q P T E
ttgcaggtaactagttctcccaactgtacagacatgagtaatgtttgtcaaccaacagag
F I S R H N I E G I F T F V D H R C V A
ttcatctcccgacacaacattgagggtatcttcacttttgtggatcaccgctgtgtggct
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1203
1263
1323
1383
1443
1503
1563
1623
1683
1743
1803
1863
1923
1983
2043
2103
2163
2223
2283
2343
2403
2463
2523
2583

T V G Y Q P Q E L L G K N I V E F C H P
actgttggctaccagccacaggaactcttaggaaagaatattgtagaattctgtcatcct
E D Q Q L L R D S F Q Q V V K L K G Q V
gaagaccagcagcttctaagagacagcttccaacaggtagtgaaattaaaaggccaagtg
L S V M F R F R S K N Q E W L W M R T S
ctgtctgtcatgttccggttccggtctaagaaccaagaatggctctggatgagaaccagc
S F T F Q N P Y S D E I E Y I I C T N T
tcctttactttccagaacccttactcagatgaaattgagtacatcatctgtaccaacacc
N V K N S S Q E P R P T L S N T I Q R P
aatgtgaagaactctagccaagaaccacggcctacactctccaacacaatccagaggcca
Q L G P T A N L P L E M G S G Q L A P R
caactaggtcccacagctaatttacccctggagatgggctcaggacagctggcacccagg
Q Q Q Q Q T E L D M V P G R D G L A S Y
cagcagcaacagcaaacagaattggacatggtaccaggaagagatggactggccagctac
N H S Q V V Q P V T T T G P E H S K P L
aatcattcccaggtggttcagcctgtgacaaccacaggaccagaacacagcaagcccctt
E K S D G L F A Q D R D P R F S E I Y H
gagaagtcagatggtttatttgcccaggatagagatccaagattttcagaaatctatcac
N I N A D Q S K G I S S S T V P A T Q Q
aacatcaatgcggatcagagtaaaggcatctcctccagcactgtccctgccacccaacag
L F S Q G N T F P P T P R P A E N F R N
ctattctcccagggcaacacattccctcctaccccccggccggcagagaatttcaggaat
S G L A P P V T I V Q P S A S A G Q M L
agtggcctagcccctcctgtaaccattgtccagccatcagcttctgcaggacagatgttg
A Q I S R H S N P T Q G A T P T W T P T
gcccagatttcTAgAcactccaaccccacccaaggagcaaccccaacttggacccctact
T R S G F S A Q Q V A T Q A T A K T R T
acccgctcaggcttttctgcccagcaggtggctacccaggctactgctaagactcgtact
S Q F G V G S F Q T P S S F S S M S L P
tcccagtttggtgtgggcagctttcagactccatcctccttcagctccatgtccctccct
G A P T A S P G A A A Y P S L T N R G S
ggtgccccaactgcatcgcctggtgctgctgcctaccctagtctcaccaatcgtggatct
N F A P E T G Q T A G Q F Q T R T A E G
aactttgctcctgagactggacagactgcaggacaattccagacacggacagcagagggt
V G V W P Q W Q G Q Q P H H R S S S S E
gtgggtgtctggccacagtggcagggccagcagcctcatcatcgttcaagttctagtgag
Q H V Q Q P P A Q Q P G Q P E V F Q E M
caacatgttcaacaaccgccagcacagcaacctggccagcctgaggtcttccaggagatg
L S M L G D Q S N S Y N N E E F P D L T
ctgtccatgctgggagatcagagcaacagctacaacaatgaagaattccctgatctaact
M F P P F S E * N Y W G E D K G W G R K
atgtttccccccttttcagaatagaactattggggtgaggataaggggtgggggagaaaa
N H C L F L K S K S F C K Q N K S S S P
aatcactgtttgtttttaaaaagcaaatctttctgtaaacagaataaaagttcctctccc
F P S L T P D M Y P L S L L A V P L L C
ttcccttccctcacccctgacatgtaccccctttcccttctggctgttcccctgctctgt
C L L R * H L * K K K
tgcctcctaaggtaacatttataaaaaaaaaaaa 2616
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1322
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1442
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>Human ARNT2
2
62
122
182
242
302

F V W R R R R L G L T G S P G L S A G L
tttgtgtggcggcggcggcgcctgggcctgaccgggtccccggggctgagcgccgggctc
R A A P P A P L P S G R L S S P S K M A
cgcgccgcccctcccgcgcccctgccaagcgggcgcctatcctctccgagcaagatggca
T P A A V N P P E M A S D I P G S V T L
accccggcggcggtcaaccctccggaaatggcttcagacatacctggatctgtgacgttg
P V A P M A A T G Q V R M A G A M P A R
cccgttgcccccatggcggccaccggacaggtgaggatggcgggggccatgcctgcccgt
G G K R R S G M D F D D E D G E G P S K
ggaggaaagcggcgttccggaatggacttcgatgatgaagatggtgaaggccccagtaaa
F S R E N H S E I E R R R R N K M T Q Y
ttttcaagagagaatcatagtgaaatcgaaaggcgcagacggaacaagatgactcagtac
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362
422
482
542
602
662
722
782
842
902
962
1022

1082
1142
1202
1262
1322
1382
1442
1502
1562
1622
1682
1742
1802
1862
1922
1982
2042
2102
2162
2222

I T E L S D M V P T C S A L A R K P D K
atcacggagctctccgacatggtccccacatgcagcgcactggctcggaagccagacaag
L T I L R M A V S H M K S M R G T G N K
ctcaccatcctccgcatggccgtctcgcacatgaagtccatgaggggtacagggaacaag
S T D G A Y K P S F L T E Q E L K H L I
tccaccgatggcgcgtacaagccttccttcctcacagagcaggaactgaagcatctcatc
L E A A D G F L F V V A A E T G R V I Y
ctCgaGgcagctgatggatttctgtttgtggtggctgctgagacagggcgagtgatttat
V S D S V T P V L N Q P Q S E W F G S T
gtgtctgactccgtcacccctgttctgaaccagccccagtcagagtggtttgggagcaca
L Y E Q V H P D D V E K L R E Q L C T S
ctgtatgaacaggtgcatcctgatgacgtggagaagctgagagagcaactgtgcacctca
E N S M T G R I L D L K T G T V K K E G
gaaaactcaatgacaggccggatcttggacctgaagactgggacggtcaagaaagaaggg
Q Q S S M R M C M G S R R S F I C R M R
cagcagtcatccatgaggatgtgcatgggctcgcggcggtctttcatctgcaggatgagg
C G N A P L D H L P L N R I T T M R K R
tgtggaaatgctcctttggaccaccttcctctaaacagaataaccaccatgaggaaaagg
F R N G L G P V K E G E A Q Y A V V H C
ttcaggaatggccttggccctgtgaaagaaggagaagcccaatatgctgtggtccactgt
T G Y I K A W P P A G M T I P E E D A D
acCggTtacatcaaggcctggccaccagcaggaatgaccatacctgaagaagacgctgat
V G Q G S K Y C L V A I G R L Q V T S S
gtgggacaaggcagtaaatattgcctcgtggcaattgggagactccaggtgaccagctct
P V C M D M N G M S V P T E F L S R H N
cctgtatgcatggacatgaatgggatgtcggtgcccacagagttcttatcccggcataac
S D G I I T F V D P R C I S V I G Y Q P
tccgatggaatcatcacatttgtggatccaagatgtatcagtgtgattggctaccaaccg
Q D L L G K D I L E F C H P E D Q S H L
caggatcttctgggaaaggacattttggaattctgccaccctgaggatcaaagccatctg
R E S F Q Q V V K L K G Q V L S V M Y R
cgtgagagcttccagcaggtggttaagctgaaaggccaagtcctgtcggtcatgtatcga
F R T K N R E W M L I R T S S F T F Q N
tttcgcaccaagaaccgggagtggatgttgatccgcaccagcagcttcacattccagaat
P Y S D E I E Y I I C T N T N V K Q L Q
ccctattctgatgagattgagtacatcatctgcaccaacaccaacgtcaagcaacttcag
Q Q Q A E L E V H Q R D G L S S Y D L S
caacagcaggcagaattggaagtgcaccagagagatggattgtcatcgtatgacttatcc
Q V P V P N L P A G V H E A G K S V E K
caggtccccgtccccaacctaccagccggtgttcatgaggccgggaagtccgtggaaaag
A D A I F S Q E R D P R F A E M F A G I
gcggatgcaatcttctcccaggaaagagatcctcggtttgctgaaatgtttgcaggaatt
S A S E K K M M S S A S A A G T Q Q I Y
agtgcatcggagaagaagatgatgagctcagcctctgcagcaggaacccagcagatctac
S Q G S P F P S G H S G K A F S S S V V
tcccaaggaagcccatttccctctggacactccgggaaggccttcagctcttcagtggtt
H V P G V N D I Q S S S S T G Q N M S Q
catgtgcctggagtgaatgatattcagtcctcttcttccacgggccagaacatgtcccaa
I S R Q L N Q S Q V A W T G S R P P F P
atctcTAgAcagctaaaccagagtcaggtggcatggacagggagtcgtccgccctttccg
G Q Q I P S Q S S K T Q S S P F G I G T
ggacagcaaatcccatctcagtccagcaagactcagtcatctccctttgggattggaacg
S H T Y P A D P S S Y S P L S S P A T S
agccacacctacccggcagacccctcttcctacagccccctctccagcccagctacctcc
S P S G N A Y S S L A N R T P G F A E S
tcgccaagtgggaatgcctactccagtcttgccaacaggactccagggttcgctgaaagt
G Q S S G Q F Q G R P S E V W S Q W Q S
ggacaaagtagcgggcagttccaagggcggccctcggaagtctggtcgcagtggcaaagc
Q H H G Q Q S G E Q H S H Q Q P G Q T E
cagcaccatggccagcagagcggtgagcagcactcccaccagcagcccggtcagactgaa
V F Q D M L P M P G D P G N E W W S P H
gtgttccaggacatgctgcccatgccaggagatccagggaatgaatggtggtctccccac
S R Q H F R Q P I S Y A R M * T L T L L
tcccggcagcactttaggcagcccataagctatgcgagaatgtgaacgctcaccttgctc
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2282
2342
2402
2462
2522
2582
2642
2702
2762
2822
2882
2942

R H G S D L P H K Q E E A S D R N S S R
cgtcacggttctgacctaccacataaacaggaagaagccagtgaccggaacagctctagg
N N K S E * K C P L Y Y Q K I W A W P K
aataacaagtcagaatagaagtgtcctttatattaccagaaaatatgggcttggcctaag
S L S P N L P G S F P T K H P I L R S H
tcgctgtctcctaacctgccggggtcattccccaccaaacaccccatactaaggagccat
E P P G H S P F L * P S G V W G N L R R
gagccacctggacattcaccttttctttgaccatctggagtctggggcaacttaaggagg
H H T V V Q A H F Q A * V S L A F V A K
caccacacagtggtgcaggcacatttccaagcgtaggtgtccctggcttttgtggccaaa
A S V M V N N R P G S V G H * P * K W Q
gctagtgttatggtcaacaacaggccagggtctgtggggcactgaccttgaaagtggcaa
N G G F T G C A G A G R L A S S N N L S
aatggaggtttcacaggctgtgcgggagcaggacggcttgcttcatctaacaatctcagt
F L * K K K E R K R F H K Q V S V D S L
ttcctttaaaaaaagaaagaaaggaaaagatttcataagcaggtgtcagtggacagttta
S T * P F L F L L M D V N C A V D K S F
agtacttaaccatttctctttcttcttatggatgtgaactgtgctgtggataaatcattt
V F L E C S L * L T V I K S V V Y M C N
gtatttcttgaatgttctctatgactaacagttattaagtcggttgtgtatatgtgtaac
* C N C L L K F H Y N K N D F A L K K K
taatgtaactgccttttaaaatttcattacaataaaaatgactttgctctgaaaaaaaaa
K K
aaaaaaa 2948
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Figure AC3. Schematic of ARNT Domain Swapping
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Fig. AC3. Schematic of ARNT domain swapping. Schematic representation of
the restriction enzyme sites generated within ARNT and ARNT2 to create
interchangeable domains. The basic,helix-loop-helix, PAS A, PAS B, and
transactivation domains are shaded. Numbers in parentheses represent the
nucleotide position of the indicated restriction enzyme site in the context of the
cDNA.
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Appendix C continued
Figure AC4. Construct Maps of p-hARNT-ID and p-mARNT2-ID
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Fig. AC4. Construct
maps of p-hARNT-ID
and p-mARNT2-ID.
Maps of the p-hARNTID and p-mARNT2-ID
plasmids. The size of
the constructs in base
pairs is shown.
Pertinent restriction
enzyme sites along with
their positions are
indicated. bHLH =
basic helix-loop-helix
domain. PAS A and
PAS B = Per ARNT
Sim domains A and B.
TAD = transactivation
domain.

Apppendix C conntinued
Figure
F
AC5.. Restriction Enzyme Digestion
D
off p-mARNT
T2-ID

Figure AC
C5. Restricttion enzymee digestion of
o p-mARNT
T2-ID. 1% agarose gel
containing ethidium brromide was loaded
l
with p-mARNT22 digested wiith the
indicated restriction ennzymes and run
r at 100V for one hourr. Left lane contains
lambda Hin
ndIII/EcoRII marker. Fraagment sizess are shown.. The labels at the bottom
m
indicate thee domain rem
moved by thhe restrictionn digestion.
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Appendix C continued
After generating the domains with the specified mutations via PCR, the
fragments were digested with the appropriate enzymes and subcloned sequentially into
pcDNA 3.1 (Clontech). The resultant constructs, named p-hARNT-ID and p-mARNT2ID (Figure AC4) were then digested with restriction enzymes and visualized in an
agarose gel to ensure the proper sized fragments were produced. A representative photo
of the agarose gel can be observed in Figure AC5. Next the constructs were used to
produce in vitro transcribed/translated proteins, however the products were ~200kD in
size, far smaller than the expected size. Sequence data did not reveal any early stop
codons. The reason for the improperly sized proteins is unclear and will require further
investigation.
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